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3Abstract
ATR-FTIR spectroscopy has been used to develop rapid and accurate methods for urine
analyses and cancer diagnoses.
Complications associated with analyses of dried samples by FTIR spectroscopy
were found to arise because of the existence of partial hydration states of some sub-
stances. Recognition and accommodation of such states is necessary to ensure precise
deconvolution of spectra. Dramatic hydration eects were observed in the IR spectrum
of urea. Four forms of urea were identied in IR spectra, corresponding to solution (1468
cm-1) and dry (1464 cm-1) states and two intermediate (1454 cm-1 and 1443 cm-1) forms
that arise from specic urea-water and/or urea-urea interactions. Less pronounced hy-
dration eects were also identied in the spectra of creatinine and other urinary com-
pounds.
ATR-FTIR spectroscopy was then applied to diagnosis of the kidney stone dis-
ease, cystinuria. A simple method for detecting and quantitating urinary insoluble cys-
tine was developed based on the integrated area of the cystine 1296 cm-1 band. Clinically
relevant levels could be detected in ATR-FTIR spectra of dried insoluble fractions of urine
samples without any requirement for chemical manipulation.
The use of ATR-FTIR spectroscopy as a point-of-care diagnostic tool for kid-
ney diseases was investigated by installation of a portable benchtop spectrometer in a
hospital clinic. Nurses recorded spectra of 295 unprocessed urine samples and the data
were correlated with clinical diagnoses. Initial results suggested that dierences in the
integrated areas of key spectral features could discriminate between healthy patients
and those with chronic kidney disease (CKD), and indicate the extent of kidney damage.
ATR-FTIR spectra of 80 pancreatic tissue samples were also recorded and anal-
ysed for spectral patterns associated with cancer using PLS logistic regression. Tumour
tissue spectra could be separated from normal tissue spectra with 90 % sensitivity. Tu-
mour samples could be further separated into cancer stages with accuracies of 64-84
%.
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Chapter 1
Introduction
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Vibrational spectroscopy has been used for over a century to probe molecular
structures. However, it is only relatively recently that major improvements in technol-
ogy have aorded the sensitivity required to study biological molecules and it is only
within the last decade or so that FTIR imaging has become available [1]. Some of the
most important technological developments include the interferometer, highly sensi-
tive detectors and array detectors, powerful light sources and attenuated total reection
(ATR) technology [2,3]. Advances in computing power have also enabled rapid process-
ing of large datasets. Here, the focus will be on the theory and application of infrared
spectroscopy in medical diagnostics. For completeness, a very brief discussion on the
complementary method of Raman spectroscopy will be included.
1.1 Introduction to infrared spectroscopy
Infrared spectroscopy uses light from the infrared (IR) region of the electromag-
netic spectrum. Infrared light is usually subdivided roughly into three regions: near-
(~14000 - 4000 cm−1 / 714 - 2500 nm), mid- (~4000 – 800 cm−1 / 2500 - 12500 nm ) and
far- (~800 – 100 cm−1 / 12500 - 100000 nm) IR. The frequency ranges of mid- and far-IR
light correspond to the energy of molecular vibrational transitions and any vibrational
mode that has a net change in dipole will absorb IR light energy and so will be IR active.
An IR photon may be absorbed by a molecule when its energy is equal to the energy
dierence between two vibrational levels. Non-linear molecules have 3n – 6 and linear
molecules have 3n – 5 (where n = number of atoms) vibrational modes, many of which
are IR active. This means that most types of molecules can be detected with IR spec-
troscopy and the spectra of biological materials are rich in information but can be very
complex with multiple overlapping bands that can be dicult to deconvolute. An addi-
tional problem in biological samples can be the strong absorbance bands of liquid water
in the mid- and far-IR range which can mask many other signals. The contribution from
water usually has to be removed, either physically by drying the sample, or computa-
tionally by subtracting a liquid water spectrum from the sample spectra. The 1800 – 800
cm−1 region of the mid-IR spectrum is particularly dense in IR absorbance bands and is
commonly referred to as the ‘ngerprint’ region [2, 4].
When the frequency of infrared light matches the energy of a molecular vibra-
tional transition, some of the photons are absorbed and the remaining light is passed to
the detector. The extent of absorption is quantitatively related to the sample concentra-
tion through the well-known Beer-Lambert law (Eq. 1.1):
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Absorbance = log10
(
I0
I
)
= .c.l (1.1)
where I0 = reference (incident) intensity, I = sample intensity at a specic wavelength,
 = extinction coecient, c = concentration and l = pathlength. The frequencies of the
absorbance bands are functions of the primary and secondary structure of the molecule
[5].
1.1.1 Fourier transform and the Michelson interferometer
Fourier transform infrared (FTIR) spectroscopy allows a wide range of wave-
lengths of light to be simultaneously passed through the sample and deconvoluted (in
contrast to dispersive-type instruments that scan each wavelength individually). The
major advantages of FTIR spectroscopy are that there is less variability in the background
as all the data are acquired simultaneously, and the signal-to-noise ratio is inherently
much higher because larger apertures can be used. To achieve this, the broadband IR
light is rst passed through a Michelson interferometer (Figure 1.1). This comprises two
mirrors perpendicular to one another: a xed mirror M1, and a moving mirror, M2, which
moves back and forth through distance x. The plane of these two mirrors is bisected by
a beam splitter that splits the incoming beam, sending 50% of the light to M1 and 50% to
M2. The two beams are reected back to the beam splitter where they recombine. Light
travelling to M1 travels through the distance 2L, whilst light travelling to M2 travels
through the distance 2(L+x). Therefore, when the two beams recombine they interfere
because they have an optical pathlength dierence of 2x. The light passes out of the
interferometer, through the sample, and is focussed at the detector. Intensity of light is
recorded as a function of the M2 mirror position to produce the interferogram (Figure 1.2
A). The interferogram is then Fourier transformed to generate a power spectrum (Figure
1.2 B) of intensity versus wavelength (or, more typically in IR spectroscopy, of intensity
versus wavenumber). By also recording an equivalent ‘background’ power spectrum in
the absence of sample the Beer Lambert law (Eq.1.1) can be applied to produce plots of
absorbance versus wavenumber that can be used for quantitative analyses [6].
1.1.2 Attenuated total reection (ATR)
For this project, FTIR spectroscopy was performed primarily in attenuated total
reection (ATR) mode. In ATR mode an appropriately optically-congured IR-transmitting
prism is used to totally internally reect the IR light and the sample is placed in direct
25
Infrared
source
Incoming beam
Beam splitter
M1
M2
L
L
x
Michelson interferometer
Figure 1.1: Schematic of the Michelson interferometer [1]. M1 = xed mirror. M2 = moving
mirror, which moves through distance, x. L = distance from beam splitter to mirror.
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Figure 1.2: Interferogram and power spectrum. (A) Example of an interferogram shown in the
OPUS software. The intensity is greatest when the mirror displacement is 0 (M1 and M2 are equal
distance from the beam splitter) as there is constructive interference when the IR beams recombine
(no loss of signal). Displacement of mirror, M2, forwards or backwards results in the two IR beams
becoming increasingly out of phase. Once the two IR beams are half a cycle out of phase the signal
is lost due to destructive interference when they recombine. (B) Power spectrum of the blank ATR
prism, generated by Fourier transforming the interferogram.
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Figure 1.3: Schematic of the ATR prism. The diagram shows how the infrared light is directed
into the ATR prism where it is totally internally reected before passing to the detector. The sample
is placed directly on top of the prism as shown.
contact with the prism surface. For total internal reection to occur the angle of in-
cidence of the light at the prism boundary must exceed the critical angle. The critical
angle depends on the refractive indices of both the internal medium (the prism material)
and the external medium (e.g. the sample). At the reecting surface an electromagnetic
disturbance extends into the external medium, called an evanescent wave. The depth of
penetration of the evanescent wave into the external medium (sample) depends on the
wavelength of the IR light, the angle of incidence and the refractive indices of the prism
and the sample, as given by:
dp =
λ1
2pi(sin2θ − n221)1/2
(1.2)
where dp is the depth of penetration, λ1 is the wavelength of the incident light divided
by the refractive index of the ATR prism material (λ/n1), θ is angle of incidence of the
IR beam and n21 is the refractive index of the external medium divided by that of the
ATR prism (n2/n1) . Depth of penetration is generally between 0.5 and 5 µm. Some of
the light is absorbed by the sample and the remaining light is passed to the detector and
can be Fourier transformed to generate power and absorbance spectra as above (Figure
1.3) [3].
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1.1.3 Pros and cons of ATR and transmission
ATR allows samples to be placed directly onto the prism with minimal or no
sample preparation and without the need to place samples between IR-transmitting win-
dows. This is a particular advantage with biological samples where treatment may dis-
rupt the native biological state. For example, biopsy samples can be analysed without
sectioning (as would be required for traditional transmission IR spectroscopy) and whole
urine samples can be spotted directly onto the prism. The non-destructive nature of FTIR
spectroscopy, and the fact that chemical manipulation or staining of samples is not re-
quired, means that samples can be easily recovered after analysis and subsequently used
for other tests or measurements. Recording a spectrum in ATR mode is usually rapid
(second – minutes) and there is a quick sample turnaround between data acquisition.
However, a consequence of the design and physics of ATR is that only the rst few
microns into the surface of samples can be detected. This can be an advantage when
studying samples with multiple layers if only the top layer is of interest; for example
tissue samples where spectra of only the epithelial layer is desired. However, problems
can arise with liquid samples, such as blood and urine, because very low concentration
components may not be detected. Low concentration can be overcome by drying sam-
ples directly on to the prism to increase their concentrations and, therefore, their signal
intensities. Selective partitioning of samples can also occur due to the hydrophobic na-
ture of the ATR prism, leading to over- or underestimation of sample components that
either concentrate at the prism surface or are excluded from the active area.
An additional factor to consider with ATR experiments is that the pathlength,
and therefore absorbance, is frequency dependent because the depth of penetration of
the evanescent wave is dependent on the frequency of the incident light. It is also de-
pendent on refractive index, which can introduce error when comparing samples with
dierent refractive indices.
Before the advent of ATR devices, IR experiments were generally run in trans-
mission mode. In general for these experiments, pathlength must be very short to enable
enough light to get to the detector so samples must be thinly sectioned and/or sand-
wiched between two IR-transmitting windows. Therefore, sample preparation for trans-
mission experiments is inherently more labour intensive than for ATR experiments and
it is not always possible to recover samples for other measurements. In addition, the
sample chamber must be purged or evacuated in order to remove water vapour from the
optical path and this increases the turnaround time of each sample.
In transmission mode the signal size is not dependent on the frequency of the
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incident light or the refractive index of the sample, so it can be used to study and com-
pare samples with varying refractive indices, but variations in sample thickness (hence
pathlength) do aect signal size and should be taken into account. Unlike in ATR experi-
ments, the entire thickness of the sample is probed allowing components throughout the
sample to be investigated, not just those at the very surface. Tissue sections studied in
transmission mode are typically 5-10 µm thickness to optimise signal size whilst allow-
ing enough light to get to the detector. Longer pathlengths are possible for less absorbing
materials. The transmission mode has a major advantage when applied to vapour be-
cause the pathlength can be increased to tens of centimetres or even metres with the use
of enclosed chambers and mirrors in the beam path, hence greatly increasing detection
sensitivity.
1.1.4 Line shapes in infrared spectra
When a molecule absorbs mid-IR energy it makes a transition from its ground
state to an excited vibrational state. In the vapour state, such transitions occur at well-
dened frequencies that produce very narrow bandwidth bands in IR spectra. However,
interaction with other molecules in the environment inuences the precise frequency of
vibration.
Initially, after excitation, groups of molecules vibrate coherently. The lineshape
of the absorbance band depends on the rate of loss of coherence (coherence lifetime, τc)
and on the rate of relaxation to the ground state (amplitude correlation time, τa), which
are in turn inuenced by inter- and intramolecular interactions. When τa is greater
than τc a Lorentzian prole is observed (Figure 1.4 A); this is the typical line shape for
gases because the rapidly moving particles rotate and collide frequently resulting in loss
of coherence. In solids, Gaussian proles are observed because the molecules are not
rotating and colliding (Figure 1.4 B). Liquids exist between these two states leading to
IR proles that combine Lorentzian and Gaussian components [7, 8]. Fitting a curve to
an IR spectrum allows individual components that contribute to the overall prole to
be extracted. This can reduce problems associated with overlapping bands but relies on
some knowledge of the expected composition of an absorbance band.
1.1.5 FTIR microspectroscopy
FTIR-microspectroscopy combines chemical imaging with high spatial resolu-
tion and can either be mapping or imaging; mapping experiments take individual spectra
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Figure 1.4: Lorentzian and Gaussian line shapes. (A) Lorentzian prole typical of gases. (B)
Gaussian prole typical of solids.
sequentially across a dened region of the sample, whilst in imaging experiments a focal
plane array (FPA) detector is used to simultaneously record multiple spectra across the
imaging area. High spatial resolution of 5 – 10 µm can be achieved, allowing imaging of
individual cells or even organelles [5].
FTIR microspectroscopy can be performed in ATR or transmission mode and
a synchrotron IR source can be used to signicantly enhance the signal-to-noise ratio,
although spatial resolution of 3-4 μm has been achieved with a globar source [9]. The
ability to generate high quality data using a small and inexpensive globar source is es-
sential if FTIR-microspectroscopy is ever going to be applied to a clinical setting. False
colour maps can be generated from FTIR-imaging data that represent the distribution of
a band of interest across the sample. Individual spectra from points of interest can also
be extracted for analysis.
FTIR microspectroscopy has been used in many areas of research, the earliest
applications being the analysis of polymer materials [10], for example, in identifying
layers in multilayer lms used in packaging [11], and for following degradation of poly-
olen lms [12]. Other applications have included structure and composition analysis
for conservation studies of articles of historical interest, such as paintings [13]; deter-
mination of cell wall composition and architecture of wheat endosperm and how it is
related to grain hardness [14]; and monitoring of biolms for bacterial activity and re-
sponses to environmental changes [15].
FTIR-microspectroscopy is increasingly being applied to biomedical science.
For example, FTIR microspectroscopy has been used to follow changes in protein sec-
ondary structure as a means of studying protein aggregation associated with diseases
30
such as Parkinson’s, Huntington’s and Alzheimer’s [16]. Kazarian and co-workers used
the technology to study polymer/drug formulations to establish mechanisms of drug re-
lease for optimising drug delivery methods [17]. Perhaps the fastest growing area of
FTIR microspectroscopy research is in cancer diagnostics. Work includes grading of tu-
mour samples (molecular histopathology) [18, 19]; distinguishing cancer types [19, 20];
metabolic and biochemical proling of tumours [21, 22]; identifying cell types [23]; as-
sessing response to chemotherapy [24]; detection of stem cells in the epidermis [25] and
stem cell-like clusters in esophageal cancer cell lines [26]; and studying cell division and
motility in cancer cells [27].
1.2 Raman spectroscopy
An alternative and complementary form of vibrational spectroscopy to IR is
Raman. Raman spectroscopy is based on scattering, rather than absorption, of photons
as is the case for IR spectroscopy. Raman scattering is inelastic scattering. Incident light
interacts with molecules causing transitions to higher virtual energy levels. In non-
resonant Raman, the frequency of the excitation light is such that a molecule is excited
to an unstable virtual energy level and quickly re-emits the photon. Resonant Raman
is a special case in which the excitation frequency is much closer to that of a molecular
electronic transition. Relaxation occurs by emission of light of the same frequency as the
incident light (elastic scattering), or of higher or lower frequency (inelastic scattering).
If the light emitted is of a lower frequency the molecule returns to a higher energy level
than the initial state, this is Stokes scattering. Anti-Stokes scattering occurs when the
emitted light is higher frequency than the incident light because the molecule returns to
a lower energy level than the initial state. Most molecular vibrations exist in the ground
state under ambient conditions so anti-Stokes scattering is weaker. The Stokes Raman
spectrum is the most commonly studied.
Although the basis of Raman spectroscopy has similarities to IR spectroscopy,
the information produced is complementary due to dierent selection rules. This often
results in normal vibrations that are strong in Raman being weak in IR, and vice versa [2].
Incident light in Raman spectroscopy is typically laser light in the visible, UV or
near-IR region. The use of near-IR wavelengths reduces the inherent uorescence that
is usually present that can mask the Raman signals of interest [28].
A major advantage of Raman in biology is that water is a poor scatterer and
does not have a strong signal in Raman spectra, in contrast to its strong bands in IR
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spectra. However, inelastic light scattering in non-resonant Raman is a rare event so
Raman signals are very weak in comparison to absorbance signals [29]. Resonant Raman
generally produces stronger signals than non-resonant Raman, but the interference from
uorescence becomes more of a problem.
Raman spectroscopy has been used for numerous biomedical applications in-
cluding; discriminating between tumour types [30–33]; characterising molecular com-
position of lung tissue for identication of lung malformations [34]; discriminating be-
tween normal and malignant ovarian tissue [35]; diagnosing breast cancer [36] and lung
cancer [37]; identifying neoplasia in Barrett’s oesophagus [38]; and cancer grading and
molecular histopathology [39, 40].
1.3 Data analysis methods
1.3.1 Feature extraction
There are a number of approaches for analysing FTIR data and the method used
largely depends on the nature of the data and what information is required. The simplest
methods involve specic peak analysis, such as correlating peak positions with reference
spectra, comparing peak intensities, integrating peak areas and measuring peak shifts.
These processes can be applied to absolute or second derivative spectra.
Peak areas can be used to quantitate specic components and can be deter-
mined through integration of the recorded spectrum or by curve tting and integration
of the simulated curve; the latter method improves the specicity of the analysis. Sin-
gle peaks may be analysed but correlating multiple peaks or points on the spectrum
to a compound of interest is more reliable because many compounds have overlapping
bands. More complex multivariate analysis methods for mixed samples are also avail-
able [41, 42]. Linear and non-linear multivariate regression can take into account the
whole spectral range or a selected subsection to generate a linear predictive model from
calibration spectra that can be used to quantitate unknown sample data. However, these
methods require that the number of observations (i.e. sample number) is greater than
the number of variables (i.e. absorbance intensity at each wavenumber in the case of IR
spectra) and, since this is often not the case in FTIR spectroscopy, a further processing
step to computationally reduce the dimensionality of the data can be applied. Principal
component analysis (PCA) and partial least squares (PLS) regression are two commonly
used methods. In PCA, a new set of linearly uncorrelated variables, called principal com-
ponents (PCs), are generated from the original dataset by projecting the data to a new
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axis. The variables in the original dataset are recombined so the new PCs are orthogonal
to one another (this reduces redundancy in the data and hence reduces dimensionality)
and capture the maximum variation in the data. PC1 describes the maximum variance
in one axis direction in the data, PC2 describes the maximum variance in an orthogonal
direction and so on. The rst few PCs typically describe 90% or more of the variation in
the data and can be used in subsequent analyses. Inclusion of PCs beyond the rst few
in these analyses often does not improve performance, but if they are to be used the PC
loadings plots, which describe which features in the data contribute to each PC, should
rst be carefully examined to ensure they do not simply represent dierences in noise.
PLS works on a similar principle as PCA except that the new components, called latent
variables (LVs), are formed so that they both maximise the variance in x (e.g. the ab-
sorbance intensity at each wavenumber) whilst maximising the covariance with y (e.g.
the disease class or concentration). The LVs generated by PLS contain more informa-
tion than the PCs generated by PCA about the relationship between the variables (y)
and observations (x). PCA or PLS can be combined with multivariate regression to build
calibration models for IR spectra [43–45].
1.3.2 Unsupervised and supervised classication methods
Alternative analytical techniques can be used to classify spectra based on spec-
tral pattern recognition. These multivariate analysis methods can be unsupervised, in
that they do not use any prior knowledge about the classication of the spectra (as is the
case for PCA described in the previous section), or supervised, in that they use knowl-
edge of group membership (PLS regression is a supervised technique) [41, 43].
Clustering methods including hierarchical cluster analysis (HCA) and k-means
clustering are common examples of unsupervised classication. Clustering analyses
measure the similarities between observations (e.g. spectra) by dening a distance mea-
sure (e.g. Euclidean distance or Mahalanobis distance) and calculating pairwise the dis-
tance between observations. Spectra can then be sorted into a dened number of clus-
ters according to their ‘closeness’ to other spectra. This allows underlying structure in
a dataset to be identied and is an unbiased means of determining whether two spectra
from the same group are more closely related to each other than to the spectra of other
group members [41–43].
Supervised classication involves generating a predictive model using a known
training dataset which can then be tested on an unknown dataset. Discriminant anal-
ysis (DA), linear DA (LDA) or PLS-LDA, multinomial logistic regression (MLR), PLS lo-
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gistic regression, support vector machine (SVM), articial neural networks (ANN) and
Bayesian inference are all commonly used supervised classication methods. In PLS lo-
gistic regression the LVs generated by PLS regression are used to build a classication
model (binary or multinomial) using logistic regression that predicts the probability of
a case being positive (i.e. the probability of a sample belonging to a given class) based
on the values of the independent variables (LVs in this case) [43].
The performance of classication models is often evaluated by calculating the
sensitivity and specicity for predicting membership to each class, and the overall ac-
curacy. Sensitivity describes the models ability to correctly identify positives in a given
group whilst specicity describes the models ability to exclude all other samples from
that group [46]. Sensitivity, specicity and accuracy are dened in Methods.
1.4 FTIR spectroscopy applied to medical diagnostics
FTIR spectroscopy and imaging have been applied in medical diagnostic re-
search for many years and the literature is expanding rapidly [47]. The technology has
been applied to disease biomarker detection in body uids such as urine and blood. For
example, glucose and cholesterol have been measured in whole blood and serum using IR
spectroscopy, oering simple alternatives for monitoring patients with diabetes [48,49];
similarly, glucose and lactic acid, as potential cancer biomarkers, have been measured
in plasma samples [50]; protein and urea have also been measured in blood, and uric
acid, phosphate and creatinine have been measured in urine [49]. FTIR spectroscopy has
been applied in reproductive biology to assess oocyte quality and in biomarker detec-
tion in synovial uid to diagnose arthritis [51]. Renal stone composition has also been
determined using FTIR spectroscopy [51–53]. Cancer diagnostics is a particularly ac-
tive area with publications including cervical [18, 54, 55], lung [19, 56], prostate [57, 58],
colon [59–62], oesophageal [63–66], gastric [21], brain [31, 67] and skin [55] cancers.
FTIR microspectroscopy has also been applied to the detection of stem cells in cancer
research [25, 26, 68] and to the characterisation of cell-cycle variations [69].
1.4.1 Biouids
Biouids, including urine, saliva, whole blood, plasma and serum, and cere-
brospinal uid (CSF), are an attractive biological sample type for clinical diagnostics
because of the relative ease with which they can be obtained. Infrared spectroscopy
oers a reagent-free means of quantifying known components in biouids and for iden-
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tication global compositional changes associated with disease (e.g. cancer). In contrast
to many traditional biochemical tests, multiple components can potentially be simul-
taneously detected and quantied from a single spectrum. However, when developing
new clinical analytical methods, the new method must be validated by comparison to
the current ‘gold-standard’ and must be tested against a set of samples that spans the
physiological range taking into account any possible interferences. Both simple univari-
ate analysis protocols, such as peak integration, as well as more complex multivariate
methods, such as PLS regression and deconvolution by peak tting, have been applied
to analyses of biouid spectra.
1.4.1.1 IR analyses of blood and blood products
Whole blood, serum and plasma have been analysed by a number of groups
using IR spectroscopy for detection and quantitation of proteins, sugars and carbohy-
drates, lipids, creatinine and metabolites as well as disease-specic biomarkers. Pattern
recognition techniques have also been applied in an attempt to discriminate between
diseased and healthy samples.
Several groups have combined transmission IR spectroscopy with multivari-
ate calibration methods to detect and quantitate glucose, triglycerides, urea, cholesterol,
albumin, lactic acid and total protein in whole blood, serum and plasma samples, and
achieved high correlation with reference methods [48, 50, 70, 71]. Quantitation of glu-
cose has frequently been achieved using the ~1200-900 cm−1 spectral region, with spe-
cic peaks identied at 1035/1033, 1078, 1104 and 1146 cm−1 [48, 71]. Budínová et al.
(1997) [48] identied spectral peaks at 955, 1057 and 1371 cm−1 as being associated with
cholesterol, whilst lactic acid is reported to contribute to absorbance at 1127 cm−1 ac-
cording to Petibois et al. (2006) [67].
ATR-FTIR spectroscopy has also been applied to the analysis of blood products.
For example, Heise et al. (1995) [72] quantied glucose from ATR-FTIR spectra of spiked
plasma samples. Hoşafçi et al. (2007) [49] analysed ATR-FTIR spectra of whole blood
and plasma samples for albumin, cholesterol, glucose, total protein, urea and triglyc-
erides. PLS regression was used to build calibration models for each analyte in the three
sample types. Good correlation between ATR-FTIR and clinical methods was obtained
for all analytes, although the precise regions of the spectra used for calibration in each
case were not dened. The method had good sensitivity for quantitation of some com-
ponents, such as urea, protein and triglycerides, but for others, thresholds were dened,
below which quantitation of the given component was inaccurate but detection was still
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possible.
Detection of specic compounds in blood samples can be used diagnostically
for known diseases. For example, Petrich et al. (2000) [73] analysed transmission spec-
tra of dried serum samples from healthy and diabetic patients. PLS analysis was used
to quantitate glucose, triglycerides and cholesterol from the IR spectra and good cor-
relation with the gold-standard analytical methods (correlation coecients r2 = > 0.9)
was achieved. A supervised discriminant analysis with leave-one-out cross validation or
bootstrapping resampling (where data are randomly assigned to training and test sets)
methods gave good sensitivity, ranging from 71 to 92 %, and specicity, ranging from 73
to 100%.
Another study (Lacombe et al. (2015) [74]) used the 1200-900 cm−1 region
of transmission IR spectra of dried blood plasma samples to diagnose galactosemia, a
metabolic disorder in which galactose accumulates in the blood and urine. The galac-
tosemia patients spectra had lower overall absorbance in this region compared to the
healthy group and to a diabetic patient group. The diabetic patient spectra had the high-
est overall absorbance in the same region. Absorbances in this region were attributed
to carbohydrate but no explanation was given to explain why the galactosemic group
showed the lowest overall absorbance despite the expectation that galactosemic blood
would contain higher concentrations of galactose than healthy blood. It may be that the
overall carbohydrate prole in galactosemic patients is dierent to healthy patients, or
that galactose does not contribute as strongly in this region. Comparison to model spec-
tra of galactose would have been useful to help determine the cause of this discrepancy.
SVM classication with leave-one-out cross validation was used to classify the spec-
tra. The model performed best for separating diabetic and galactosemic patients spectra
where sensitivity was 93-95% with 97-100% specicity, but the accuracy for discriminat-
ing between healthy and galactosemic patients spectra was lower. However, no loadings
plots were presented to show which specic spectral features were contributing to the
separation of the groups.
Other diseases studied using transmission IR spectroscopy of serum samples
include liver brosis [75] and bovine spongiform encephalopathy (BSE) in cows [76].
The cow serum samples were measured both wet and dried, with dried samples aording
the best sensitivity and specicity. This study demonstrated that there is a compromise
to be made between the ease of sample preparation and reproducibility aorded by liquid
sample analyses, and the lower sample volume requirements and improved accuracy of
dried sample analyses [76]. Since the limitation in measuring the liquid samples, in this
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case, was due to the material used in the optical windows (CaF2 rather than the ZnSe
used for dried samples) there is potential for further optimisation, using transmission
or even ATR sampling methods, to improve the model performance when using liquid
samples.
Methods of detecting several cancer types in ATR-FTIR spectra of blood and
plasma samples have been developed, including bladder cancer [77], glioma [78], ovar-
ian and endometrial cancers [79]. Ollesch et al. (2013) [77] identied problems with
reproducibility when drying plasma and serum samples, including the need for very
precise volume measurements and samples drying in uneven layers, that resulted in
spectral artifacts that would make clinical translation dicult. They developed a robotic
dispensing system to overcome these problems and were able to obtain 93 % sensitivity
for detecting bladder cancer, but at only 46% specicity.
ATR-FTIR spectra of serum samples has also been applied to the diagnosis of
renal failure by Khanmohammadi et al. (2013) [80]. Samples were recorded unprocessed
and wet and analysed using a supervised pattern recognition method using soft indepen-
dent modeling of class analogy (SIMCA). Spectral dierences at 1470, 1370 and 1320 cm−1
were identied between normal and renal failure patients. A spectral window encom-
passing these wavenumbers was used to build the classication model which performed
with 100% sensitivity and 91.3% specicity.
1.4.1.2 IR analyses of urine
Urine can be collected non-invasively and without the need for a trained pro-
fessional to be present. It can also be collected frequently and stored for several days. It
is therefore ideal as a diagnostic medium if it can provide clinically useful information.
Like blood, urine has been studied with IR spectroscopy and methods have been
developed to detect and quantitate specic urinary components from IR spectra. Heise et
al. (2001) [81] used ATR-FTIR spectroscopy to analyse urine samples for urea, creatinine,
uric acid, glucose, total protein, phosphate and sulphate. Spectroscopic determination of
pH was also achieved by monitoring the equilibrium of mono- and di-basic phosphate,
which dier in their IR spectra. PLS analysis of the following spectral regions was used
for calibration: 1600-1000 cm−1 for urea, creatinine and uric acid; 1200-950 cm−1 for glu-
cose; and 1600 - 1250 cm−1 for protein. Correlation coecients for the ATR-FTIR method
versus the reference methods were generally high, ranging from r2= 0.934 for pH, to r2=
0.996 for sulphate, although calibration was not possible for glucose and protein.
Similarly, in the study by Hoşafçi et al. (2007) [49], mentioned in the previous
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section, 100 urine samples were analysed by ATR-FTIR spectroscopy for urea, uric acid,
phosphate and creatinine concentrations. Calibration models for additional urine com-
ponents were built using spectra of articial urine samples containing urea, phosphate,
creatinine, ammonia, sulphate, hydroxybutyric acid, acetoacetate, acetone, glucose and
uric acid. Again, good correlation with the reference methods was achieved.
Disease biomarkers have also been detected in urine using ATR-FTIR spec-
troscopy. Markus et al. (2001) [82] combined the technology with PLS regression to
analyse urine samples for diagnosis of alkaptonuria, a metabolic disorder in which high
levels of homogenistic acid are excreted into the urine. Urine samples spiked with ho-
mogenistic acid were used to build and test the model before it was tested against urine
from 4 alcaptonuria suerers. The 1530-1150 cm−1 spectral region was found to be op-
timum for building the model. High correlation of the ATR-FTIR calibration model with
clinical results was obtained for the validation samples (r2= 0.998). Homogenistic acid
was also successfully detected and quantied in the alcaptonuria patient urine, although
no comparison was made to the reference method. A point to consider is that the model
was built using 7 PLS factors but 98% of the variability in the calibration samples was
reportedly described by only the rst three. Noise may contribute to the remaining 4
factors and the model discrimination may be partly based on noise rather than clinically
relevant dierences in the spectra.
Many of the studies described here have used leave-one-out cross validation
when assessing the performance of the classication models. In most cases, replicas of
the test samples were included in the training set, which may lead to exaggerated model
performance.
1.4.1.3 Enhancing sensitivity of IR measurements of biouids
Laminar uid diusion interface (LFDI) microuidic devices have been pro-
posed as a preprocessing technique to enhance the sensitivity of FTIR measurements
of biouids. This technique can be used to separate components in samples based on
their molecular weight. It is particularly useful for analysing samples where high con-
centration components, such as proteins in serum samples, dominate the IR spectrum
making it dicult to detect more minor components. In the LFDI device a sample stream
and a receiver (e.g. water) stream run in parallel in laminar ow so that there is diusion
between the streams without mixing. Low molecular weight compounds diuse more
quickly into the receiver stream than larger molecular weight compounds such as pro-
teins, so that it becomes enriched with low molecular weight components. The resultant
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receiver stream can then be analysed in much the same way as the original sample in
transmission or ATR mode, wet or dried.
Shaw et al. (2009) [83] tested the use of an LFDI device to improve the sen-
sitivity of detecting creatinine in serum samples. After centrifugation, dried lms of
either 2 μL unprocessed plasma, or 40 or 120 μL LFDI receiver streams, were measured
in transmission mode. PLS calibration models were built using the second derivative
transformations of the IR spectra. The LFDI-processed samples showed a 17-fold in-
crease in the creatinine to albumin ratio compared to the unprocessed plasma samples.
Absorbance signals from creatinine could then be enhanced by increasing the thickness
of the sample and hence increasing the eective pathlength of the IR light. There was
also a more than 4-fold improvement in the standard error of calibration for the 120 μL
LFDI-processed sample compared to the 2 μL unprocessed sample. However, the sep-
aration and drying procedures followed here are laborious and time-consuming so not
suitable for clinical translation, and the use of LFDI technology to detect and quantitate
other diagnostic compounds in biouids has not yet been demonstrated. Nevertheless,
with further optimisation and integration with ATR technology the LFDI system could
provide an eective method of increasing the sensitivity of IR measurements for point-
of-care diagnostics.
1.4.1.4 IR analyses of kidney stones
FTIR spectroscopy has proved a useful method for compositional analysis of
kidney stones.
Channa et al. (2007) [52] recorded transmission FTIR spectra of 8 commonly
occurring stone compounds as references for analyses of 58 renal stones. 83% of stone
types were either mixed calcium oxalate and uric acid or pure calcium oxalate. Stru-
vite, pure uric acid, and mixed calcium oxalate and aspartate stones were also observed.
Cystine was not detected in any of the stones studied.
In stones from a Polish population studied by transmission FTIR spectroscopy
by Paluszkiewicz et al. (1988) [53] a high proportion were pure calcium oxalate, or a
mixture of calcium oxalate and phosphate. Struvite, calcium phosphate, uric acid and a
small proportion of cystine stones were also detected.
Mulready and McGoldrick (2012) [84] compiled a library of ATR-FTIR spectra
of kidney stones that combined standard reference spectra from common kidney stone
components (including calcium oxalate monohydrate, calcium oxalate dehydrate, cal-
cium hydrogen phosphate, hydroxyapatite, carbapatite, magnesium ammonium phos-
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phate and uric acid, as well as some rarer components including cystine and 2,8- dihy-
droxyadenine) with spectra from ‘real’ kidney stones from patients in the Republic of
Ireland. The use of real stones in the construction of the library allowed minor peak
shape and position variations, which are dependent on composition and environment,
to be taken into account. It was found that FTIR-based methods had superior sensitivity
to wet chemical methods and were able to detect minor or rare stone components more
readily. However, for some compounds, such as magnesium ammonium phosphate, ad-
ditional chemical tests were needed for accurate detection.
1.4.2 Tissue analyses and cancer diagnostics
FTIR spectroscopy can potentially detect changes in the biochemical compo-
sition of tissues during the progression from normal healthy tissue to invasive cancer.
In combination with multivariate analyses, spectral patterns that distinguish cancerous
from healthy tissue can be identied; this has become known as spectral histopathol-
ogy (SHP). Alternatively, analyses of specic wavenumbers can identify associated bio-
chemical changes indicative of disease, for instance glycogen and DNA are repeatedly
reported to be altered in cancerous samples and such changes have been detected using
FTIR spectroscopy.
1.4.2.1 Cervical and prostate cancers
Mordechai et al. (2004) [55] and Mark et al. (2004) [18] reported that spectra
of sectioned cervical cancer tissue samples imaged in transmission mode had lower ab-
sorbance at wavelengths associated with carbohydrate/glycogen, and higher RNA/DNA
peak intensity ratios at 1121/1020 cm−1 than spectra of normal cervical tissue. Mark et al.
(2004) [18] applied a probabilistic neural network (PNN) to their cervical cancer dataset
and achieved correct diagnoses for 90.95 % of normal, 84.28 % of mildly dysplastic, 89.46
% of moderately dysplastic and 83.26 % of severely dysplastic cervical tissue.
A diagnostic model using transmission FTIR microspectroscopy and principal
component discriminant function analysis was built for prostate tissue and scored 92.3%
overall sensitivity and 98.9 % overall specicity for classifying tissues into a three band
grading system [57]. The same group later applied their methods to evaluate 40 prostate
biopsies from 39 men. Importantly, when building their supervised classication model
patients included in the training set were not included in the test set. The resultant
classications based on the same three band grading system gave lower sensitivities of
70-84% and specicities of 72-88% than were previously reported by the group, probably
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as a result of the independent training and test sets used [85].
1.4.2.2 Lymph nodes
Bird et al. (2009) [86] analysed second derivative spectra extracted from trans-
ection FTIR images of lymph node tissue. They combined HCA with Ward’s clustering
algorithm of the ‘phosphate region’ between 1350 and 900 cm−1 using 9 clusters to reveal
the location of micro-metastases in lymph nodes.
1.4.2.3 Barrett’s oesophagus
Several groups have applied FTIR spectroscopy to the detection of Barrett’s oe-
sophagus and pre-malignant stages of oesophageal cancer. Wang et al. (2007) [66] ap-
plied LDA with leave-one-out cross validation to ATR-FTIR tissue spectra to distinguish
normal squamous tissue from Barrett’s oesophagus and gastric tissues, achieving 100 %
sensitivity and 97 % sensitivity. Samples containing Barrett’s dysplasia showed elevated
DNA absorbance bands at 1026, 1081 and 1154 cm−1 compared to non-dysplastic Bar-
rett’s. A unique band at 1117 cm−1 in gastric tissue was attributed to increased glycopro-
tein. Likewise, Quaroni and colleagues (2009) [65] combined HCA and Ward’s clustering
algorithm of the 1300-930 cm−1 spectral region using 5 clusters to discriminate between
normal squamous tissue, Barrett’s oesophagus and oesophageal adenocarcinoma from
transection FTIR images. Bands at 1029, 1079 and 1150 cm−1 in second derivative spec-
tra were attributed to accumulation of glycogen in Barrett’s tissue compared to normal
and adenocarcinoma tissue. Barrett’s tissue was also associated with absorbance bands
at 1080, 1124, 1171 and 970 cm−1 which were attributed to mucin.
1.4.2.4 Lung cancer
Lung cancer has also been studied by transmission FTIR spectroscopy, ATR-
FTIR spectroscopy and FTIR microspectroscopy. Yano et al. (1996) [87] attributed ele-
vated absorbance of the 1045 cm−1 peak in transmission spectra of lung carcinoma sam-
ples to increased glycogen. They later used FTIR imaging to study lung tissue cryosec-
tions and proposed a decrease in the 1467 cm−1 band of cancerous samples compared to
normal could be due to reduced cholesterol levels [20]. A study of FTIR images of lung
sputum recorded in reectance mode also suggested elevated glycogen in cancer sam-
ples based on increased absorbances at 1024 cm−1 and 1049/1051 cm−1 (normal/cancer).
The study also found amide I and II peaks were increased in cancer samples versus nor-
mal [56]. Similarly, increases in intensity of the 970 cm−1 and 1085 cm−1 bands in the
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reectance FTIR spectra of lung cancer cell lines were attributed to changes in DNA
structure or concentration [88]. Bird and colleagues (2012) [19] demonstrated the use
of spectral histopathology (SHP) as a tool for diagnosing lung cancer using a tissue mi-
croarray of 10 normal tissue spots and 70 lung disease tissue spots of dierent types.
FTIR images of the tissue spots were recorded in reection mode. An articial neural
network was used to develop a binary classication for diagnosing the dierent tissue
types. Normal tissue spectra could be distinguished from all other samples with high sen-
sitivity (99.3 %) and specicity (94.4 %). Sensitivities and specicities of over 90 % were
also reported for discriminating between most of the lung cancer tissue types studied.
ATR-FTIR spectra were analysed by Sun et al. (2013) [89] who reported signicant dif-
ferences between healthy and lung cancer samples for band widths at ~1303 and ~1240
cm−1, and for peak intensities at 1120 and 1546 cm−1. These features achieved 96.7 %
sensitivity.
1.4.2.5 Breast and ovarian cancers
Walsh et al. (2012) [90] studied breast tissue microarrays using ATR imaging
and Bayesian classication for structural characterisation as an alternative to traditional
H&E histology. They were able to identify newly formed blood vessels in the tumour
tissue and distinguish these from surrounding stromal cells. They also reported distinc-
tions between myoepithelial cells, which acts as markers for malignancy, and normal
epithelial cells, with spectral dierences occurring at 3800-2700 cm−1. However, since
this region can be inuenced by small changes in hydration and because these spectra
were normalised to the amide I band, where water also absorbs, changes may also be
inuenced by the extent of hydration of the dried tissue sections. Finally, terminal duc-
tal lobular units, where many breast cancers originate, were identied in ATR-images
by increased absorbance at 1300-1200 cm−1 compared to epithelial cells. This was at-
tributed to increased levels of collagen in intralobular stroma, with only low levels of
collagen in epithelial cells.
Normal, benign and malignant ovarian tissue transmission FTIR images were
studied by Krishna et al. (2007) [35]. Malignant tissue spectra had additional absorbance
bands at 828 an 857 cm−1, an increase in absorbance between 1200 and 1000 cm−1 and
an increased absorbance at 1734 cm−1, attributed to lipid. Normal tissue was found to
contain higher amounts of protein as judged by positive amide I and II peaks at 1652
cm−1 and 1553 cm−1 in dierence spectra. Benign tissue was found to have increased
DNA and lipid content, indicated by positive peaks at 1035, 1086 and 1131 cm−1, whilst
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positive peaks in malignant tissue spectra suggested increased lipid (1738 cm−1), DNA
(1092 and 1248 cm−1) and glycogen (1045 and 1074 cm−1).
1.4.2.6 Brain cancers
Gajjar et al. (2013) [31] applied ATR-FTIR spectroscopy to the discrimination
of dierent brain tumour types (meningioma, glioma including 3 subtypes, and brain
metastasis) using linear discrimination analysis (LDA) or PCA-LDA. Lipid (1740 cm−1)
to protein (1400 cm−1) ratios in were reportedly higher in normal tissue than in tumour
tissue. Phosphate (1045 cm−1) to carbohydrate (1545 cm−1) was reduced in high-grade
gliomas, whereas RNA (1121 cm−1) to DNA (1020 cm−1) ratios were reduced in menin-
gioma and slightly reduced in metastatic tumours. Absorbance bands contributing to
the discrimination between normal and dierent brain tumour type spectra were tenta-
tively assigned to glycogen (1018 cm−1), carbohydrate (1173 cm−1), amide I (1543, 1620,
1628, 1686 cm−1), amide II (1582, 1504, 1551 cm−1), lipids (1740, 1470, 1701 cm−1) and
phosphate backbone (1103, 1234 cm−1). However, these are speculative assignments
as without multiple peak correlations to model spectra it is impossible to assign these
changes to specic biochemical constituents. Many of these assignments overlap and
are even in contradiction to earlier assignments made when looking at absorbance ra-
tios. Furthermore, the results were not quantied in terms of sensitivity and specicity
so it is dicult to evaluate the ecacy of their method.
1.5 Aims
Although the research described in the preceding sections demonstrates the
potential of IR spectroscopy in diagnosing a variety of diseases, there has not always
been an adequate focus on developing methods that could easily be employed in the
clinic, and/or that provide signicant advantages over current diagnostic methods. For
example, simple diagnostic tests already exist for diabetes with simple glucose assays,
and galactosemia can be eectively screened for in newborns by a range of methods,
including colorimetric and chromatographic assays of galactose concentration in blood
and urine, enzyme activity assays, and genetic testing of blood samples [73, 74]. So,
there may not be a compelling need to develop FTIR-based diagnostic methods for such
diseases. Conversely, cancer diagnosis remains expensive and time-consuming and so
there is a need for improved methods of detection and staging. FTIR methods have been
applied to cancer diagnostics, though these methods also are generally complex and
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time-consuming, and so are dicult to translate to a clinical setting unless they can be
simplied.
FTIR-methods that are able to detect several compounds simultaneously in a
given sample may oer advantages even if simple clinical tests for those individual com-
pounds are available. For example, Hosafci (2007) [49], Heise (2001) [81] and Jessen
(2014) [70], described the quantitative analysis of multiple components in urine, whole
blood and blood plasma. However, these methods have not yet been translated into
clinical uses for the diagnosis of specic medical conditions.
The aims of the research presented in this thesis were to develop reproducible IR
spectroscopy methods that might be developed into clinical tools for diagnosing diseases
for which the current diagnostic methods are lacking in some way. Particular focus was
on developing statistically robust methods that are suciently simple and inexpensive
so that translation into clinical uses could become feasible.
A model compound spectral library is presented at the outset, which was used
to help assign features in biological sample spectra presented in subsequent chapters,
and can be used to to assess assignments made by others in published work.
Much of the clinical literature describes the analysis of dried samples (e.g. [73],
[74], [83], [90], [91]) but the potential dierences between wet and dried sample spec-
tra are only acknowledged by a handful of groups (e.g. [77], [76]). Because of this, the
inuence of hydration state on the infrared spectra of biological compounds, speci-
cally urinary components, was investigated and is described in Chapter 4. These anal-
yses highlighted the dramatic shifts that can occur between IR spectra of wet, dry and
partially-hydrated states. They showed the importance of recognition of such hydra-
tion eects when interpreting spectra of complex biological samples so that shifts due
to dierence in hydration are not erroneously interpreted as clinically-relevant signal
dierences.
Compositional analysis of kidney stones using FTIR spectroscopy has already
been incorporated into clinical use (see section 1.4.1.4), but, whilst this is useful in diag-
nosis, a method that can detect and identify multiple stone constituents in urine prior to
stone formation is desirable for better disease management. Kidney stone diseases, es-
pecially rare types such as cystinuria, are challenging to diagnose accurately by conven-
tional methods and therefore represent good targets for development of FTIR methods.
Chapter 5 describes development of a method for detecting and quantifying cystine, the
causative agent of cystinuria, from ATR-FTIR spectra of cystinuric patient urine samples.
The possibility of translation of FTIR spectroscopy in to the clinic is often al-
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luded to in the literature but in order to make this a reality the FTIR spectrometer must
be simple and stable enough for hospital installation. In addition, the operation protocol
must be fast and simple enough to be performed by a non-specialist. Several spectrome-
ter manufacturers now make small, benchtop ATR-FTIR spectrometers with room tem-
perature detectors that are stable to vibrations and easy to use. Chapter 6 describes how
one such machine was installed in a clinic at the Royal Free Hospital to analyse urine
samples in order to assess whether the data generated were of sucient quality for di-
agnostic use. This study also gives an insight into the practicality of routinely operating
such a machine in a clinical setting by medical sta with limited FTIR training.
Finally, the single-element detector ATR-FTIR methods used for urine analyses
were applied to pancreatic tissue analyses for detection of spectral changes associated
with cancer. Much of the FTIR cancer diagnostics literature focuses on using imaging
techniques, which, although promising in terms of their ability to detect early biochem-
ical changes associated with disease, are expensive, time-consuming and complex. Since
tissue samples are inherently more complex than urine samples they are more challeng-
ing to study with simple ATR-FTIR methods, but such methods have a better chance
of clinical adoption as, if eective, they oer considerable savings in time, money and
resources.
To summarise, the specic aims of this thesis were to:
• Generate a library of absorbance and second derivative ATR-FTIR spectra of wet
and dried compounds/materials, in particular focussing on human urine of healthy
and diseased patients, and healthy and tumorous human tissue.
• Investigate and explain the eects hydration states have on the infrared spectrum
of urea and other urinary compounds, including creatinine, ammonium ions, sul-
phate, phosphate and cystine.
• Develop a method to detect and quantitate urea and creatinine in urine samples
using ATR-FTIR spectroscopy.
• Rene protocols for measuring insoluble material in aqueous samples using ATR-
FTIR spectroscopy, particularly cystine, with the aim of developing a new diagnos-
tic method for cystinuria. Extend these urine analyses to other disease biomark-
ers, including dihydroxyadenine (DHA) for APRT-deciency, and trimethylamine
(TMA) as a marker for trimethylaminuria.
• Establish a large database of patient urine ATR-FTIR spectra and medical case
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histories using a simple benchtop ATR-FTIR spectrometer installed in a hospital
kidney clinic and correlate with clinical data.
• Analyse infrared signatures of fresh pancreatic tissue resections from normal and
pancreatic cancer patients.
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Chapter 2
Materials and methods
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2.1 Materials
2.1.1 Chemicals
Ammonium chloride, cystine, glucose, hydrochloric acid, potassium hydroxide,
potassium phosphate, sodium chloride, sodium dodecyl sulphate and sodium hydroxide
were purchased from VWR International BDH. Creatinine, picric acid, potassium sul-
phate and urea were purchased from Sigma-Aldrich. Sodium phosphate was purchased
from Fisons Chemicals.
2.1.2 Clinical samples
Five urine samples were collected from volunteer healthy donors at University
College London and Imperial College London, UK, for hydration eect analyses. These
were donated anonymously and so age/sex information is not available.
For developing urinary cystine analyses urine samples from 22 cystinuric pa-
tients, 5 healthy donors (controls) and 11 patients with other renal conditions (for crea-
tinine analysis only), were collected by Professor Robert Unwin and nurses, Faith Matjiu
and Cameron Davey, at the Kidney and Urology Centre, Royal Free Hospital, London,
UK. Urine was collected in 30 mL Sterilin specimen containers and measured fresh where
possible, a small number of samples were frozen and stored at -20 ºC before analysis. All
urine samples were collected after obtaining informed consent. The study was approved
at Royal Free London NHS Foundation Trust (R&D ref: 7727; REC number: 05/Q0508/6).
For dihydroxyadenine analyses a 2,8-dihydroxyadenine (DHA) stone/crystal
sample and additional urine samples were supplied by Kristin Hafsteinsdóttir, Reykjavik,
Iceland. Urine samples from two patients, one diagnosed with APRTd and the other with
suspected APRTd, were supplied by Professor Robert Unwin, Royal Free Hospital, Lon-
don. Three additional urine samples from three members of a family of APRTd suerers
were supplied by Emma Miler, Southend University Hospital, UK. Two urine samples
from a rat-model of APRTd (adenine-fed) and one urine sample from a control rat were
supplied by Richard Fish, Royal Free Hospital, London. All urine samples for DHA anal-
yses were received frozen and stored at -20 ºC before analysis.
For analyses of urine samples for kidney-related diseases using a benchtop spec-
trometer, 295 urine samples from 256 patients were collected by sta nurses, Faith Matjiu
and Cameron Davey, at the Kidney and Urology Centre, Royal Free Hospital, London.
Forty two additional urine samples from healthy volunteers with no known medical con-
ditions were collected at the Royal Free Hospital, Universtiy College London (UCL) and
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Imperial College London. All samples collected at the Royal Free Hospital were mea-
sured fresh. Samples collected at UCL and Imperial were stored at 4ºC and measured
within 24 hours.
Forty-three pairs of matched human pancreas tissue (43 tumour and 43 normal)
resections plus 3 unmatched tumour resections and 1 unmatched normal pancreas resec-
tion were collected during major pancreatic surgery at Hospital Curry Cabral, Universi-
dade Nova de Lisbon, Portugal, and immediately frozen on dry ice. Each pair of matched
tissue samples came from one individual, where the ‘normal’ pancreas tissue samples
were taken from regions of ‘healthy’ pancreas distant from the site of the tumour. The
tissue samples were shipped to UCL, London by Graça Soveral, Lisbon University, via
courier on dry ice.
2.2 Spectroscopic methods
2.2.1 ATR-FTIR and transmission FTIR spectroscopy
Spectra were recorded with a Bruker IFS/66S FTIR spectrometer with a globar
light source, liquid nitrogen-cooled MCT detector and a KBr beam splitter. The inter-
ferometer scanner velocity was set to 40 kHz and the optics were purged with dry air.
Experiments in ATR mode were run using a SensIR 3 reection silicon microprism with
ZnSe optics with a 1.5 mm aperture (Figures 2.1 and 1.3). Samples were placed in direct
contact with the microprism and the depth of penetration of the evanescent infrared
wave was approx. 0.5 - 2 μm depending on the wavelength and the refractive indices of
the prism and sample. For transmission mode experiments a 1 mm aperture was used
and samples were sandwiched between 2 mm thick CaF2 windows.
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BA
Figure 2.1: Bruker IFS/66S spectrometer. (A) The FTIR spectrometer is tted with (B) a SensIR 3
reection silicon microprism (also shown as a schematic in Figure 1.3).
Data were recorded in the mid-infrared range between 4000 – 600 cm−1. In or-
der to reduce noise 500 interferograms at 4 cm−1 resolution were coadded before Fourier
transformation to generate the power spectrum. The absorbance spectra were computed
versus a background of the clean prism surface (1000 interferograms) by application of
the Beer-Lambert law. Frequencies given are accurate to approx. 1 cm−1. All samples
were at room temperature during analysis.
2.2.2 FTIR spectroscopy using a benchtop FTIR spectrometer in
the clinic
Spectra were recorded with a Bruker Alpha FTIR spectrometer (Figure 2.2) with
an air-cooled globar source, a room temperature DTGS detector and a multi-layer coat-
ing Quarz beam splitter. The Alpha was tted with a permanently aligned RockSolid
interferometer with gold-mirrors. The housing was sealed and water vapour minimised
by convective desiccation. Experiments were run in ATR mode using a Platinum ATR
single reection diamond microprism. Data were recorded between 4000 – 600 cm−1.
The scanning speed of the Alpha interferometer is inherently slower than that of the
IFS/66S. Therefore, 50 interferograms at 4 cm−1 resolution were coadded before Fourier
transformation to provide a compromise between acquisition time and signal-to-noise
ratio of spectra. The absorbance spectra were computed versus a background of the
clean prism surface (100 interferograms). The Alpha was programmed to run diagnostic
tests to check wavenumber accuracy and water vapour every three months.
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Figure 2.2: Bruker Alpha FTIR spectrometer.
2.2.3 Transmission FTIR spectroscopy of volatiles
Spectra were recorded with a Bruker Vertex 80v FTIR spectrometer with a glo-
bar light source, liquid nitrogen-cooled MCT detector and a KBr beamsplitter. The inter-
ferometer scanner velocity was set to 40 kHz and the optics were evacuated. Experiments
were run in transmission mode with a 3 mm aperture and using a custom-built device de-
signed to contain vapour whilst providing a long (23 cm) optical pathlength through the
sample to increase sensitivity. Data were recorded between 4000 - 800 cm−1. 500 interfer-
ograms at 1 cm−1resolution were coadded before Fourier transformation and absorbance
spectra were computed versus a background of water vapour (500 interferograms).
2.3 Sample handling
2.3.1 ATR-FTIR measurements of liquid samples
All frozen samples were thawed at room temperature before analysis. Samples
were mixed by vortexing prior to analysis to ensure homogeneous distribution of solutes
throughout the sample. Spectra of solutions and liquids were recorded by pipetting a 20
μL aliquot of a sample on to the ATR microprism and recording FTIR spectra as described.
In some cases it was necessary to cover the sample with a small, concave volatiles cover
to avoid evaporation of solution constituents during measurement.
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2.3.2 Drying samples anddealingwith insolublematerial forATR-
FTIR spectroscopy
In some cases the signal intensities arising from compounds of interest were
much smaller than those of the many other IR-active components. In addition, since
only the rst few microns of a sample are probed by the evanescent wave of the IR beam
in ATR mode, settling of any particulate material onto the prism surface will lead to
unstable spectra. To both increase sensitivity and avoid instabilities due to insoluble
particle sedimentation, liquid samples were often dried on to the prism surface. After
mixing by vortexing, a 1-5 μL aliquot (depending on concentration) of a sample was
placed on the prism. Samples were dried by passing a gentle stream of dry nitrogen gas
over the sample at a ow rate of 300 mL/min (Figure 2.3). Extent of drying was judged
by the absence of water bands in the 3500 – 3100 cm−1 and 2100 cm−1 spectral regions.
The silicon microprism has hydrophobic properties, often causing more hy-
drophilic materials to dry unevenly or ‘clump’ slightly above the surface of the prism.
This leads to poor reproducibility and reduced sensitivity. Therefore, once dried, even
pressure was applied to the sample using a standard press (from SensIR) to ensure more
even and reproducible contact between the samples and the surface of the ATR prism.
Figure 2.3: Drying a sample on to the ATR prism with a gentle stream of dry nitrogen gas.
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2.3.3 Separating insoluble material
The sensitivity of detection of insoluble materials was increased by removing
soluble components from the sample before analysis. Typically, 1 mL sample aliquots
were centrifuged at 16000 gAV for 5-40 minutes to separate soluble and insoluble frac-
tions. Each pellet was resuspended in 1 mL double distilled water and mixed by vor-
texing. 5 µL aliquots of these suspensions were dried onto the prism surface and their
spectra recorded as described.
2.3.4 ATR-FTIR measurements of solids
Solid materials were ground into a ne powder before analysis. A small amount
of the powder was placed directly on to the ATR prism and even pressure was applied
using a standard press from SensIR to ensure good contact between the powder and the
prism surface.
2.3.5 Monitoring spectral changes associatedwithhydration states
2.3.5.1 Controlled rehydration of urea
3 µL of a 50 mM urea solution, prepared in double distilled water, was dried onto
the crystal with a gentle stream of dry nitrogen gas at a ow rate of 300 mL/min. This led
to loss of liquid water bands in the 3500–3100 and 1700-1600 cm−1 regions. Drying was
continued until the absorbance spectrum was stable in the 1700-1400 cm−1 region. The
sample was then allowed to equilibrate for several hours in atmospheres of controlled
humidities, imposed by placing dierent saturated salt solutions [92] (Table 2.1) in a well
within a chamber that enclosed the sample (Figure 2.4). Spectra were recorded when the
1700-1400 cm−1 region had stabilised.
Dried sample on ATR 
crystal
Humidification 
chamber Saturated salt solution 
placed in well of chamber
Figure 2.4: Schematic of the humidication chamber device.
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Table 2.1: Salt solutions and corresponding humidity at room temperature.
Saturated salt solution Humidity at room temperature (%)
H2O (no salt) (taken as)100
KNO3 94
KCl 84
NH4SO4 81
NH4Cl 79
NaCl 75
NaNO3 74
2.3.5.2 Serial dehydration of urinary components and urine
Spectral changes associated with varying hydration states were tracked by record-
ing serial spectra during the dehydration process. Three microlitre aliquots of dierent
solutions (50 mM urea, 10 mM creatinine, 29 mM ammonium chloride pH6, 100 mM
potassium sulphate pH7, 50 mM potassium phosphate pH7, 25 mM glucose, 12 mM cys-
tine suspension) and urine samples (diluted 1 in 4) were dried onto the prism and rehy-
drated by placing double distilled water in the humidication chamber described above.
Once the spectrum had stabilised, the humidication chamber was removed and a se-
ries of spectra (each an average of 10 interferograms; approx. 4 s data acquisition time)
were recorded whilst dry nitrogen gas was passed over the sample until the sample had
stabilised (typically 50-100 spectra over 3-7 minutes).
2.3.6 ATR-FTIR measurements of tissues
Samples were thawed on ice before their ATR-FTIR spectra were recorded as
described. In order to allow for possible heterogeneity of the tissue surfaces, two spectra
were recorded per sample and for each spectrum the sample was placed in a dierent
orientation on the prism. The prism was cleaned with double distilled water and ethanol
between recording the rst and second spectra of each sample. Morphological features
such as colour, texture and rmness were noted.
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2.3.7 Vapour phase measurements of volatile samples in trans-
mission mode
A custom-built module compatible with the Bruker Vertex 80v spectrometer
was built in order to enable measurement of transmission FTIR spectra of volatile sam-
ples (Figure 2.5). The device consisted of a stainless steel tube with CaF2 windows at
either end to allow the IR beam to pass through. In the centre of the tube there was a
small well on a removal plate in which the sample was placed. This allowed volatiles to
evaporate and their vapours to ll the tube through which the IR beam was passed. Once
the samples were placed inside the device, it was sealed and left for several minutes at
room temperature to allow the vapour and solution to equilibrate before recording the
spectra.
Figure 2.5: Vapour chamber device for transmission measurements of volatiles. Dry nitro-
gen gas can be passed through the tube to purge atmosphere before sample insertion.
2.4 Data processing and analyses
Spectral pre-processing techniques can be used to correct interferences and
measurement artefacts, remove noise, simplify spectra for easier deconvolution, and
normalise spectra. The following data processing steps were performed in OPUS 7, Orig-
inPro 8.6 or MATLAB R2012b using in-house scripts.
2.4.1 Data preprocessing
A major consideration when recording and analysing IR spectra is the strong
absorbance bands of water and water vapour. Since biological materials, and in particular
biouids such as urine, are high in liquid water, it is often necessary to remove the water
contribution from IR spectra to make deconvolution of other constituents easier. In cases
where samples cannot be dried before measurement, or where drying is undesirable,
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pure liquid water spectra can be subtracted from sample spectra (Figure 2.6 B). The water
band at approx. 2200 - 1900 cm−1 falls in a region of the spectrum that is relatively free
from other bands and the loss of this band in the sample spectrum can be used to monitor
the extent of subtraction. This can be an eective pre-processing method, although the
spectrum of water can be inuenced by solutes, particularly strongly hydrogen-bonding
compounds, resulting in less accurate subtractions. Where samples have been prepared
in other solvents, buers or media such as paran, spectra of these can also be subtracted
from sample spectra.
Here, a spectrum of liquid water was subtracted from each wet sample spectrum
until the integrated peak area between 2200 - 2000 cm−1 was minimised, whilst not
distorting the rest of the sample spectrum.
Contributions from water vapour can be partially removed from spectra by frac-
tional subtraction of a pure water vapour spectrum (Figure 2.6 A). However, this can
be imprecise as the water vapour spectrum is a distortion of the true spectrum since
the very narrow bands cannot be accurately resolved. Therefore it is best to minimise
water vapour contributions at the time of measurement. This can be achieved by purg-
ing the optics of the spectrometer with dry air/nitrogen gas or desiccants or keeping
them under vacuum to remove any internal water vapour. Since environmental water
vapour varies and is inuenced by weather, humidity and human breath, it is important
to record background spectra close in time to sample measurements to minimise the dif-
ference in atmospheric water between background and sample scans. In addition, water
vapour spectra for subtraction should be recorded on the same instrument and with the
same measurement parameters as the sample spectrum with environmental conditions
matched as closely as possible [41, 93, 94].
The contributions of water vapour variations in the optical path were removed
from all sample spectra by fractional subtraction of a pure water vapour spectrum un-
til further subtraction began to introduce baseline distortions in the 2100 – 1250 cm−1
region.
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Figure 2.6: Water vapour and liquid water spectra. (A) Pure water vapour spectrum. A back-
ground measurement of the clean prism was recorded. The purge gas to the optics was then turned o
and water vapour was allowed to accumulate for 20 minutes before a sample spectrum was recorded
of the clean prism. The spectrum is characterised by many sharp absorbance bands between ~2080
and 1290 cm−1 and between ~3270 and 4000 cm−1. (B) Liquid water spectrum. Liquid water has a
strong broad absorbance band between ~3750 and 3000 cm−1 and a prominent sharper band at 1638
cm−1. There is also a broad low intensity absorbance band between 2300 and 1900 cm−1.
True random noise can be reduced by simply averaging multiple scans of the
same sample. Further de-noising of spectra can be achieved through smoothing, com-
monly using the Savitsky-Golay algorithm, although care must be taken to avoid in-
terpreting distortions as true signal variations and to avoid smoothing out true signals.
Other methods of de-noising include wavelet de-noising (WDN), which is thought to be
most eective when the sample gives rise to high-frequency absorbance bands. Spectra
recorded on the benchtop Alpha spectrometer were smoothed using the Savitsky-Golay
algorithm with a 9 point window.
The Savitsky-Golay algorithm is also frequently applied before dierentiation
of absorbance spectra since dierentiation inherently enhances spectral noise. Calcula-
tion of the second derivative of the absorbance spectrum narrows peaks allowing easier
deconvolution, particularly in spectral regions where multiple absorbance bands over-
lap, and removes broad baseline drifts. Comparison of derivative spectra with corre-
sponding absorbance spectra can be useful to help identify which bands are noise and
which are true signals. Baseline correction techniques, such as piecewise linear and rub-
ber band baseline correction can also be applied to spectra [41, 42]. Second derivatives
of the absorbance spectra were computed using the Savitzky-Golay algorithm with a 17
point window (or a 9 point window for pre-smoothed spectra recorded on the Alpha
benchtop spectrometer).
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Normalisation of spectral data is often required to allow for dierences in sam-
ple thickness or concentration so that dierent sample spectra can be directly compared.
Spectra can be normalised to the intensity (min-max) or area of a peak expected to be
constant between samples (often, amide I or II peaks for tissue samples or a urea peak in
urine). In general, it is best to avoid normalisation to a peak where water also absorbs
as water content can vary between samples. Vector normalisation is often applied to
derivative spectra where specic single peak for normalisation cannot be identied; the
data are scaled so that the sum of the square of all intensity values equals one. Stan-
dard normal variate (SNV) normalisation is another alternative that can also be used for
scatter correction [41, 42, 95, 96].
Here, spectra were typically normalised to the intensity of a dominant band in
the spectrum. Tissues samples were normalised to the intensity of the amide II band
in the second derivative spectra (intensity at 1547 cm−1 minus intensity at 1527 cm−1).
Urine samples were normalised to the area of the urea band at 1468 cm−1 in the ab-
sorbance spectra (integrated area between the spectrum and a linear baseline between
1487 and 1436 cm−1).
2.4.2 Ramping of ATR-FTIR spectra
In general, the thickness of the samples was sucient to ll the entire active
volume above the prism surface. Hence, in order to adjust the ATR spectra for the dis-
tortion caused by the frequency-dependency of the pathlength [3], ATR data of urine
samples between 1510 and 1410 cm−1 were ramped before tting of components by
multiplying absorbance values by a factor of (wavenumbermax/wavenumber) to allow
for the inverse relation between eective pathlength and wavenumber. However, be-
cause the wavenumber range used for tting is very narrow (100 cm−1), this correction
is extremely small and, in practice, does not signicantly alter the tting parameters or
the relative areas of the best ts.
2.4.3 Curve tting
Decomposition of spectra using curve tting analysis was performed using the
‘Peak Analyzer’ function in Origin version 8.6. Spectra were simulated with combina-
tions of Gaussian, Lorentzian and/or pseudo-Voigt functions. The functions used to t
the Gaussian (Eq. 2.1), Lorentzian (Eq. 2.2) and pseudo-Voigt (Eq. 2.3) components were
as follows:
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where y0 = baseline oset, A = amplitude, mu = prole shape factor, w = full width at
half maximum peak height (FWHM) and xc = peak centre. The pseudo-Voigt function
is the weighted sum of a Gaussian and a Lorentzian functions, where the prole shape
factor (mu) species the fraction contribution of the Lorentzian function to the overall
t. A single width (w) was used to describe Gaussian and Lorentzian components of the
pseudo-Voigt function [7, 8, 97, 98].
2.4.4 Integration analysis
A simple integration analysis was used to assess the dierences between spectra
from dierent groups of samples. Once bands of potential signicance were identied
in the spectra, limits of integration for each band were dened. Generally, these limits
were selected in order to include at least two-thirds of the band. The area of the band was
then found by integration between the spectrum and a linear baseline between the de-
ned limits according to the trapezium rule using an in-house script written in MATLAB
R2012b software.
Where univariate analyses were performed, the Shapiro-Wilk test of normal-
ity was rst performed on the data in OriginPro 8.6 with a signicance level of 0.05.
This conrmed whether or not the data were normally distributed and, hence, whether
parametric or non-parametric analyses should be applied.
Mann Whitney U analysis was performed with OriginPro 8.6 software to quan-
titatively compare the feature areas. Two-tailed tests were applied in which the null
hypothesis in each case was that there was no dierence between the distributions of
feature areas of the two groups in question. The alternative hypothesis was that there
was a dierence between the distributions. The signicance level used was 0.05 which
equates to 0.025 at either end, but p-values are also included to show which features are
also dierent at a signicance level of 0.01.
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2.4.5 Bland-Altman analysis
Bland-Altman plots [99] were used to compare the FTIR and Jae methods for
quantitating creatinine and the FTIR and ion-exchange chromatography methods for
quantitating cystine. The mean bias for each plot was calculated and plotted as a dashed
line and 95% condence limits (mean bias +/- 1.96 standard deviations) are indicated by
dotted lines.
2.4.6 Partial least squares (PLS) logistic regression
Tissue spectra were analysed by PLS logistic regression. PLS regression was ap-
plied to generate latent variables (LVs) from the original dataset (see introduction for de-
tails). In this case, the x-variables represented the absorbance values at each wavenum-
ber, and the y-variables represented the normal pancreas or tumour class assignments.
The LVs represent the variations between spectra. Each sample spectrum is compared to
each LV/loading and scores are assigned based on how much each loading contributes to
the given sample spectrum. A classication model was then built by performing logistic
regression using the PLS LVs as covariates.
PLS logistic regression was performed using the PLS_toolbox (from Eigenvec-
tor) in MATLAB R2012b. Spectra were cut between 1800 and 950 cm−1 and all data (x and
y) were mean centred. The default SIMPLS algorithm in the PLS_toolbox was applied for
PLS regression. Leave-one-patient-out cross validation was used to assess the predictive
ability of the model (part of this process utilised a script written by Liberty Foreman).
The spectral region and number of LVs used to build the PLS logistic regression models
were optimised on a case by case basis as detailed in results Chapter 7.
2.4.7 Calculation of sensitivities and specicities
The performances of the PLS logistic regression models were evaluated by cal-
culation of the sensitivities, specicities and overall accuracies. Sensitivity describes the
extent to which positive cases for a given group are correctly identied as such and false
negatives are minimised. Sensitivity is calculated as shown in equation 2.4. Specicity
describes the extent to which false positives are minimised as shown in equation 2.5.
The calculation for accuracy is shown in equation 2.6.
Sensitivity =
TP
TP + FN
(2.4)
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Specificity =
TN
TN + FP
(2.5)
Accuracy =
TP + TN
TP + TN + FP + FN
(2.6)
where TP = true positive, FP = false positive, TN = true negative and FN = false negative
[46].
2.5 Electronic structure modelling of urea-water and
urea-urea structures
Infrared spectra of urea-water and urea-urea molecular ensembles were mod-
elled. Firstly, nominal molecular models were built by stepwise addition of water or urea
using Facio 18.6.2 [100]. Structures were then energy minimised using Gaussian 09 soft-
ware [101] with the B3LYP density function in conjunction with the 6-31G(d) basis set,
using the UCL Legion supercomputer facility. Calculations were performed in vacuum.
Vibrational spectra were then simulated with the energy-minimised structures. Sim-
ulated frequencies were visualized with Facio 18.6.2 after scaling [102] with the Facio
default factor of 0.9614. The predicted infrared spectrum of creatinine was modelled in
the same manner.
2.6 Urine analyses
2.6.1 Generation of urea and creatinine calibration curves
Solutions of urea (25 mM – 200 mM) and of creatinine (2 mM – 30 mM) were
prepared in double distilled water. A mixture of 100 mM urea and 10 mM creatinine was
also prepared. 20 µL aliquots were placed on the ATR prism and the FTIR spectra were
recorded as described. Signal intensities were used to generate calibration curves for
these compounds to enable quantitation of urea and creatinine in urine.
2.6.2 Generation of a cystine calibration curve
A 32 mM stock solution of cystine was prepared by dissolving microcrystalline
cystine in 1M HCl; 50 mM sodium phosphate was added followed by 1M NaOH to neu-
tralise, generating a very ne precipitate of cystine. The suspension was adjusted to
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pH 7 with NaOH. This stock suspension was mixed by vortexing and diluted with urine
from healthy human donors to give 1 mL samples of 0 to 3 mM total cystine. After mix-
ing the insoluble fractions were separated and ATR-FTIR spectra of dried aliquots were
recorded as described. A calibration curve was generated based on signal intensities to
enable quantitation of cystine in urine (intensity 1296 cm−1 minus 1280 cm−1).
2.6.3 Quantitation of creatinine by the Jae reaction
The Jae reaction is the current method used in standard clinical practice for
quantitating urinary creatinine. The Jae working reagent was prepared by mixing ve
parts of 200 mM NaOH with one part of 40 mM picric acid. Absorbance at 510 nm
was monitored using a Shimadzu 50000 UV/Visible spectrophotometer at 25 °C. 0-30
mM creatinine standards and urine samples were diluted 50-fold. Three millilitres of
working reagent were placed in a glass cuvette and the rate of change of absorbance at
510 nm was recorded on addition of 200 µL diluted creatinine or urine. The initial rates of
reaction after addition of known quantities of creatinine were plotted versus creatinine
concentrations to generate a calibration curve for estimation of urine creatinine levels.
2.6.4 Standard clinical quantitation of cystine
Ion-exchange chromatography is the gold standard in clinical amino acid anal-
ysis [103, 104]. Urine samples were sent to the Camelia Botnar Laboratories at Great
Ormond Street Hospital for urinary cystine analysis using a Biochrom 30+ Amino Acid
Analyzer. Samples were warmed to room temperature, deproteinised with sulphosaly-
cic acid containing norleucine internal standard, then loaded onto a column linked to
sulphonate groups to permit charge-charge interaction. Amino acids were sequentially
eluted over 2-3 hours with increases in temperature, pH and ion strength using lithium
citrate.
2.6.5 Vapour phase measurements of trimethylamine (TMA)
Ten millimolar and 1 mM solutions of TMA in double distilled water were pre-
pared. One hundred microlitre aliquots were placed inside the vapour-measurement
device and spectra recorded as described.
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2.6.6 Solution phase measurements of TMA and TMA N-oxide
Solutions of 50 mM TMA in 50 mM phosphate buer pH 7.25; 25 mM TMA
N-oxide in 25 mM phosphate buer pH 7; and 5 mM TMA N-oxide in 5 mM phosphate
buer pH 7 were prepared. Spectra were recorded with a Bruker IFS/66S FTIR spec-
trometer as described except that 1000 interferograms were averaged. The absorbance
spectra were computed versus a background of phosphate buer (at pH and concentra-
tion corresponding to each sample) or of the clean prism surface (5000 interferograms).
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Chapter 3
Model compounds
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3.1 Introduction
Since most biological compounds are infrared active, spectra of biological sam-
ples tend to be complex, with many overlapping absorbance bands. This can make de-
convolution of the spectra dicult and it is not always possible to make assignments
based on only a single band. In some cases, it can be possible to positively identify a
specic compound if several associated absorbance bands are present at the expected
relative intensities. Model spectra of individual compounds under dierent conditions
(i.e. in solution versus dried or at dened pH values) can be compared to complex sample
spectra to determine whether the unique spectral band patterns can be seen.
When comparing sample spectra to model compound spectra it is important
that the environment of the model matches the environment of the sample as closely
as possible. For example, hydrogen bonding can cause an upshift in absorbance band
positions, therefore spectra of compounds in solution can dier from spectra of the
same compound dried. Furthermore, interactions with surrounding molecules can in-
uence the relaxation rate and/or coherence of vibrating molecules and lead to dier-
ences in lineshapes between solid, liquid and gaseous states. An additional consideration
is whether the compound of interest contains any ionisable groups, in which case it is
important to consider the pH/ionic strength of the sample and model, as dierent pro-
tonation states will have dierent IR spectra.
As well as aiding in the identication of specic compounds of interest, model
spectra of dominant compounds in a sample can be subtracted from sample spectra to
better reveal underlying minor components that would otherwise be hidden. Model
spectra can also be used to generate calibration curves, based on intensity or area of
absorbance bands, that can be used to quantitate specic compounds in some types of
biological samples.
3.2 Urine-related compounds
After water, urea is the next most dominant component in urine. Creatinine is
also a major component and is typically used clinically for normalising urine concen-
trations. Other constituents include chlorides, ammonium ions, phosphates, sulphates
and other minor metabolites including organic compounds and organic and inorganic
salts [105–107]. Some diseases can result in elevated levels of certain metabolites, for
example, patients with kidney stone disease may have raised urinary oxalate, urate, uric
acid, carbonates or cystine, and diabetic patients may have excess glucose in their urine.
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Breakdown products of certain foods and drugs may also be excreted in urine at de-
tectable levels [52, 108].
For detecting and quantitating major components, such as urea and creatinine,
wet spectra of urine are adequate. In some cases it is necessary to dry the urine to
remove the dominant absorbance bands of water and increase the relative concentration
of more minor metabolites in the active area of the prism to increase their absorbance
band intensities. Therefore, a solution spectrum and a dried spectrum were recorded for
each compound. In some cases a spectrum of the solid, crystalline compound was also
recorded. Compounds with ionisable groups were buered with potassium phosphate
to pH 6 or 7, as this is the approximate pH range of a typical urine spectrum. In such
cases, pH-dependent spectra of the phosphate buer can be subtracted to leave the pure
model compound spectrum.
Figures 3.1 to 3.5 show the model spectra of the main urinary constituents, in-
cluding urea, creatinine, ammonium chloride (adjusted to pH 6 with phosphate buer),
potassium phosphate (pH6) and potassium sulphate (pH 7). For each compound a solu-
tion spectrum after subtraction of pure water and water vapour spectra, and the corre-
sponding dried spectrum, are shown, along with the second derivative transformations
of each absorbance spectrum (shown immediately below).
Figure 3.1 shows model spectra of solution and dried urea. Urea is a waste prod-
uct formed during the metabolism of nitrogen-containing compounds, such as dietary
protein, in the body [106]. The IR spectrum of urea is relatively simple in the ‘nger-
print’ region. Distinct bands can be seen at 1468 cm−1 (solution) or 1464 cm−1 (dried) due
to the antisymmetric CN stretch, and at 1159/1152 cm−1 due to NH rocking vibrations.
Three overlapping bands are also seen between 1700 and 1500 cm−1 in absorbance spec-
tra (symmetric and antisymmetric NH bend and CO stretch) [109, 110], which become
reasonably well resolved in the second derivative transformations.
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Figure 3.1: Model spectra of urea. (A) Solution absorbance spectrum after subtraction of pure
water and water vapour spectra. (B) Dried absorbance spectrum. (C) Second derivative of spectrum
in A. (D) Second derivative of spectrum in B.
Creatinine is a larger molecule than urea, and is produced from the breakdown
of creatine phosphate in muscle [106]. It has a more complex absorbance spectrum (Fig-
ure 3.2) with prominent bands at 1492, 1348 and 1253 cm−1 in the solution absorbance
spectrum, as well as other overlapping band between 1750 and 1550 cm−1 and lower
intensity bands at 1427 and 1099 cm−1 (Figure 3.2 A).
67
100011001200130014001500160017001800
Wavenumber (cm−1)
A
bs
or
ba
nc
e
100011001200130014001500160017001800
Wavenumber (cm−1)
d2
(A
bs
)/d
2
(c
m
−1
)
100011001200130014001500160017001800
Wavenumber (cm−1)
A
bs
or
ba
nc
e
100011001200130014001500160017001800
Wavenumber (cm−1)
d2
(A
bs
)/d
2
(c
m
−1
)
A
C D
B1492
16
95
16
35
16
03
13
48
12
53
14
27
10
99
16
66
15
89
14
99
14
19
13
32
12
44
11
09
10
391
21
3
16
95
16
35
16
00
1492
14
26
13
49 12
52 11
00
16
98
15
90
1666
14
98
14
23
13
31
12
43
12
10
11
12
10
39
Figure 3.2: Model spectra of creatinine. (A) Solution spectrum after subtraction of pure water
and water vapour spectra. (B) Dried spectrum. (C) Second derivative of spectrum in A. (D) Second
derivative of spectrum in B.
Ammonium ions (Figure 3.3) are produced during renal metabolism [111]. Its
main absorbance is at around 1406 cm−1 with a shoulder at about 1441 cm−1. The
absorbance bands between 1150 and 950 cm−1 are mainly attributed to the phosphate
buer, which has not been subtracted in this case since the absorbance bands of phos-
phate do not overlap with those of ammonium ions.
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Figure 3.3: Model spectra of ammonium ions. All solutions were buered to pH6 with phosphate
buer. (A) Solution spectrum of ammonium chloride after subtraction of pure water and water
vapour spectra. (B) Dried spectrum. (C) Second derivative of spectrum in A. (D) Second derivative
of spectrum in B.
Phosphate (Figure 3.4) and sulphate (Figure 3.5) ions absorb strongly between
1200 and 900 cm−1, with the rest of the ngerprint regions up to 1800 cm−1 being rela-
tively featureless.
Phosphate ions in solution have strong absorbance bands at 1157 and 1076 cm−1
(Figure 3.4 A) due to the PO stretch [4]. The positions of these bands are very sensitive
to changes in pH and can be used to deduce the pH of a sample.
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Figure 3.4: Model spectra of potassium phosphate at pH 6. (A) Solution spectrum after sub-
traction of pure water and water vapour spectra. (B) Dried spectrum. (C) Second derivative of spec-
trum in A. (D) Second derivative of spectrum in B. The solution was adjusted to pH6 with potassium
hydroxide.
Sulphate has a strong broad band at 1085 cm−1 in the solution absorbance spec-
trum (Figure 3.5 A).
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Figure 3.5: Model spectra of potassium sulphate at pH 7. (A) Solution spectrum after subtrac-
tion of pure water and water vapour spectra. (B) Dried spectrum. (C) Second derivative of spectrum
in A. (D) Second derivative of spectrum in B. The solution was adjusted to pH7 with potassium
hydroxide.
In addition to these major urinary constituents there are a number of more mi-
nor metabolites and disease-associated compounds that are found in some urine samples.
These include compounds such as sugars, stone-forming compounds and other indica-
tors of kidney malfunction, such as protein [108] (model protein spectra are shown in
the next section describing tissue-related compounds).
Figure 3.6 shows the model spectra of glucose in solution after subtraction of
pure water and water vapour spectra, and dried. The second derivative transformations
of the absorbance spectra are also shown immediately below. The main absorbance
bands are between 1200 and 950 cm−1 attributed to CO stretching and bending vibrations
[4].
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Figure 3.6: Model spectra of glucose. (A) Solution spectrum after subtraction of pure water and
water vapour spectra. (B) Dried spectrum. (C) Second derivative of spectrum in A. (D) Second deriva-
tive of spectrum in B.
Figure 3.7 shows the model spectra of selected stone-forming compounds. Since
these are particularly hydrophobic in nature their absorption band peak positions do not
shift signicantly between wet and dried states so only dried or solid spectra of each
compound have been shown.
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Figure 3.7: Model spectra of selected stone-forming compounds. (A) Dried cystine. (B) Solid
dihydroxyadenine. (C) Second derivative of spectrum in A. (D) Second derivative of spectrum in B.
(E) Dried solution of oxalate, buered to pH 6 with phosphate buer. (F) Dried solution of citrate,
buered to pH 6 with phosphate buer. (G) Second derivative of spectrum in E. (H) Second derivative
of spectrum in F. (I) Solid sodium urate. (J) Solid uric acid. (K) Second derivative of spectrum in I.
(L) Second derivative of spectrum in J.
3.3 Tissue-related compounds
Tissue spectra are more complex than urine spectra, since they contain many
dierent types of proteins, carbohydrates, lipids, small metabolites, DNA and RNA. Spec-
tra are usually dominated by the amide I and amide II absorption bands of protein, al-
though it is usually not possible to distinguish between dierent types of protein, since
all are made up of dierent combinations of the same amino acids in approximately equal
distribution. The absorbance signals of the amino acid side chains are therefore aver-
aged in the nal protein spectrum. It is sometimes possible to distinguish proteins that
contain a particularly high proportion of a particular amino acid, or if covalently bound
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to another type of compound, such as a sugar. In fresh tissue, water also contributes
signicantly to the absorbance spectrum, although not to the same extent as is seen in
wet urine spectra. In dried tissue, partial rehydration can occur when exposed to at-
mospheric moisture. Since this can have a signicant eect on infrared spectra of some
compounds it is important to control the atmospheric humidity during measurements.
Figure 3.8 shows the model absorbance spectrum and second derivative trans-
formation of solid bovine serum albumin (BSA), as a general model for protein. The
amide I band is centred around 1648 cm−1 and the amide II band is centred around 1533
cm−1 [4]. The amide I or amide II bands can be used to normalise tissue spectra, however
since the amide I band overlaps with a strong absorption band of water normalisation
to the amide II band is the preferred method.
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Figure 3.8: Model spectrum of solid bovine serum albumin. (A) Absorbance spectrum. (B)
Second derivative of absorbance spectrum.
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Collagen is an extracellular protein and the main constituent of connective tis-
sue. Although it is generally not possible to distinguish dierent types of protein by IR
spectroscopy as the overall amino acid composition is often very similar, it is potentially
possible to detect dierences in the collagen spectrum due to the high content of hydrox-
yproline (Figure 3.9). The model spectra of hydroxyproline can also be seen in Figure
3.16. Changes in collagen content of dierent types of breast tissue were identied by
Walsh et al. (2012) [90].
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Figure 3.9: Model spectra of collagen. (A) Solution spectrum after subtraction of pure water
and water vapour spectra. (B) Dried spectrum. (C) Second derivative of spectrum in A. (D) Second
derivative of spectrum in B.
Creatine is found in high concentrations in human muscle cells, where it is used
to store and liberate energy via ATP. It is also found in high concentrations in the blood
as it is transported from its site of synthesis, primarily in the kidney and liver, to muscle
(and brain) cells. Its model spectra are shown in Figure 3.10.
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Figure 3.10: Model spectra of creatine. (A) Solution spectrum after subtraction of pure water
and water vapour spectra. (B) Dried spectrum. (C) Second derivative of spectrum in A. (D) Second
derivative of spectrum in B.
Lipids are found in cell membranes and changes in lipid content of tissue has
been correlated with various cancers [20,31,35,112]. The model spectra of phosphatidyl-
choline and cholesterol are shown in Figures 3.11 and 3.12, respectively. As well as the
ngerprint regions from 1800 to 950 cm−1, spectra showing absorbances up to 4000 cm−1
are also included (Figures 3.11 A & C and 3.12 A & C) since lipids have strong absorbance
bands between 3000 and 2750 cm−1, attributed to CH stretching vibrations [4], which
are regions that are relatively free of contributions from other compounds.
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Figure 3.11: Model spectra of phosphatidylcholine. (A) Full spectrum from 4000 - 950 cm−1.
(B) Fingerprint region only, 1800 - 950 cm−1. (C) Second derivative of spectrum in A. (D) Second
derivative of spectrum in B.
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Figure 3.12: Model spectra of cholesterol. (A) Full spectrum from 4000 - 950 cm−1. (B) Fingerprint
region only, 1800 - 950 cm−1. (C) Second derivative of spectrum in A. (D) Second derivative of
spectrum in B.
Glycogen is a glucose storage polysaccharide found mainly in liver and muscle
cells. Many studies have correlated changes in tissue glycogen content with cancer [18,
31, 35, 55, 56, 65, 66, 87]. Unsurprisingly, the absorbance spectrum of glycogen (Figure
3.13) is similar to that of glucose (Figure 3.6), with the main absorbance bands being
found between 1200 and 950 cm−1 due to CH stretching and bending, OH bending and
CC stretching vibrations [4].
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Figure 3.13: Model spectra of glycogen. (A) Absorbance spectrum. (B) Second derivative of
absorbance spectrum.
Figure 3.14 shows the model spectra of RNA and DNA (DNA spectral data pro-
vided by Liberty Foreman). Strong absorbance bands can be seen the the 1200-950 cm−1
region corresponding to phosphate and are likely to be contributed to by the PO−2 stretch-
ing of the backbone and CO stretching vibrations [4]. The broadening of all the bands
in the ngerprint region suggests that some water remained in the sample during mea-
surement. Changes in RNA/DNA of cancerous tissue have been reported by a number
of research groups [31,35,86,88,113], with specic bands of DNA being identied at 970
and 1085 cm−1 [88], 1020 cm−1 [18, 31, 55], 1092 and 1248 cm−1 [35], and at 1121 cm−1
for RNA [18, 31, 55].
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Figure 3.14: Model spectrum of RNA and DNA. (A) Absorbance spectrum of RNA. (B) Ab-
sorbance spectrum of DNA (DNA spectral data provided by Liberty Foreman). (C) Second derivative
of spectrum in A. (D) Second derivative of spectrum in B.
Mucins are proteins secreted by epithelial cells and are the main constituent
of mucus. They are highly glycosylated, which helps distinguish their IR spectra from
that of other proteins. Their spectra (Figure 3.15) contain many absorbance bands in the
ngerprint region between 1800 and 950 cm−1, with strong absorbance signals between
1150 and 950 cm−1 due to the sugars.
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Figure 3.15: Model spectra of mucin. (A) Absorbance spectrum. (B) Second derivative of ab-
sorbance spectrum.
Figures 3.16 to 3.17 show the model spectra of selected amino acids with dis-
tinctive IR spectra. If a protein contains a high percentage of such amino acids it may
be possible to detect their IR signals in complex mixtures.
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Figure 3.16: Model spectra of hydroxyproline. (A) Solution spectrum after subtraction of pure
water and water vapour spectra. (B) Solid spectrum. (C) Second derivative of spectrum in A. (D)
Second derivative of spectrum in B.
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Figure 3.17: Model spectra of selected poly-amino acids. (A) Solid poly-L-tryptophan. (B) Solid
poly-L-tyrosine. (C) Second derivative of spectrum in A. (D) Second derivative of spectrum in B.
3.4 Discussion and conclusions
The spectra presented here represent some, but not all, of the compounds that
might be expected in human urine and tissue samples.
Human urine is a relatively simple mixture and most compounds in urine can
be condently identied and quantitated by comparison to model compound spectra
(e.g. [49, 81, 82]). Since water makes up 95 % or more of urine it is usually necessary to
remove the contribution of liquid water from sample spectra in order to extract infor-
mation about the other components. After water, urea is the next most concentrated
component in urine and can be identied by the absorbance band at 1468 cm−1 in so-
lution spectra (Figure 3.1 A). The strong absorbance bands of urea between 1700 and
1550 cm−1 are also useful for conrming the urea assignment but residual water can
inuence the shape and intensity of these bands. Similarly, creatinine has a similar ab-
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sorbance band pattern between 1700 and 1550 cm−1 making it dicult to discriminate
between the two compounds using this region alone.
Creatinine has a strong absorbance band at 1492 cm−1 in solution, which shifts
up to 1499 cm−1 in dried spectra (Figure 3.2 A & B). Although this band overlaps the
1468 cm−1 band of urea, the peak falls in a region that is free from absorbances of other
major urinary components and would appear as a distinctive shoulder on the urea band.
This is a useful feature as quantitation of creatinine is used clinically for normalising the
concentrations of other urine constituents. The 1348 cm−1 band of creatinine, though
lower intensity than the 1492 cm−1 band, also falls in a relatively clear region of the
spectrum and could be used to conrm the presence of creatinine.
Phosphate (Figure 3.4) and sulphate (Figure 3.5) ions absorb predominantly be-
tween 1200 and 1000 cm−1 but can be distinguished by the additional band at 1157 cm−1
of phosphate ions and because the phosphate ion bands tend to be sharper. Glucose also
absorbs in this region (Figure 3.6); urine from a healthy individual would not typically
contain glucose but its presence could be determined by the unique absorbance pattern,
with sharp peaks at 1150, 1107, 1080 and 1034 cm−1 in solution, and broad absorbances
between 1500 and 1200 cm−1.
All of the kidney stone materials presented have multiple sharp peaks. When
diagnosing a kidney stone disease from IR spectra, several of these peaks would need to
be present for positive identication, whilst absence of specic peaks could be used to
eliminate compounds from the search. Stone materials are generally low concentration
compared to the major urine components, however, since stone materials are insoluble
they can be easily separated and concentrated by centrifuging the urine samples.
Tissue spectra are far more complex than urine spectra, containing many dif-
ferent types of proteins, carbohydrates, lipids and other metabolites. Spectra of diseased
tissues are often characterised by subtle changes that cannot be assigned to specic com-
pounds.
Global changes in protein content can be identied by changes in the position
and shape of the amide I and amide II bands of protein at ~1650 and ~1550 cm−1, respec-
tively. However, there are many dierent types of protein in tissue and all have very
similar IR spectra, meaning assignment to a specic protein is not generally possible.
The 1200 - 1000 cm−1 region of tissue IR spectra is particularly complicated,
with contributions from carbohydrates/sugars (including glycoproteins), DNA, RNA and
lipids. The absorbance bands of many of these compounds overlap signicantly so
that accurate assignment cannot be made, although many research groups have ten-
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tatively assigned observed changes in tissue spectra to specic components, including,
DNA/RNA [18, 31, 35, 55, 66, 88], mucin [65], collagen [90], cholesterol [20] and glyco-
gen [18, 31, 35, 55, 65, 87].
Lipids, including phosphatidylcholine (Figure 3.11) and cholesterol (Figure 3.12),
have strong sharp absorbances between 3000 and 2750 cm−1 and at around 1730 cm−1,
which are regions relatively free from contributions from other tissue components. These
bands in tissue IR spectra can be attributed to lipids, but assignment to a specic type of
lipid is more dicult.
Comparisons of model compounds spectra with biological sample spectra can
be further complicated by the fact that the precise shape and position of absorbance
bands can be inuenced by factors such as hydration and the presence of other inter-
acting compounds. This has already been illustrated by the dierences seen between
the solution and dried spectra and will be further discussed in results Chapter 4. Small
shifts of 1-2 wavenumbers in the bands of compounds in mixed samples relative to pure
solution are common but assignments may still be made in spite of such dierences.
However, correlating multiple peaks is often necessary for condent assignments, and
often it is only possible to tentatively suggest a general type of compound that might be
contributing to an IR spectrum.
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Chapter 4
Hydration eects on infrared spectra
87
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4.1 Introduction
There is a rapidly increasing literature on applications of vibrational infrared
spectroscopy to analyses of complex biological tissues and uids in order to identify
distinguishing signatures of cell types, diseased tissues and diagnostic markers of spe-
cic diseases [48–50,73,81,91,114–117]. The mid-infrared (IR) spectra of such materials
are inevitably complex combinations of many overlapping IR-active components. Diag-
nostic features of interest are in general minor components of these spectra and their
small IR intensities are usually overlapped by much stronger bands from more dominant
components.
Biological samples, particularly biouids and thin tissue biopsy sections, are of-
ten dried before analysis [91, 116]. Drying removes the strong, broad absorbance bands
of water and, in the case of measurements in attenuated total reection (ATR) mode,
increases the IR intensities of all other components by maximising their concentrations
across the IR-active volume into which the evanescent wave penetrates. When applying
analytical protocols to IR data obtained from dried and hydrated materials, it is impor-
tant to take into account the fact that the IR spectra of many materials are dierent in
aqueous solution versus the fully dried states. However, a further complication is that
some materials can also exhibit additional distinct states during drying whose IR char-
acteristics dier from both the solution and fully dried forms. This can be an important
additional consideration when analysing materials in which residual water levels are
not easy to remove in a consistent manner since such intermediate states can become
trapped within the material as it dries.
Urea, with its strong interactions with water, is a particularly clear example
of such behaviour. Its strong hydrogen bonding propensity results in its well-known
chaotropic eects in aqueous solutions [118]. Molecular modelling of its interaction with
an increasing number of water molecules suggests that the rst four water molecules
form the primary hydration sphere and three more form the secondary hydration sphere
[119–121]. Additional types of urea-water complexes are also predicted [119]. Such
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urea-bound water molecules have been detected directly in aqueous solutions of urea
by polarization-resolved mid-IR pump-probe spectroscopy [122]; bulk water molecules
beyond the hydration sphere around urea are not signicantly perturbed [120,122–124],
though this has been questioned with NMR studies of long range order [123]. At high
concentration, urea may also form dimers or higher order structures [119,121,125,126],
although several studies have questioned their existence [124, 127, 128]. Some of these
controversies may arise due to the dierent nature of the probe between dierent spec-
troscopic techniques. For an extensive review see ref. [128].
Here, IR spectroscopy is used to demonstrate the dierent forms of urea that can
form at dierent hydration states and how these inuence the infrared spectra of wet and
dried urine samples. IR analyses of creatinine and dehydration proles of other urinary
constituents are also described to further illustrate the need to consider hydration state
when interpreting IR data of biological samples.
Urea is an important breakdown product of nitrogen-containing compounds in
the body, such as dietary and muscle protein. It provides a safe way for the body to
excrete nitrogen as it is highly soluble in water and non-toxic. Creatinine is a byprod-
uct of muscle metabolism, with its production in the body being proportional to body
mass [106]. Urea and creatinine are two major components of urine that are often mea-
sured clinically (by non-IR methods) and can be used as markers for urine concentration
against which other components can be normalised. Creatinine can also be used as an
indicator of renal function and is used to calculate the glomerular ltration rate. Sev-
eral methods for quantitation of urea and creatinine in wet urine samples have been
described that are based on their well-dened solution IR spectra [49, 81]. For exam-
ple, as described here, urea concentrations in aqueous solution or in wet urine can be
quantitated by tting a Gaussian component to its strong vas (asymmetric CN stretch)
band at 1468 cm−1 [109]. When urea is completely dry this vas(CN) band shifts to 1464
cm−1. However, in dried urine samples, the position of the vas(CN) band of urea does
not correspond to either the wet or dried forms of pure urea (Figure 4.1).
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Figure 4.1: Variation in the vas(CN) band of urea in wet and dried pure urea and urine
spectra. The shoulder at around 1492 cm−1 in the wet and dried urine spectra is due to creatinine.
It was found that at least two additional states of urea with a vas(CN) band
at 1454 or 1443 cm−1 can be observed in partially-hydrated urea. Similar, though less
dramatic, hydration eects were observed with creatinine and at least one intermediate
form was identied in partially-hydrated samples. When whole urine is dried, the solid
materials tend to trap these intermediate forms. Hence, accurate protocols for compo-
nent deconvolution, or for comparison of wet and dried biological uids and tissues,
should accommodate such additional states.
4.2 Transmission IR spectra of urea
Spectra recorded in ATR mode can be inuenced by the refractive index of the
sample. To ensure that the observed change in urea vas(CN) band position and shape was
not simply due to a dierence in refractive index of wet versus dried samples, spectra
of urea were recorded in transmission mode. The transmission mode spectra of a pure
urea solution dried and partially rehydrated show the same shifts as those seen in the
ATR spectra, with the vas(CN) band centred at 1465 cm−1 in the dried spectrum (1 cm−1
higher than observed in ATR spectra) and shifting to 1454 cm−1 in the partially hydrated
spectrum (Figure 4.2). This suggests that the changes in the spectra between wet and
dried pure urea and urine samples are not the result of a dierence of refractive index.
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Figure 4.2: Transmission spectra of urea. 8 μL of a 50 mM solution of urea was dried on to a 2
mm thick CaF2 window. A dried spectrumwas recorded (red trace) before the sample was rehydrated
by placing drops of water around the dried urea spot and a second spectrum recorded (black trace).
4.3 Kinetic resolution ofmultiple urea hydration states
As expected with a small molecule that forms multiple hydrogen bonds with
water, the majority of bands of urea change their frequencies and relative intensities
between the solution and fully dried states. Dehydration resulted in loss of the underly-
ing broad absorbance bands of liquid water in the 1700-1600 cm−1 and 3700-2900 cm−1
ranges, with concurrent intensication of narrower bands of urea in these regions (Fig-
ure 4.3 A & B). The rehydrated spectrum is very similar to the solution urea spectrum
and the fully dried spectrum is essentially the same as that of pure, crystalline urea (Fig-
ure 4.4 A & B) [109, 110]. However, the behaviour was clearly not a simple transition
between these two states. For example, the vas(CN) band in the rehydrated spectrum was
centred at 1466 cm−1, close to its position at 1468 cm−1 in the spectra of urea in solution
at physiological concentrations. As the sample became dehydrated this peak gradually
downshifted, transiently reaching a minimum at 1448 cm−1 before rapidly upshifting to
the 1464 cm−1 value characteristic of the fully dried state (Figure 4.3 C & D).
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Figure 4.3: Serial spectra of a rehydrated urea sample during drying. 3 μL of a 50 mM
solution of urea were rstly dried on the prism and rehydrated in a water-saturated atmosphere.
Spectra were then recorded during drying over an approx. three minute period. (A) the 1800- 1000
cm−1 ‘ngerprint’ region; (B) the 3800-2800 cm−1 region. (C andD) 2D and 3D plots of the 1500–1400
cm−1 region showing the vas(CN) peak behaviour. Rehydrated spectra are shown in blue and dried
spectra in red.
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Figure 4.4: Solution and crystalline spectra of urea. (A) spectrum of 200mM pure urea in
solution after subtraction of pure water and water vapour spectra. (B) crystalline urea with band
assignments.
4.4 Stepwise rehydration of urea
By controlling the relative humidity of the environment surrounding the sam-
ple, it was possible to stabilise the intermediate partially-hydrated forms of urea. For
example, Figure 4.5 summarises the peak positions of the vas(CN) band after stabilisa-
tion at dierent relative humidities. As the humidity decreased, the peak at 1468 cm−1
in solution spectra downshifted to an intermediate state of 1456 cm−1 at 79 % humidity.
However, as the humidity was further decreased, the peak then upshifted towards the
fully dried value of 1464 cm−1.
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Figure 4.5: Spectra of the vas(CN) band of urea between 1510 and 1410 cm−1 at xed rela-
tive humidities. The vasC-N band peak at 1468 cm−1 in solution downshifts as relative humidity
decreases to 79 %, before upshifting towards the 1464 cm−1 position characteristic of dry urea at
lower relative humidities (spectra are not shown to scale).
4.5 Component tting to urea spectra
Combinations of Gaussian and pseudo-Voigt components were tted to the
vas(CN) urea peak of typical spectra obtained between 1510 and 1410 cm−1 as the relative
contributions of hydrated, partially-hydrated and fully dried forms varied during dry-
ing. Before tting, a correction was made for the ramping of spectral intensities caused
by recording in ATR mode (see Methods). Four components (Table 4.1) were required to
adequately t all spectra in this frequency range based on the root mean square error
compared to a three of fewer component t. Fitting with additional components did not
improve the error of the t.
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Table 4.1: Parameters of components required for simulation of urea spectra between 1510
and 1410 cm−1 corresponding to the vas(CN) band. [92]
Component
centre of the
urea vas(CN)
band
(cm−1)
Function type
mu(fraction of
Lorentzian
component)
FWHM
(cm−1)
1468 Gaussian n/a 32
1464 Pseudo-Voigt 0.61 19
1454 Pseudo-Voigt 0.66 36
1443 Pseudo-Voigt 0.97 41
The tting data with these components are shown in Figure 4.6. For reference,
the best t of combinations of these same components to this region of urea in solution is
shown in Figure 4.7; this is dominated by the Gaussian component centred at 1468 cm−1
that also dominates the rehydrated spectrum (Figure 4.6 A). As the rehydrated sample
dried, the 1468 cm−1 component diminished and components at 1454 and 1443 cm−1
emerged (Figure 4.6 B). As the drying progressed, the 1443 cm−1 component became the
dominant species (Figure 4.6 C) before the band rapidly upshifted to the 1464 cm−1 form
that is characteristic of fully dried urea (Figure 4.6 D).
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Time: 0 s
Time: 64 s
Time: 180 s Time: 196 s
Figure 4.6: Component ing to the vas(CN) band of urea during the transition from
rehydrated to dry states. Four spectra were selected from the series obtained during drying of
rehydrated urea of Figure 4.3. Times from beginning of the dehydration are indicated on each panel.
Before tting, spectra were corrected for eects of ramping caused by recording in ATR recording
mode, followed by optimal tting of the intensities of the four components of xed frequencies and
bandwidths (Table 4.1), together with unrestricted linear sloping baselines. (A) rehydrated; (B and
C) intermediate partially-hydrated; (D) dry states. The residuals for each overall t are shown un-
derneath each panel at the same scale as the corresponding component t, with the centre dotted line
representing zero.
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Figure 4.7: Component ing to the vas(CN) band of urea in solution. A spectrum of 200
mM urea in aqueous solution was recorded. Absorbance contributions of bulk water were rstly
subtracted using an ATR spectrum of pure water and the 1510–1410 cm−1 region was then corrected
for the eects of ramping caused by recording in ATR recording mode. An optimal t was then made
of intensities of the four components of xed frequencies and bandwidths (Table 4.1), together with
an unrestricted linear sloping baseline. Fractions of each component were calculated from the peak
areas (integrated intensities). The residual for the overall t is shown underneath at the same scale
as the component t, with the centre dotted line representing zero.
4.6 Hydration states of creatinine
Hydration-dependent variations in absorbance band frequencies and intensities
occur with other urinary components, though none that were studied were as marked
as those seen with urea. Creatinine is a second major urinary component and has an ab-
sorbance band at 1492 cm−1 in solution that partly overlaps with the vas(CN) absorbance
band of urea. Based on previously published work [129, 130] and frequency predictions
performed in Gaussian 09 [101] of pure creatinine in a vacuum (dielectric constant = 1.0)
matrix, this creatinine band can be assigned to a single complex normal mode (v(C=N)
(30) v(CN) (27) δ(NCH) (24)). Spectra were recorded during drying and components were
again tted to the data between 1520 and 1470 cm−1 after correction for the ramping ef-
fect of recording in ATR mode. The 1492 cm−1 band upshifted during dehydration to an
intermediate position at 1501 cm−1 (Figure 4.8). Continued drying resulted in a slight
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downshift to 1499 cm−1, the same position as the band in dry, crystalline creatinine
(not shown). In both solution and rehydrated states, this band can be approximately
described by a single Lorentzian component centred at 1492 cm−1 with FWHM of 24
cm−1 (Figure 4.9 A and Table 4.2). After drying, or in crystalline creatinine, the band
approximates to a single Lorentzian component at 1499 cm−1 with FWHM of 29 cm−1
(Figure 4.9 D). However, an additional Gaussian component at 1501 cm−1 with FWHM of
23 cm−1 is required in order to adequately simulate all spectra obtained in the partially
hydrated conditions arising between these extremes (Figure 4.9 B & C). All spectra could
be adequately represented by a combination of these three components.
A B
C
Figure 4.8: Serial spectra of a rehydrated creatinine sample during drying. 3 μL of a 10 mM
solution of creatinine was rstly dried onto the prism surface and rehydrated in a water-saturated
atmosphere. Spectra were then recorded during drying over a three minute period. (A) the 1800- 1000
cm−1 ‘ngerprint’ region; (B) the 3800-2800 cm−1 region. (C) the 1500–1400 cm−1 region showing
the (v(C=N) (30) v(C-N) (27) δ(NCH) (24)) band behaviour. Rehydrated spectra are shown in blue
and dried spectra in red.
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Figure 4.9: Component ing to the 1520 and 1470 cm−1 spectral region of creatinine
during the transition from rehydrated to dry states. 3 μL of a 10 mM solution of creatinine
were rstly dried onto the prism surface and then rehydrated in a water-saturated atmosphere. Four
spectra were selected from the series obtained during drying of this rehydrated sample. Spectra
shown were corrected for eects of ramping caused by recording in ATR recording mode, followed by
optimal tting of the intensities of the three components of xed frequencies and bandwidths (Table
4.2), together with unrestricted linear sloping baselines. (A) rehydrated; (B and C) intermediate
partially-hydrated; (D) dry states. The residuals for each overall t are shown underneath each
panel at the same scale as the corresponding component t, with the centre dotted line representing
zero.
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Table 4.2: Parameters of components required for simulation of creatinine spectra be-
tween 1520 and 1470 cm−1 corresponding to the (v(C=N) (30) v(CN) (27) δ(NCH) (24)) band.
Component centre
of (v(C=N) (30)
v(C-N) (27) δ(NCH)
(24)) band
(cm−1 )
Function type
FWHM
(cm−1)
1492 Lorentzian 24
1499 Lorentzian 29
1501 Gaussian 23
4.7 Hydrated forms of urea in dried urine samples
The dehydration protocol was repeated with urine samples from healthy donors.
Figure 4.10 shows how the spectra of two typical urine samples varies during drying.
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Figure 4.10: Serial spectra of rehydrated urine samples during drying. 3 μL of 1 in 4 diluted
urine samples were rstly dried onto the prism surface and rehydrated in a water-saturated atmo-
sphere. Spectra were then recorded during drying over a three minute period. (A and B) the 1800-
1000 cm−1 ‘ngerprint’ regions samples N1 (A) and N2 (B); (C and D) the 3800-2800 cm−1 regions.
(E and F) the 1500–1400 cm−1 regions. Rehydrated spectra are shown in blue and dried spectra in
red.
Figure 4.11 shows the dehydration spectra of the vas(CN) band of urea for four
additional urine samples.
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Figure 4.11: Serial spectra of the vas(CN) band of urea in four additional urine samples
during drying. 3 μL of 1 in 4 diluted urine samples were rstly dried onto the prism surface and
rehydrated in a water-saturated atmosphere. Spectra were then recorded during drying over a three
minute period.
The 1510-1410 cm−1 region of spectra rehydrated human urine samples is dom-
inated by the vas(CN) band of urea, together with a smaller contribution from the 1492
cm−1 normal mode of creatinine. Spectra were analysed by tting the four components
of pure urea (Table 4.1) together with additional smaller contributions from the possible
forms of creatinine (Table 4.2) and unrestricted linear sloping baselines (Figure 4.12).
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A:N1 hydrated B:N1 dried
C:N2 hydrated D:N2 dried
Figure 4.12: Fiing of urea and creatinine components to the 1510–1410 cm−1 region of
spectra of human urine. 3 μL samples of two typical healthy human urine samples were dried
onto the prism surface and rehydrated with a water-saturated atmosphere. Spectra were recorded
after stabilisation ((A) rehydrated sample N1; (B) rehydrated sample N2). Samples were then dried
and spectra were rerecorded after they had stabilised ((C) dried sample N1; (D) dried sample N2).
The fractional contributions of each component were determined from integrals of peak areas. The
residuals for each overall t are shown underneath each panel at the same scale as the corresponding
component t, with the centre dotted line representing zero.
In the rehydrated state, as expected, the spectrum is dominated by the 1468
cm−1 form of urea together with a 10-15% contribution from the 1492 cm−1 form of
creatinine (Figure 4.12 A & C). This is similar to that observed with fresh liquid urine
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(Figure 4.13).
Figure 4.13: ATR-FTIR spectrum of a typical urine sample. Also shown are the solution
spectra of urea and creatinine. Samples were recorded wet and pure water and water vapour spectra
were subtracted from the sample spectra.
However, even after drying by extensive exposure to the dry nitrogen ow, the
urea components (Figure 4.12 B & D) corresponded to those of its partially-hydrated
(1454 and 1443 cm−1) states (Figure 4.6 C), rather than the 1464 cm−1 band of the fully
dried form. Because the enhancement of the urea band intensity on drying is much
greater than that of creatinine (compare Figures 4.3 and 4.8), the creatinine contributions
to this region of the dried spectra become much smaller (< 3%). In Figure 4.12 B and
4.12 D, a single component at 1492 cm−1, corresponding to hydrated creatinine, appears
adequate, consistent with water retention in the dried urine samples, though accurate
assignment to its dierent states cannot be made with condence because of its very low
relative intensity.
The retention of intermediate hydration states of urea in dried urine samples is
also clearly seen in the 3700 - 2900 cm−1 region of spectra of dried urine (Figure 4.10 C
& D). Whereas it is clear that the broad band of condensed liquid water has been lost,
indicating that no bulk liquid water remained, the remaining urea bands resembled those
of the partially-hydrated forms, rather than those of the fully dried states (Figure 4.6 D).
Hence, again, it is clear that drying had trapped predominantly the intermediate states
of urea, rather than the fully dried form.
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4.8 Factors in urine aecting observed behaviour
The question arises as to what factor(s) control the dierent behaviours of urea
when dried in pure solution versus urine. A ‘simulated urine’ solution was prepared
containing 115 mM urea, 50 mM NaCl, 29 mM NH4Cl, 19 mM KH2PO4, 10 mM K2SO4
and 5 mM creatinine, buered to pH 6 with potassium hydroxide [106]. When a 3 μL
sample was dried onto the ATR prism, the vas(CN) band of urea stabilised around 1445
cm−1 (Figure 4.14), reproducing the behaviour of urea in urine. However, the relative
amount of the 1464 cm−1 component formed on drying increased when one of the major
components (ammonium chloride, creatinine or phosphate) was omitted, or if the mix-
ture was diluted substantially before drying a 3 μL sample. In contrast, if one component
was omitted but a replacement solute was added to maintain the solute mass, then the
urea again failed to form the 1464 cm−1 component. Furthermore, if urine samples were
extensively diluted, then a signicant fraction of the 1464 cm−1 form of urea appeared
on drying. It is therefore concluded that the urinary eect is a non-specic one, caused
simply by the mass of dried components (in urine, urea accounts for only 25-50% of total
solutes) creating a surface barrier that prevents complete dehydration of the material
close to the prism surface.
Figure 4.14: Behaviour of the vas(CN) urea band in dried ‘simulated urine’. 3 μL of ‘simu-
lated urine’ containing 115 mM urea, 50 mM NaCl, 29 mM NH4Cl, 19 mM KH2PO4 , 10 mM K2SO4
and 5 mM creatinine were dried onto the prism surface and the spectrum was recorded after stabil-
isation (solid line). Also shown are spectra of 3 μL 50 mM urea after drying (dotted line) and 3 μL
healthy donor urine after drying (dashed).
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4.9 Electronic structure modelling and physical basis
of intermediates
Changes in the spectra of pure urea during dehydration must arise from changes
in urea-water and/or urea-urea interactions. A similar phenomenon has already been re-
ported by Grdadolnik and Maréchal [120] and Jung et al. [125] who observed a shift in
the urea vas(CN) band in very concentrated solutions; these were assigned to specic
urea-urea and/or urea-water interactions in the limited water environments. In aqueous
solution, urea interacts directly with 4 water molecules [119–121]. Gaussian 09 software
was used to calculate the IR spectra of urea alone, in dierent hydration states and in
interactions with other urea molecules. The predicted frequency of the vas(CN) band
(Table 4.3) downshifted from 1470 to 1381 cm−1 as the number of surrounding water
molecules decreased from 4 to 0. This downshift was due to the loss of H-bonding inter-
actions, in particular between water hydroxyls and the carbonyl oxygen of urea [120].
In support of this, the most dramatic predicted changes corresponded to the removal
of the last two waters which, in these simulations, were those interacting with the car-
bonyl group. Conversely, the predicted frequency of the vas(CN) band of anhydrous urea
upshifted from 1386 to 1445 cm−1 as its carbonyl oxygen made an increasing number
of H-bonds with adjacent urea –NH2 group(s) (Table 4.3). Although multiple vas(CN)
frequencies were predicted (one for each urea molecule), the highest wavenumber cor-
related with those ureas with the greatest number of H-bonding interactions of their
carbonyl oxygen. For example, the 1381 cm−1 band in isolated urea upshifted to 1470
cm−1 in a urea with three H bonds in the 5 urea ensemble. Although the precise peak
positions predicted during the simulation vary from those observed in the experimental
data, these calculations, at least qualitatively, support a proposal that the experimentally
observed initial frequency downshift of the vas(CN) band on drying is due to dehydra-
tion of urea, and the subsequent upshift arises from direct urea-urea interactions as the
last waters are removed.
106
Table 4.3: Predicted frequencies of vas(CN) band of urea in combination with water or
other urea molecules. Calculations were performed with Gaussian 09. Where larger urea ensem-
bles were modelled, only the frequencies of those ureas with the highest number of H-bonds to their
carbonyl oxygen are listed (see text for details).
Structure
Number of H-bonds
to the carbonyl
oxygen
Wavenumber (cm−1)
1 urea + 4 H2O 2 1470
1 urea + 2 H2O 2 1462
1 urea + 1 H2O 1 1420
1 urea 0 1381
2 ureas 1 1410, 1428
3 ureas 2 1419, 1439
5 ureas 3 1470
4.10 Hydration eects of other compounds in urine
When analysing spectra of biological material for changes associated with dis-
ease, it is often the subtle spectral changes that are important. As has been demon-
strated with urea and creatinine, it is important to consider environmental humidity
when analysing spectra of dried or partially-dried samples. It is useful to be aware of
the IR dehydration proles of the sample constituents to avoid mistaking a hydration
state change as a signicant biological marker of disease. Since urine samples are often
analysed by IR spectroscopy in the dried state the dehydration proles of the main urine
constituents have been recorded, along with a few disease biomarkers. For each com-
pound the ‘ngerprint’ region has been plotted along with the 3800 - 2800 cm−1 region
to show how the broad water band changes during dehydration.
4.10.1 Ammonium chloride
Ammonium ions have a buering role in human urine and can be excreted in
response to a drop in pH. Ammonium ions in urine are predominantly generated in
the cells of the proximal tubule of the kidney, primarily from the metabolism of the
amino acid, glutamine [111]. Ammonium ions, like urea, interacts strongly with water
so some spectral changes are seen during dehydration (Figure 4.15), in particular a strong
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absorbance band appears at around 1410 cm−1 in the dried spectrum that is present only
as a subtle shoulder in the hydrated spectrum. The intensity of the band at around
1290 cm−1 also increases signicantly during drying. There are small downshifts in
the position of these absorbances bands but the changes are not as remarkable as those
seen for urea. Since the sample represented in Figure 4.15 was buered with phosphate
buer, some of the changes occurring in the 1200 - 1000 cm−1 region can be attributed
to phosphate. Comparison of Figure 4.15 with Figure 4.17, which shows the dehydration
spectra of phosphate, can be used to identify which spectral changes can be attributed
to ammonium chloride.
A B
Figure 4.15: Serial spectra of a rehydrated ammonium chloride sample during drying. 3
μL of a 29 mM solution of ammonium chloride (adjusted to pH 6 with phosphate buer) was rstly
dried on the prism and rehydrated in a water-saturated atmosphere. Spectra were then recorded
during drying over an approx. three minute period. (A) the 1800- 1000 cm−1 ‘ngerprint’ region; (B)
the 3800-2800 cm−1 region. Rehydrated spectra are shown in blue and dried spectra in red.
4.10.2 Sulphate
Sulphates are a product of amino acid metabolism in the body, particularly that
of sulphur-containing methionine and cysteine. Urinary levels of sulphates are therefore
inuenced by dietary intake of protein [131]. The main absorbance bands of sulphate
occur in the 1200 - 950 cm−1 region, so the dehydration spectra shown in Figure 4.16
have been plotted to include the whole of this region.
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Figure 4.16: Serial spectra of a rehydrated potassium sulphate sample during drying. 3 μL
of a 100 mM solution of potassium sulphate (adjusted to pH 7 with potassium hydroxide) was rstly
dried on the prism and rehydrated in a water-saturated atmosphere. Spectra were then recorded
during drying over an approx. three minute period. (A) the 1800- 1000 cm−1 ‘ngerprint’ region; (B)
the 3800-2800 cm−1 region. Rehydrated spectra are shown in blue and dried spectra in red.
4.10.3 Phosphate
Phosphates are important in a number of bodily functions including in bone
formation, energy production and cell signalling. The body’s requirement for phosphate
is met by a normal diet and excess phosphate in the blood is ltered by the kidneys and
excreted in the urine [132].
Most of the changes observed in the dehydration spectra of potassium phos-
phate (Figure 4.17) were increases in intensity of phosphate bands as the water was
removed from the sample along with the appearance of small but sharp shoulders be-
tween 1200 and 1100 cm−1. There was a small downshift of the band centred around
1080 cm−1 in the nal stages of dehydration. Unusually, the absorbance intensity in
the 3800-2800 cm−1 region increased as the sample dried (Figure 4.17 B) suggesting that
phosphate contributes to the absorbance in this region.
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Figure 4.17: Serial spectra of a rehydrated potassium phosphate sample during drying.
3 μL of a 50 mM solution of potassium phosphate (adjusted to pH 7 with potassium hydroxide)
was rstly dried on the prism and rehydrated in a water-saturated atmosphere. Spectra were then
recorded during drying over an approx. three minute period. (A) the 1800- 1000 cm−1 ‘ngerprint’
region; (B) the 3800-2800 cm−1 region. Rehydrated spectra are shown in blue and dried spectra in
red.
4.10.4 Glucose
In healthy individuals, any glucose that is ltered by the glomerulus is reab-
sorbed in the proximal tubule. Some conditions, such as diabetes mellitus where blood
glucose levels are elevated, are associated with elevated urinary glucose (glycosuria) be-
cause the amount of glucose ltered into the urine exceeds the capacity of the proximal
tubule to reabsorb it. Other conditions which aect blood glucose or the kidney function
can also lead to glycosuria [108].
Glucose is highly soluble in water and this is expected to be reected in its IR
spectrum at dierent levels of hydration (Figure 4.18).
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Figure 4.18: Serial spectra of a rehydrated glucose sample during drying. 3 μL of a 25 mM
solution of glucose was rstly dried on the prism and rehydrated in a water-saturated atmosphere.
Spectra were then recorded during drying over an approx. three minute period. (A) the 1800- 1000
cm−1 ‘ngerprint’ region; (B) the 3800-2800 cm−1 region. Rehydrated spectra are shown in blue and
dried spectra in red.
4.10.5 Cystine
Cystine is an amino acids hyperexcreted in to the urine of some individuals with
a rare kidney stone disease called cystinuria. It is highly insoluble in water and urine at
physiological pH and hence precipitates to form stones [133]. Unlike compounds such as
urea and creatinine, it does not form hydrogen bonds or interact signicantly with water
molecules, therefore its IR spectrum, in terms of the position and shape of the absorbance
bands, is not inuenced by the extent of hydration (Figure 4.19). Since increasing hydra-
tion of a sample dilutes the concentration of other compounds, an intensity change in
the cystine spectrum is expected with increased hydration as water molecules replace
some of the cystine molecules in the active area of the prism.
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Figure 4.19: Serial spectra of a rehydrated cystine sample during drying. 3 μL of a 12 mM
suspension of cystine was rstly dried on the prism and rehydrated in a water-saturated atmosphere.
Spectra were then recorded during drying over an approx. three minute period. (A) the 1800- 1000
cm−1 ‘ngerprint’ region; (B) the 3800-2800 cm−1 region. Rehydrated spectra are shown in blue and
dried spectra in red.
4.11 Discussion and conclusions
In the context of IR analyses of urinary samples, at least four IR-distinct forms
of urea should be considered, with their relative amounts dependent on hydration level.
These correspond to the rehydrated form (equivalent to the solution form), a dried form
and two additional partially hydrated forms. These dierent forms are likely to corre-
spond to specic urea-urea and urea-water structures, the likes of which have been pre-
viously identied in the literature. In support of this model, Gaussian modelling of such
urea structures and their predicted IR spectra suggests that the absorbance frequency of
the vas(CN) band of urea downshifts from a fully hydrated to a fully dried state before
upshifting as an increasing number of urea-urea interactions are formed.
A selection of the modelled urea-water and urea-urea structures are shown in
Figure 4.20. Based on structures A-C in Figure 4.20 it appears that the hydration starts
from the carbonyl group, rather than the amino terminal as suggested by Nandel et al.
(1998). [121] However, the urea-water and urea dimer structures are consistent with
those predicted by Lee et al. (1995) [119] and with the notion that the primary hydration
sphere contains four water molecules [119,121]. The ve-urea structure shown in Figure
4.20 D shows that when there are relatively few urea molecules the environment of the
vas(CN) band diers for each, resulting in dierences in their vibrational frequency.
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Figure 4.20: Modelled urea-urea and urea-water structures. (A) Urea with a single water
molecular. (B) Urea with two water molecules. (C) Urea with four water molecules. (D) Two urea
molecules. (E) Five urea molecules.
Multiple hydration states can also exist for other materials, as demonstrated
here with creatinine. The (v(C=N) (30) v(CN) (27) δ(NCH) (24)) absorbance band of crea-
tinine in dried and rehydrated/wet spectra can each be described by single components.
In partially rehydrated creatinine spectra a combination of one of these components plus
a single intermediate centred at 1501 cm−1 can be used to adequately t the data.
Spectra of dried urine samples show that the partially hydrated states of urea
tend to become trapped in the dense matrix of dried urinary components, with a pre-
dominance of the lowest wavenumber (1443 cm−1) form, preventing direct urea-urea
interactions. The retention of such partially hydrated forms with altered IR signatures
complicates the analysis of infrared spectra of dried samples such as urine, and it is
important that they are recognised in diagnostic analyses of dried biological tissues and
uids. However, the limited number of distinct forms can easily be accommodated in de-
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composition procedures for quantitative analyses, as shown here with the contributions
of dierent states of urea in dried urine samples.
Urea and creatinine in urine have been quantitated by other groups using FTIR
spectroscopy [49, 81], but samples were analysed wet and so the problems of hydration
would not have been encountered. Shaw et al. (2000) [91] discussed the quantitation
of urea, creatinine and protein using FTIR spectroscopy of dried urine lms. PLS re-
gression analysis was applied to the 1400 - 1800 cm−1 region for creatinine quantitation
and the 3100-3550 cm−1 region for urea. Both of these regions have been shown to be
inuenced by the extent of hydration of the sample, but control of hydration was not
mentioned and no spectra were presented in the report for critical analysis. Similarly,
dried mouse urine was analysed for urea by Furlan et al. (2004) [134] without men-
tion of controlled hydration or presentation of spectra. Other groups have used FTIR
spectroscopy to analyse dried blood products for urea, creatinine and other components
without considering hydration eects [73,74]. However, Fabian et al. (2005) [76] noticed
that peak intensities in spectra of dried serum lms were inuenced by relative humidity
and acknowledged that environmental conditions should be carefully controlled during
analysis. Ollesch et al. (2013) [77] also discussed how reproducibility of dried serum and
plasma sample spectra was adversely aected by inhomogenous dried lms. The ‘coee-
ring’ drying patterns described probably resulted in varying degrees of hydration across
the sample. They also demonstrated how bands can shift and change shape between wet
and dried spectra of serum samples, with particular focus on amide I and II absorbance
bands. They were able to improve reproducibility by using a robotic dispensing system
that could generate dried sample spots of homogenous thickness. Control of environ-
mental humidity combined with automated sampling could oer an alternative way of
reducing the inuence of the hydration eect and reducing the need for computational
compensation post-measurement.
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Chapter 5
Analyses of urine FTIR spectra for
disease diagnosis.
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ered clinical guid-
ance. Annalisa Vilasi performed preliminary work upon which the project was extended.
Additional data has been included.
5.1 Case study: cystinuria
5.1.1 Introduction
Cystinuria is an autosomal inherited aminoaciduria caused by mutations in one
or both of the subunits of the b0,+ amino acid transport system. It results in a fail-
ure to reabsorb freely ltered cystine in the proximal tubule of the kidney, causing in-
creased urinary excretion of cystine and the dibasic amino acids lysine, arginine and or-
nithine [133,135]. Cystine is a dimer of cysteine formed by oxidation of their sulphydryl
groups to form a disulphide bond. Cystine is poorly soluble in water in the physiological
pH range [136]. Its solubility limit in urine is ~ 1 mM [133,137] and it forms a microcrys-
talline precipitate above this concentration. Insoluble cystine can form stones that may
cause obstruction of the kidneys and lead to irreversible damage and loss of function.
Cystinuria has a global prevalence of around 1 in 7000, ranging from 1 in 2000
to 1 in 100 000, depending on the population. Cystine stones account for only around
1-2 % of all renal stones in adults and 6-8 % in children. The rst incidence of stone
formation may occur at any age but over half of patients develop their rst stone before
the age of 20 [104, 133].
Cystine levels in cystinuric patients typically range from 1-2 mM, but concen-
trations over 4 mM have been reported [138]. Patients with urinary cystine concentra-
tions over 1 mM have a signicantly increased risk of stone formation. Many patients
respond to simple treatments in the form of increased uid intake, especially overnight,
urinary alkalinisation, an alkaline ash or low methionine (animal protein) diet, and di-
etary salt restriction. Dithiol drugs can also decrease the urinary cystine concentration
by disulphide bond reduction to form more soluble drug-cysteine complexes. However,
these measures do not treat the underlying cause of the disease and are most eective
when used prophylactically [133, 135]. Once stone formation has occurred, shock-wave
lithotripsy or surgery is usually required.
Cystinuria is usually diagnosed by measuring urinary cystine. Early diagnosis
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and preventive maintenance therapy are essential and both require the ability to detect
and quantitate cystine quickly, easily and repeatedly. Qualitative colorimetric screening
tests that can provide rapid results are available, but these have low specicity. For ex-
ample, the sodium-nitroprusside test (Brand’s technique) can produce a positive result
in a few minutes. However, the use of cyanide has associated hazards, and the reac-
tion is subject to interference from ketones, homocystine from the diet, ascorbic acid
and acidic conditions, which can all give false positive results [133, 139]. The Shinohara
and Padis method [140] is an alternative colorimetric method for estimating urinary
cystine concentration by measuring the concentration of SH groups, but also suers
from interference. Derivatisation followed by ion exchange chromatography is the cur-
rent clinical gold standard for amino acid analyses, including cystine. However, such
chromatographic techniques are time-consuming and expensive in personnel and equip-
ment [104]. As a result, they are not generally available at the point of care. Furthermore,
before analysis by ion exchange chromatography urine samples must be treated to in-
crease the solubility of cystine as this method is only able to measure soluble cystine.
Generally, this is achieved by raising or lowering the pH of the sample but the solubility
of cystine does not increase dramatically except at the very extremes of pH meaning ion
exchange chromatography may underestimate the total cystine load in samples with a
very high concentration of cystine. Alternatively, an individual’s urinary cystine sol-
ubility threshold can be quantitated by a cystine capacity assay [141]. This involves
incubating a known amount of solid cystine with a 24 hour patient urine sample. The
sample is spun down and the insoluble fraction weighed to give a measure of cystine
saturation in the urine. However, this, again, is a labour-intensive procedure that is not
widely available. Hence, a faster, simpler and more cost-eective routine method for
quantitating urinary cystine would be of signicant clinical value.
ATR-FTIR spectroscopy is an ideal candidate for an alternative method of de-
tecting and quantitating cystine in urine because it is quick, specic and has the poten-
tial sensitivity required for detection of the levels of cystine found in cystinuric urine.
Cystine has a unique IR spectrum with a number of distinct bands. Attempts have al-
ready been made to detect cystine in kidney stones. Marickar et al. (2009) [142] used
scanning electron microscopy-elemental distribution analysis in combination with FTIR
spectroscopy in order to identify cystine in 30 renal stone samples. They compared their
transmission spectra to a cystine standard spectrum and standard spectra of other stone-
forming compounds in order to correlate sample peaks with those of the known com-
pounds. Peaks quoted as being characteristic of cystine include 3026, 1618, 1485 and 846
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cm−1. Cystine stones were also detected by Paluszkiewicz and co-workers (1988) [53] in
a study of Polish populations. However, FTIR spectroscopy has not been applied to the
detection and quantitation of cystine in fresh urine samples, which is the simplest diag-
nostic test. In this report the potential of ATR-FTIR spectroscopy as a rapid, reagent-free
method for detecting and quantitating insoluble cystine in urine has been explored.
5.1.2 Quantitation of urea and creatinine in urine by ATR-FTIR
spectroscopy
Since patient uid intake before urine collection cannot be easily controlled,
and because glomerular ltration rate (GFR) varies and can aect solute excretion, uri-
nary creatinine concentration is commonly used clinically to normalise concentrations
of other compounds in urine. Urinary urea can also be an indicator of urine dilution.
These can be determined from IR spectra of whole urine by various methods [49,81,91].
In this study, urea and creatinine were determined by deconvolution of the 1510-1445
cm−1 region of whole urine spectra, which is dominated by absorbance bands of urea
and creatinine.
The ‘Peak Analyzer’ function of the Origin 8.5 software was used to nd opti-
mal parameters for component tting of spectra of pure solutions of urea and creatinine
in double distilled water. A spectrum of a pure solution of urea after subtraction of
contributions of bulk water and water vapour was best tted with a single Gaussian
component centred at 1468 cm−1 with full width at half maximum height (FWHM) of 33
cm−1. A pure spectrum of creatinine treated in the same way could be tted with a sin-
gle Lorentzian component centred at 1492 cm −1 with FWHM of 24 cm−1. Unrestricted
linear baselines were used in both instances. A solution of 100 mM urea plus 10 mM cre-
atinine was prepared as a simplied model for human urine to determine whether the
same parameters could be used to a t and simultaneously quantitate urea and creati-
nine in a mixture. The previously determined parameters for tting urea and creatinine
individually were used as starting parameters but were allowed to vary during the t-
ting of the mixed solution spectrum. It was found that the peak centres and lineshapes
remained unchanged for tting urea and creatinine in the mixed solution spectra but the
FWHM of the urea component was reduced to 32 cm −1 for optimal tting. The nal
parameters for tting urea and creatinine in mixed spectra are dened in Table 5.1.
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Table 5.1: Final parameters for quantitative component ing of urea and creatinine in
mixed solution spectra.
Compound
Vibrational
assignment
Component
centre
(cm−1 )
Function
type
FWHM
(cm−1)
Urea vas(CN) 1468 Gaussian 32
Creatinine
(v(C=N) (30)
v(CN) (27)
δ(NCH) (24))
1492 Lorentzian 24
To validate the component tting the parameters in Table 5.1 were used to t a
series of spectra of urea and creatinine mixtures at known concentrations. The integrals
of the tted components of the calibration sample (100 mM urea plus 10 mM creatinine)
were used to estimated the concentrations of the test samples. The results are shown in
Table 5.2. The method is generally accurate for mixtures of urea and creatinine but is
less accurate when the mixture contains a very low concentration of urea or creatinine.
By tting to spectra of the seven prepared solutions of 100 mM urea plus 10 mM creati-
nine the average predicted concentrations of urea and creatinine were 100 mM (± 1 mM
standard deviation) and 10.6 mM (±0.5 mM standard deviation) respectively.
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Table 5.2: Validation of urea and creatinine component ing.
Actual [urea]
(mM)
Actual
[creatinine]
(mM)
Predicted
[urea] (mM)
Predicted
[creatinine]
(mM)
200 30 200 30
200 30 203 30
100 15 101 15
100 15 103 15
100 10 100 11
100 10 101 10
100 10 100 10
100 10 100 11
100 10 99 11
100 10 99 10
100 10 100 10
100 0 95 1
50 0 46 0
0 10 6 10
0 5 1 5
0 2 1 2
The component tting method is illustrated in Figure 5.1, which shows the ATR-
FTIR spectra of pure urea and creatinine and a mixture in aqueous solution (Figure 5.1 A,
B & C), along with the component t of the 100 mM urea plus 10 mM creatinine mixture
in Figure 5.1 D.
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Figure 5.1: ATR-FTIR spectra of urea and creatinine in solution and deconvolution of
mixtures. Spectra of (A) 200 mM urea, (B) 30 mM creatinine and (C) a 100 mM urea/10 mM creati-
nine mixture in water are shown after subtraction of contributions of water solvent. In (D) data of (C)
between 1510 and 1445 cm−1 (dashed box) were simulated with a combination of peaks from urea
(Gaussian peak at 1468 cm−1 with FWHM of 32 cm−1; shown in green) and creatinine (Lorentzian
peak at 1492 cm−1 with FWHM of 24 cm−1; shown in cyan):- recorded data (black); simulated curve
(red); linear baseline (blue). The residual for the overall t is shown underneath at the same scale as
the component t, with the centre dotted line representing zero.
Calibration curves (Figure 5.2) were generated for urea and creatinine based on
the integrals of tted curves with xed parameters as described in above Figure 5.1 and
Table 5.1.
121
A B
Figure 5.2: Calibration curves for urea and creatinine in water. ATR-FTIR spectra of a range
of aqueous urea and creatinine solutions were recorded. After subtraction of water contributions,
curves were tted between 1510 and 1445 cm−1, with the parameters given in Figure 5.1. The areas
of the tted curved were plotted versus concentrations of (A) urea; (B) creatinine.
Since urea and creatinine are the dominating components of the 1510-1445 cm−1
region of whole urine spectra (Figure 5.3 A), the same algorithm could be applied to de-
termine their concentrations in urine samples. Figure 5.3 B shows an example of the t
to a typical ATR-FTIR spectrum of urine from a cystinuric patient. Figure 5.4 summarises
the urea and creatinine concentrations determined by this method in urine samples from
22 cystinuric patients (labelled from P1 to P24) and 5 healthy controls. Urea concentra-
tions were 28 – 443 mM, while creatinine concentrations were <1 – 20 mM, which are
typical ranges. As expected, the concentrations of urea and creatinine tend to correlate
and no pattern dierence between cystinuric and healthy samples was evident.
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Figure 5.3: Deconvolution of urea and creatinine in whole urine spectra. (A) A typical ATR-
FTIR spectrum of a whole (undried) urine sample; (B) curve tting of peaks of urea and creatinine in
the 1510-1445 cm−1 region (dashed box in A) with xed parameters as in Figure 5.1:- recorded data
(black); simulated curve (red); linear baseline (blue); urea component (green); creatinine component
(cyan). The residual for the overall t is shown underneath at the same scale as the component t,
with the centre dotted line representing zero.
BA
Figure 5.4: Urea and creatinine concentrations in urine samples. (A) Urea and (B) creatinine
concentrations in whole urine determined fromATR-FTIR spectra. Concentrations were deconvoluted
as described in Figure 5.3 using the calibration plots of Figure 5.2. Pn: cystinuric patient; Nn: healthy
control urine samples. Samples were measured in triplicate and error bars represent standard errors
of mean.
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5.1.3 Comparison of ATR-FTIR and Jae reaction methods for
creatinine quantitation
To validate the ATR-FTIR method for urinary creatinine quantitation, creati-
nine concentrations in the same urine samples were also determined using the Jae
reaction since this is the most widely used clinical method [107, 143, 144]. A reason-
able correlation was observed between the two methods (Figure 5.5 A) with a Pearson
correlation coecient of r=0.75 (r=0.83 if two outliers are removed), although the Jae
method tended to predict slightly higher concentrations. A Bland-Altman analysis [99]
was also performed to establish the similarity between the results generated by the two
methods (Figure 5.5 B). The dashed line shows the mean bias and the dotted lines show
95% condence limits (± 1.96 standard deviations from the mean). The mean bias was
1.4 mM, demonstrating that the Jae reaction tended to indicate higher creatinine con-
centrations. Two outliers had large discrepancies between the creatinine concentrations
predicted by the Jae and ATR-FTIR methods; the origin of these discrepancies was not
investigated further. The remaining data points all fell within the 95% condence limits.
A B
Figure 5.5: Comparison of ATR-FTIR spectroscopy and Jae methods of creatinine quan-
titation in whole urine samples. (A) Circles represent those samples for which cystine content
has also been measured. Squares represent additional urine samples. (B) Bland-Altman plot to assess
the similarity between the Jae and FTIR methods for quantitating creatinine. The X-axis shows the
mean of the creatinine measurements by the two methods whilst the Y-axis shows the dierences of
each method from the mean. Mean bias is shown by the dashed line with the 95% condence limits
shown by the dotted lines at mean bias ± 1.96 standard deviations.
124
5.1.4 Development of measurement of insoluble compounds in
urine
Cystine is poorly soluble in aqueous solutions between pH 2 and 12 [136]. Since
only the rst few microns of sample depth are probed by the evanescent wave of the IR
beam in ATR mode, settling of any particulate cystine onto the prism surface will lead to
unstable spectra. Hence, to avoid instabilities due to insoluble particle sedimentation, a
quantitative protocol was developed in which samples were dried onto the prism surface
(Materials and methods). However, initially, problems were encountered with poor re-
producibility when quantitating cystine from dried sample spectra and several attempts
were required to generate a reproducible cystine calibration curve.
The rst variable tested in an attempt to improve reproducibility of cystine mea-
surements was drying times. A 6.5 mM suspension of cystine was prepared and 5 µL
aliquots were dried on to the prism by passing N2gas over the sample at a controlled
ow rate. The ow rate was varied to increase or decrease the drying time. Fast drying
(over a 4 minute period) was achieved with a N2ow rate of over 800 mL/min. Slow dry-
ing (over a 9 minute period) was achieved with a N2 ow rate of 300 mL/min. The area of
the 1303 - 1293 cm−1 cystine band in the nal dried absorbance spectrum was calculated
for each repeat and the mean and standard deviation for the slow and fast drying groups
were calculated. Although the results (Figure 5.6) show an intensity dierence between
the two groups, the main conclusion is that slow drying of cystine suspension samples
leads to better reproducibility as evidence by the smaller standard deviation of the slow
drying group compared to the fast drying group.
Figure 5.6: The eect of drying time on reproducibility of cystine spectra. Reproducibility
was assessed by calculating the mean area and standard deviation between 1303 and 1293 cm−1 of
the spectra of cystine dried at a fast (4 mins or 800+ mL/min N2 ow rate) or slow (9 mins or 300
mL/min N2 ow rate) ow rate. Four repeats were performed for each group.
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It was then observed that the intensity of the 1296 cm−1 band of dried cystine
varied between cystine stock solutions. Although, all stock solutions were prepared fol-
lowing the same protocol, at consistent volume, concentration and pH, it might be that
cystine precipitation as the stock solution was neutralised from acidic pH is very sensi-
tive to subtle dierences, such as in the speed of neutralisation, that result in dierences
in particle formation. This could, in turn, inuence the amount of cystine that is picked
up in any 5 µL aliquot. To counter this, 1 mL aliquots of the same stock suspensions were
homogenised by hand for 5 minutes to break up any large cystine particles and ensure
all cystine particles were approximately equal size. New spectra were recorded of dried
5 µL aliquots of these homogenised suspensions. This process signicantly improved the
reproducibility of the dried cystine measurements as can be seen in Figure 5.7 (columns 1
and 2), which compares the area and standard deviation of the 1296 cm−1 band in spectra
of dried 5 µL aliquots of 20 mM unhomogenised and homogenised cystine suspensions.
However, further investigation revealed that application of gentle pressure to the dried
samples greatly increased the intensity of the 1296 cm−1 band (Figure 5.7, column 3). Ap-
plying pressure to the samples also improved the reproducibility of the measurements
whether the sample was homogenised prior to drying or not. This suggested that the
cystine layer can partition away from the prism surface as it dries.
Figure 5.7: The eect of homogenisation and gentle pressure on the reproducibility of
cystine spectra. Reproducibility was assessed by calculating the mean area and standard deviation
between 1303 and 1293 cm−1 of the spectra of dried cystine. In each case, 5 µL aliquots of 20 mM
cystine suspensions were dried on to the prism by passing a gentle stream of N2 across the sample at
300 mL/min. In the relevant cases, even pressure was applied to the dried sample using a standard
press from SensIR.
Based on these results, all subsequent IR measurements of cystine were per-
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formed by drying cystine-containing samples on to the prism with a gentle stream of
N2 at 300 mL/min and gentle, even pressure was applied to the dried samples using a
standard press from SensIR to ensure good contact between the sample and the prism
surface.
5.1.5 Analysis of cystinuric urine samples
The structure of cystine is shown in Figure 5.8 and the ATR-FTIR spectrum
of a dried L-cystine sample is shown in red in Figure 5.9 A. For reference, the dried
solution and solid spectra of arginine, lysine and ornithine are also shown in Figure 5.10
as these amino acids are also hyperexcreted into urine in cystinuria. A calibration curve
(Figure 5.11) for cystine was generated from heights of its 1296 cm−1 band, measured
from second derivatives of absorbance spectra of a set of dried cystine suspensions with
concentrations ranging from 0 to 3 mM at pH 7. The data were tted with a linear
function conrming that ATR-FTIR spectroscopy can be used to quantitate cystine in this
concentration range, up to at least 3 mM. This calibration curve is likely to be applicable
to urine samples at any physiological pH since the solubility of cystine only increases
signicantly when pH is below 2 or above 12 [136].
Figure 5.8: Structure of cystine.
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Figure 5.9: Absorbance spectra of cystine and insoluble cystinuric urine. (A) Absorbance
spectrum of dry cystine (red) and a dried insoluble fraction of a cystinuric urine sample (black). (B)
Second derivative transformation of absorbance spectrum of dry cystine (red) and a dried insoluble
fraction of a cystinuria urine sample (black).
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Figure 5.10: Absorbance spectra of other urinary amino acids associated with cystinuria.
(A) Spectrum of dried solution of L-arginine. (B) Spectrum of dried solution of L-lysine. (C) Spectrum
of dried solution of L-ornithine. (D) Spectrum of solid L-arginine. (E) Spectrum of solid L-lysine. (F)
Spectrum of solid L-ornithine. All solutions were adjusted to pH6 with phosphate buer. The solid
compounds were prepared with chloride as the counter ion, therefore the dierences between the
dried solution and solid spectra are likely to be a result of pH, or counter ion/buer interaction.
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Figure 5.11: Cystine calibration curve. Calibration curve for cystine dried from suspensions in
water. To generate the calibration curve suspensions of 0 - 3 mM cystine in water at pH7 were
prepared and 5 µL aliquots (homogenised by vortex mixing) were dried onto the prism. Pressure was
applied on the sample before spectra were recorded. The height of 1296 cm−1 cystine band in the
second derivative spectra were plotted against cystine concentration (intensity 1296 - 1280 cm−1). A
linear t through the origin was calculated with no error weighting.
Even in cystinuric urine, cystine levels will be low in comparison with many
other urinary components and can be dicult to detect in whole urine spectra. Drying
the urine sample on the ATR prism before analysis will increase the concentration of cys-
tine in the active area of the ATR prism and, therefore, the intensities of its absorbance
bands. However, absorbance bands of urea, creatinine and other dominating compo-
nents that might mask some cystine bands will also be amplied. Since the clinically
important cystine is the insoluble fraction, the urine samples were centrifuged to pellet
the insoluble components, which could then be resuspended and dried onto the prism
for quantitation. This removed contributions from soluble components and allowed ac-
curate analysis of insoluble cystine from its characteristic band pattern (Figure 5.9, red),
which could clearly be seen in the spectra of many of the dried, insoluble fractions of
cystinuric urine samples (Figure 5.9, black). This demonstrates that urinary cystine can
easily be detected by this method when it exceeds the critical solubility limit.
In brief, the insoluble material was rst pelleted from 1 mL aliquots of each
urine sample by centrifugation, hence removing any possible interference from soluble
urinary components. Pellets were resuspended in 1 mL water. The sample was thor-
oughly vortexed before 5 µL were taken and dried onto the ATR prism surface and an
FTIR spectrum was recorded. The cystine calibration curve (Figure 5.11) was used to
estimate the concentration of insoluble cystine in the original urine samples. Twenty
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two cystinuric (see Table 5.3 for summary of patient demographics) and 5 control urine
samples (4 females aged 24-35 years, 1 male, unknown age) were analysed (Figure 5.12).
Control urine samples were donated by healthy volunteers at the Royal Free Hospital,
London.
Seventeen of the cystinuric samples had detectable insoluble cystine of up to 3.1
mM. Five cystinuric samples and all healthy controls had no detectable insoluble cystine,
indicating that their urinary cystine concentrations were below the solubility limit of≤1
mM.
Figure 5.12: Levels of cystine measured in cystinuric (Pn) and control (Nn) urine samples
by ATR-FTIR spectroscopy. Patient urine samples were centrifuged and the pellets resuspended in
water. Aliquots of the resuspended pellets were dried onto the ATR prism and pressure was applied
before spectra were recorded. For cystine quantitation the spectra were converted to second derivative
and the heights of the 1296 cm−1 bands were compared to the cystine calibration curve. Samples
were measured in triplicate and error bars represent standard errors of mean.
5.1.6 Comparison of FTIR and clinical methods of cystine quan-
titation
The cystine concentrations determined by ATR-FTIR spectroscopy were com-
pared with the values obtained using the clinical gold standard method for urinary cys-
tine estimation by ion exchange chromatography after derivatisation (performed ex-
ternally at the Camelia Botnar Laboratories at Great Ormond Street Hospital) (Figure
5.13) [103]. Since the ATR-FTIR method measures only insoluble cystine, while the clin-
ical method reports total cystine, in order to compare the two methods an additional
1 mM was added to each of the values obtained by ATR-FTIR (where there was a de-
tectable level of insoluble cystine). Hence, samples for which ATR-FTIR detected no
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insoluble cystine (5 cystinuric samples and 5 controls) may contain up to 1 mM soluble
cystine, represented by points at 0.5 mM ± 0.5 mM in Figure 5.13 A. After osetting the
ATR-FTIR values by 1 mM to allow for this, there was a good correlation between the
results obtained by the two methods (Pearson correlation coecient r=0.915), as shown
by the Bland-Altman plot (Figure 5.13 B).
A B
Figure 5.13: Comparison of cystine quantitation in urine by ion exchange chromatogra-
phy and by ATR-FTIR spectroscopy. (A) Comparison of cystine concentrations measured by ion
exchange chromatography and ATR-FTIR spectroscopy. A 1 mM oset has been applied to the ATR-
FTIR values for cystinuric samples to account for the additional soluble fraction that was discarded
after centrifugation. Samples containing no insoluble cystine (5 cystinuric samples and 5 controls)
are plotted as 0.5 ± 0.5 mM cystine to represent an unknown level of soluble cystine ranging from 0
up to 1 mM. (B) Bland-Altman plot to assess the similarity between ion exchange and FTIR methods
(including 1 mM cystine oset) for quantitating cystine. Only samples containing measurable levels
of insoluble cystine (determined by ATR-FTIR method) have been included. The X-axis shows the
mean of the cystine measurements by the two methods whilst the Y-axis shows the dierences from
mean of each method. Mean bias is shown by the dashed line with the 95% condence limits shown
by the dotted lines at mean bias ± 1.96 standard deviations.
5.2 Application of methods to other urinary disease
biomarkers. Case study: APRT-deciency
The methods described here for the detection and quantitation of insoluble cys-
tine are likely to be adaptable for the detection of other diagnostic materials in urine,
provided those materials have distinct absorbances in the mid-IR range and are present
at suciently high concentrations. The present method developed for cystine is most
suitable for measuring insoluble materials so most other kidney stone diseases are good
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targets for further investigation. A short investigation into the development of the ATR-
FTIR method for diagnosis of APRT-deciency is described in this section as an example.
5.2.1 Introduction to APRT-deciency
Adenine phosphoribosyltransferase deciency (APRTd) is a rare, inherited dis-
order in which mutations in the gene encoding APRT lead to loss of function or produc-
tion of the enzyme. APRT catalyses the conversion of adenine to adenosine monophos-
phate (AMP) but when the enzyme is decient adenine is instead converted to 2,8-
dihydroxyadenine (2,8-DHA), which is excreted into the urine. 2,8-DHA is poorly solu-
ble in urine so can crystallise to form kidney stones. It is also toxic and can potentially
lead to a decline in kidney function. Diagnosis of APRTd can be achieved by urine mi-
croscopy and identication of 2,8-DHA crystals by their distinctive round shape and
reddish-brown colour. Biochemical stone analysis cannot always distinguish 2,8-DHA
from uric acid, another stone-forming compound, but UV spectroscopy and x-ray crys-
tallography can distinguish the two. Other diagnostic tests include measuring APRT
activity and genetic testing [145–147]. These methods are generally either non-specic
or relatively expensive and time-consuming. A sensitive and specic method for detec-
tion of 2,8-DHA in urine samples is not widely available. Here, a simple method for
detection of 2,8-DHA in urine samples using ATR-FTIR spectroscopy is described.
5.2.2 Analysis of APRTd patient stone and urine samples
In order to generate a reference, an FTIR spectrum of pure synthesised 2,8-DHA
(structure shown in Figure 5.14) was recorded (Figure 5.15, black). This was compared to
a spectrum of a 2,8-DHA stone obtained from an APRTd patient (Figure 5.15, red). The
comparison conrmed that the stone sample was formed of 2,8-DHA and was relatively
pure. It also showed that the biological sample of 2,8-DHA that had formed a stone had
a very similar spectral signature to a pure 2,8-DHA sample.
Figure 5.14: Structure of 2,8-dihydroxyadenine.
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Figure 5.15: Reference absolute absorbance spectra of 2,8-DHA. The black trace is a spectrum
of dry, synthesised 2,8-DHA, whilst the red trace shows a stone sample from a patient diagnosed with
APRTd.
The second derivative of the absorbance spectrum of the synthesised 2,8-DHA
sample was calculated to facilitate easier deconvolution of overlapping bands, as shown
in Figure 5.16.
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Figure 5.16: Second derivative of the absorbance spectrum of synthesised 2,8-DHA.
Urine samples (A-F) from patients diagnosed with APRT-deciency (APRTd)
were collected and their IR spectra recorded to determine whether it is possible to detect
DHA in urine. Urine sample C was collected from a suspected APRTd patient. Urine
samples D-F were collected from three members of a family of APRTd suerers. The
urine samples were centrifuged before analysis to remove most of the dominating soluble
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components and dried, to remove the absorbance bands of liquid water and increase the
intensities of all non-volatile component. Figure 5.17 A shows the absolute absorbance
spectrum of the resuspended pellet derived from urine sample A after drying; Figure 5.17
B shows the second derivative of the same spectrum with the pure 2,8-DHA spectrum
overlaid.
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Figure 5.17: IR spectra of APRTd patient urine A. Superimposed IR absorbance spectra of dried
patient pelleted urine sample (red) and synthesised 2,8-DHA (black) as absolute (A) and second
derivative (B).
Several characteristic bands of 2,8-DHA are evident in the absolute urine spec-
trum, most clearly those at 883 cm−1, 980 cm−1 and 1119 cm−1. Since the second deriva-
tive transformation tends to sharpen bands (absorbance peaks become troughs in the
transformation) and remove broad baseline eects additional bands related to DHA can
be seen in the second derivative including those at 1390 cm−1, 1117 cm−1, 979 cm−1, 932
cm−1 and 881 cm−1.
Similar analyses of additional urine samples B-F, including three from members
of the same family (samples D-F), did not show any detectable trace of 2,8-DHA, that is,
there were insucient spectral features similar to the IR spectra of 2,8-DHA present in
the spectra of the urine samples. Figure 5.18 A, B & E-G shows the absolute spectra of the
insoluble fractions of urine samples B-F, overlaid with the spectrum of pure 2,8-DHA;
the equivalent spectra in second derivative are shown in Figure 5.18 C, D & H-J. There
are one or two bands that correlate between the reference 2,8-DHA spectrum and each
of the urine sample spectra, for example bands at 1246 cm −1and 1117 cm−1, however,
other stronger bands, such as those at 881 cm−1, 932 cm−1 and 979 cm−1, are absent.
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Figure 5.18: IR spectra of APRTd patient urine B-F. Superimposed IR spectra of dried patient
pelleted urine samples D-F (red) and synthesised 2,8-DHA (black). (A & C) Urine sample B. (B & D)
Urine sample C. (E&H) Urine sample D. (F & I) Urine sample E. (G& J) Urine sample F. First and third
rows show absolute spectra and second and fourth rows show the second derivative transformations
of the absorbance spectra immediately above.
Analyses of the supernatants of urine samples D-F also showed no indication
of presence of 2,8-DHA (Figure 5.19)
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Figure 5.19: IR spectra of APRTd patient urine D-F supernatants. Superimposed IR spectra of
dried supernatant of patient urine samples D-F (red) and synthesised 2,8-DHA (black).Top row shows
absolute spectra and bottom row shows the second derivative transformations of the absorbance
spectra immediately above.
In an attempt to determine the composition of the insoluble materials in urine
samples B-F their spectra were compared to spectra of other stone-related compounds
including oxalate, citrate, urate and uric acid (Figure 5.20). No clear correlations were
observed.
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Figure 5.20: Comparison of APRTd patient urine D-F with model compounds. Spectra of
the insoluble fractions of urine samples D-F compared to known stone-forming compounds, oxalate
(black), citrate (blue), urate (green) and uric acid (cyan). (A & C) Urine sample B. (B & D) Urine
sample C. (E & H) Urine sample D. (F & I) Urine sample E. (G & J) Urine sample F. First and third
rows show absolute spectra and second and fourth rows show the second derivative transformations
of the absorbance spectra immediately above.
In addition to human urine samples, urine samples from rat models of APRTd
were also collected and provided by Dr. Richard Fish, UCL. These samples were treated
in the same way as the human urine samples. The spectra of the insoluble fractions of
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urine samples from two rats (rat X and rat Y) are shown in Figure 5.21.
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Figure 5.21: IR spectra of urine from rat model of APRTd. Superimposed IR spectra of dried
insoluble fractions of rat model urine samples X (A&C) and Y (B &D) (red) and synthesised 2,8-DHA
(black). Top row shows absolute spectra and bottom row shows the second derivative transformations
of the absorbance spectra immediately above.
Although the rat urine spectra diered to the human urine spectra, with RatY
having a strong absorbance band at around 1000 cm−1 that was absent from human urine
spectra, and very little absorbance in other regions of the spectrum (Figure 5.21 B), and
RatX having an additional absorbance band at around 1740 cm−1, neither appeared to
contain any detectable 2,8-DHA.
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5.2.3 Analysis of a transmission spectrum of urine from a sus-
pected APRTd patient
A transmission FTIR spectrum of a urine sample from a suspected APRTd patient was
supplied by Michael P Metz, SA Pathology.
Comparison of the transmission IR spectrum of dried, pelleted urine from a
patient with suspected APRT-deciency with the absorbance IR spectrum of 2,8-DHA
measured at UCL indicates that this urine does not contain 2,8-DHA. Figure 5.22 shows
the comparison of these two samples and reveals the absence of bands that would indi-
cate the presence of 2,8-DHA.
Figure 5.22: Transmission spectrum of urine from a patient with possible APRT-
deciency (top) aligned with spectra of 2,8-DHA and sodium urate (boom).
The aligned spectra show that the supplied patient urine spectrum has ab-
sorbance bands at 1434 cm−1, 1387 cm−1, 1352 cm−1, 1260 cm−1, 1004 cm−1 and 887
cm−1, all of which can be seen in the spectrum of sodium urate. The bands in the urine
spectrum at 1004 cm−1 and 1260 cm−1 are clearly absent from the DHA spectrum. In ad-
dition, the DHA bands at 1237 cm−1, 1179 cm−1, 1119 cm−1, 980 cm−1 and 932 cm−1 are
absent from the patient urine spectrum. It is concluded that the urine pelleted material
has a large urate content but does not contain signicant amounts of DHA.
(Note:- the supplied spectrum was taken in transmission mode, whereas ours are
shown in absorbancemode; hence the inversion. Also, there is some distortion of bands in the
transmission spectra, probably caused by well-known physical phenomena that can aect
ATR spectra in certain congurations. It is also likely that the sample was not completely
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dried, contributing to the broad absorbance around 1650 cm−1. There may be additional
minor component(s) that account for possible additional bands).
5.3 Case study: trimethylaminuria
5.3.1 Introduction to trimethylaminuria
Trimethylaminuria is a hereditary condition in which excess levels of the ter-
tiary aliphatic amine, trimethylamine (TMA), are excreted into bodily uids, including
urine and sweat. This foul-smelling compound results in an unpleasant body odour that
has lead to the condition sometimes being referred to as ‘sh odor syndrome’. Although
not a life-threatening condition, trimethylaminuria can have severe psychosocial conse-
quences and is associated with depression and an increased rate of suicide [148].
TMA is produced by bacteria in the gut from dietary precusors, such as choline,
and is usually absorbed rapidly from the gut before being converted to non-odorous
TMA N-oxide by the enzyme, avin-containing monooxygenase 3 (FMO3). TMA N-
oxide is then excreted into the urine. Trimethylaminuria results from a defect in this
metabolic pathway and in particular, is associated with mutations in the gene that codes
for FMO3 [149]. The structures of TMA and TMA N-oxide are shown in Figure 5.23.
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Figure 5.23: Structures of trimethylamine (TMA) and TMA N-oxide. (A) Structure of TMA. (B)
Structure of TMA N-oxide.
Diagnosis of trimthylaminuria is typically achieved by assessment of clinical
symptoms and from the ratio of TMA to TMA N-oxide in urine samples. The identica-
tion of the genetic mutations associated with the condition, and the signiant reduction
in the cost of gene sequencing means that genotyping is now also a diagnostic option.
However, diagnosis is still problematic due to the variability in the symptoms within and
between individuals, and because the disease is associated with several dierent genetic,
and potentially non-genetic causes [148, 149].
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The potential of FTIR-spectroscopy as a rapid and sensitive alternative method
of detecting TMA and TMA N-oxide in urine samples was investigated. Such a method
could have potential uses clinically and experimentally when trying to detect, diagnose
and characterise trimethylaminuria.
5.3.2 Vapour and solution phase spectra of trimethylamine
Since TMA is particularly volatile, vapour phase transmission FTIR spectra of
TMA solutions were recorded to determine whether clinically relevant concentrations
could be detected. Figure 5.24 A shows the vapour spectrum of a 10 mM sample of TMA
between 3000 cm−1 and 2500 cm−1. The peaks centred around 2823 cm−1 and 2774 cm−1
are due to the TMA. Figure 5.24 B shows the vapour spectrum of a 1 mM sample of TMA
in the same region; the TMA peaks are not detectable at this concentration under the
conditions used.
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Figure 5.24: Vapour phase transmission spectra of TMA solutions. (A)10 mM. (B) 1 mM.
Figure 5.25 A shows the solution spectrum between 1800 and 850 cm−1 of 50
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mM TMA after subtraction of background buer and water vapour spectra. Figure 5.25
B shows the same spectrum between 3000 and 2500 cm−1. Whilst the signals are small
there is one clear feature at 1487 cm−1. This feature could not be detected in the vapour
phase spectra as it falls in a region where water vapour absorbs strongly. The absorbance
of water vapour in the vapour phase spectra was at least 100 times greater than the 10
mM TMA absorbance. The features between 1200 and 900 cm−1 in the solution spectra
are caused by phosphate. Figure 5.25 B reveals that the peaks at 2823 cm−1 and 2774
cm−1 seen in the vapour phase are not detectable above the intrinsic noise in the solution
phase spectrum at this concentration.
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Figure 5.25: Solution ATR spectra of TMA. 50 mM TMA in buered solution (pH 7) with buer
background and water vapour subtracted. (A) Spectrum between 1800 and 850 cm−1. (B) Spectrum
between 3000 and 2500 cm−1.
Solution phase spectra of non-volatile TMA derivative, TMA N-oxide, were also
recorded. Figure 5.26 A & B show the solution spectra between 1800 and 850 cm−1 of
25 mM and 5 mM TMA N-oxide respectively, treated as described for TMA. Peaks at
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1481, 1466, 1240 and 950 cm−1 can be detected at both concentrations. The strong peak
at 950 cm−1 is likely to be caused by the NO stretch. The negative peak at around 1630
cm−1 is likely to be the result of TMA N-oxide interacting with water, altering the water
structure and leading to an imperfect subtraction. Again, there are no peaks at 2823
cm−1 and 2774 cm−1 as can be seen in Figure 5.26 C.
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Figure 5.26: Solution ATR spectra of TMAN-oxide. 1800 - 900 cm−1 regions of the spectra of 25
mM (A) and 5 mM (B) TMA N-oxide solutions. (C) 3000-2500 cm−1 region of 25 mM TMA N-oxide
solution. All samples were adjusted to pH7 in phosphate buer and the same buer was used as a
background during spectra acquisition. A spectrum of pure water vapour was subtracted from each
sample spectrum.
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5.4 Discussion and conclusions
The purpose of this study was to assess whether ATR-FTIR spectroscopy could
be used as a tool for detecting disease biomarkers in urine. The main focus was to eval-
uate the technology as a fast, cost-eective method for routine monitoring of urinary
cystine. To achieve this goal, we focused on assessing the level of the insoluble cystine,
because it can be separated from possible interfering soluble components and because it
is this insoluble material that promotes stone formation and causes the cystinuric disease
complications.
Since patient uid intake before urine collection cannot be controlled easily,
insoluble cystine load was also compared to urinary creatinine concentrations to take
account of urine dilution. Both urea and creatinine can be quantitated using IR spectra
of whole (i.e. undried) urine samples [49, 91]. Creatinine was determined with a simple
algorithm that deconvoluted the overlapping bands of urea and creatinine that dominate
the 1510-1445 cm−1 region of whole urine spectra (Figures 5.1 - 5.4). These ATR-FTIR de-
rived values were validated by comparison with values obtained by the clinical standard
Jae reaction. A reasonable correlation between values determined by the two meth-
ods was found, although the Jae reaction tended to give slightly higher values. This
could be a result of additional chromogens in urine that interfere with the Jae reac-
tion method [143, 150, 151]. However, there were also two signicant outliers showing
large discrepancies between the creatinine measured by the two methods for reasons
that have not been resolved. The remaining data points fell within the range dened by
the 95% condence interval (± 1.96 standard deviations of the mean bias) [99]. For 67%
of the samples the dierence between the two methods was less than 2 mM creatinine
and for 81% of samples the dierence was less than 3 mM creatinine.
Suciently accurate quantitation of the insoluble cystine in these dried samples
was possible by comparison of the height of its 1296 cm−1 band in second derivative to
a calibration curve of the same band in spectra of dried, pure cystine suspensions. This
band was chosen because there is no strong absorber at this frequency in whole urine or
in other insoluble components that might be present in urine from patients with other
kidney conditions (including oxalate, urate and dihydroxyadenine). A line of best t
through the origin (Figure 5.9 B) was linear to at least 3 mM cystine and all but one
(where the cystine concentration was 3.1 mM) of the cystinuric samples measured fell
within this range.
A good correlation was found between the cystine levels measured by the FTIR
and clinical ion exchange chromatography methods. Notably, the FTIR method measures
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only the insoluble cystine in a sample, whilst the clinical method aims to measure total
cystine without specically reporting on insoluble cystine. In order to compare the two
methods, a 1 mM oset is applied to the FTIR values to account for the additional soluble
component included in the clinical values. However, the ability to assess only the level
of insoluble cystine in urine may be most useful clinically as it is this insoluble fraction
that leads to disease complications.
Since the cystinuric patients included in this study were advised on uid intake
and diet, and some were receiving drug treatment (Table 5.3), it could be expected that
some of the urine samples contained no insoluble cystine. Indeed, four cystinurics with
no detectable urinary insoluble cystine (P5, P13, P20 and P23) and three patients (P7,
P8, P11) with low insoluble cystine were receiving cystine-decreasing treatments. An
additional patient (P14) urine sample contained low insoluble cystine despite no drug
treatment, but the creatinine concentration was also very low indicating highly dilute
urine. P3 also had no detectable insoluble cystine, but was not on drug treatment and
the creatinine concentration was not particularly low, suggesting that this patient suf-
fered from only mild cystinuria. In contrast, high levels of cystine were recorded in
P1, P6, P15, P18 and P19; these patients were either not receiving drug treatment for
cystinuria (P6, P15 and P19) and/or had concentrated urine as judged by relatively high
creatinine concentrations (P1, P15 and P18). When assessing stone formation risk, a
more useful clinical parameter than absolute cystine concentration may therefore be the
cystine/creatinine ratio (Figure 5.27). For example, P1 and P18 had comparatively high
insoluble cystine concentrations, but P1 had a much higher cystine to creatinine ratio,
suggesting that this patient might have a more severe case of cystinuria.
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Table 5.3: Data on cystinuric patients used in study. Cystine and creatinine data are those
determined by ATR-FTIR methods described here (od = once daily, bd = twice daily, tds = thrice daily,
qds = four times per day, nocte = at night, mane = in morning).
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Figure 5.27: Urinary cystine to creatinine ratios. Bar graph showing the insoluble cys-
tine:creatinine (µM:mM), both determined by the ATR-FTIR spectroscopy methods, for the 22 cystin-
uric samples and 5 controls.
In summary, we show here that cystine can be quantitated from FTIR spectra
of the dried insoluble fractions of urine samples without any requirement for chemical
manipulation. A single band at 1296 cm−1 was selected for a simple quantitation; how-
ever, further enhancement of sensitivity and specicity for cystine could be achieved
if required by inclusion of additional cystine bands (e.g. those at 845 and 775 cm−1) in
the analytical algorithm or by other types of quantitation methods. The protocol could
also be adapted for use with a high throughput, automated sampling system, for exam-
ple on silicon plates with transmission mode FTIR spectrometer, thus providing a rapid
means for diagnosing cystinuria that could be labour- and cost-eective. Such an ability
to accurately measure urinary cystine concentrations on a regular basis in patients with
cystinuria would be of signicant benet both for diagnostic screening and for monitor-
ing the eectiveness of treatments.
A smaller pilot study was performed to determine whether the same approach
could be used to detect DHA in urine as a diagnostic assessment for APRT-deciency.
The region between 850 cm−1 and 1000 cm−1 is likely to be particularly useful for detec-
tion and quantitation of insoluble DHA in human urine samples, because the bands are
relatively strong and fall in a region of the urine spectrum that is less dense with bands
from other components.
The analysis of the 2,8-DHA stone sample and urine sample A from an APRT-
deciency patient indicates that FTIR-spectroscopy can be used to detect multiple char-
acteristic bands of DHA in urine samples. Pelleting and drying the samples before mea-
surement, coupled with analysis of second derivative spectra increases the sensitivity
of the method. However, it was not possible to condently detect 2,8-DHA in the other
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5 urine samples B-F. This may be because those samples did not contain any 2,8-DHA
or contained only very low quantities beyond the detection sensitivity of the method
described here. It is also possible that patient C is not APRT decient.
Comparison of urine samples B-F with other known stone-forming compounds
did not provide any further insight into the composition of the insoluble material in the
urine. Some of the absorbance bands arise from residual urea and creatinine that can-
not be easily separated from the insoluble pellet after centrifugation. Urea has strong
absorption bands at 1468 cm−1and between 1715 - 1580 cm−1 in absolute spectra. Cre-
atinine has a strong absorption band at 1492 cm−1 in absolute spectra. Spectra of all of
the human urine samples, both insoluble and soluble fractions, showed bands associated
with urea and creatinine. Urine samples E and F are also quite likely to contain signif-
icant protein in the insoluble fractions (Figure 5.18 F&G) based on the presence of the
amide II absorption band at around 1550 cm−1.
Development into a quantitative method is feasible with generation of appropri-
ate calibration curves and such analyses with a simplied bench top instrument within
the clinic should be possible. However, more urine samples would have to be analysed
to determine whether the sensitivity of the method is adequate for clinical application.
Comparison of the synthesised 2,8-DHA FTIR spectrum with a query spectrum
of urine from a patient with suspected APRT-deciency (Figure 5.22) reveals that this
is unlikely to be the correct diagnosis since no signicant 2,8-DHA was detected. This
spectrum instead indicated signicant levels of urate and this could itself be a cause of
stone formation [152].
Analysis of the insoluble fractions of urine from a rat model of APRTd also
did not show any evidence of the presence of 2,8-DHA. There were, however, several
additional bands that are not seen typically seen in healthy human urine. Further in-
vestigation would be needed to identify the origin of these bands and to develop a more
comprehensive analytical protocol for rat urine samples.
As well as kidney stone constituents, other compounds can be found in human
urine that are diagnostic for other types of disease. FTIR spectroscopy can be a useful tool
for detecting those compounds that are dicult to measure by other means. However,
many of these are soluble and so cannot be measured using the procedures described for
cystine and DHA. Here, the possible use of FTIR spectroscopy was also applied to the
detection of soluble trimethylamine (TMA) in solutions to determine whether clinically
relevant levels of TMA or TMA N-oxide could be detected in either vapour or solution
phases.
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It was possible to detect TMA in the vapour phase at 10 mM and in solution at
50 mM using FTIR spectroscopy. Lower concentrations can be detected under vapour
phase conditions because long path lengths can be used, and because absorbance bands
are much sharper in the vapour phase compared to the solution phase. Under the experi-
mental conditions used in this preliminary study, the expected limit of detection of TMA
in the vapour phase would be around 5 mM. However, it may be possible to detect lower
concentrations with optimised conditions, for example by using mirrors to increase the
pathlength of the IR light through the vapour or by adjusting the instrument settings
(e.g. increasing the number of background/sample scans and adjusting the scanner ve-
locity). It is unlikely that TMA can be detected in the solution phase at physiological
concentrations because the signals are weak and the peaks are broadened through in-
teraction with the aqueous environment. Furthermore, the symmetrical nature of TMA
means there are few infrared active vibrational modes.
TMA N-oxide is non-volatile so cannot be studied by vapour phase FTIR spec-
troscopy. However, the N-oxide group is strongly infrared active could be detected using
solution phase ATR-FTIR spectroscopy. TMA N-oxide produced a distinctive IR spec-
trum and could be detected down to 5 mM, although detection of lower concentrations
in solution would be challenging. Drying the samples would increase the signals in pure
solutions, and may oer a way of increasing the signals in urine samples.
A summary of the diagnostic methods for cystinuria, APRTd and trimethy-
laminuria, including the diagnostic materials and potential detection ranges, is presented
in Table 5.4.
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Table 5.4: Summary of diagnostic methods developed using FTIR spectroscopy for detec-
tion of urinary disease biomarkers.
D
isease
D
iagnostic 
m
aterial
M
ethod used
D
etection range
Physiological range
C
ystinuria
C
ystine
ATR
-FTIR
 spectroscopy of dried insoluble m
aterial. 
A
rea 1296 cm
-1 band in second derivative spectra 
calculated.
0.1-3+ m
M
 insoluble cystine
1-4+ m
M
 total cystine.
A
P
R
Td
2,8-D
H
A
ATR
-FTIR
 spectroscopy of dried insoluble m
aterial.
Identification of absorbance bands at 1390 , 1117, 979, 932 
and 881 cm
-1 in second derivative spectra.
N
ot established.
D
etection lim
it likely to be at 
least 0.1 m
M
.
S
olubility lim
it is 0.009 m
M
 
D
H
A
.
Trim
ethylam
inuria
TM
A
/TM
A N
-oxide
Identification of absorbance bands at 2823 and 2774 cm
-1 in 
vapour phase transm
ission spectroscopy of TM
A
.
Identification of absorbance bands at 1481, 1466, 1240 and 
950 cm
-1 in solution phase ATR
-FTIR
 spectroscopy of TM
A 
N
-oxide.
4-5+ m
M
 TM
A in vapour phase.
5+ m
M
 TM
A N
-oxide in solution 
phase, likely to be low
er if 
dried.
0.08-0.8 m
M
 TM
A
.
151
Chapter 6
ATR-FTIR spectroscopy as a
point-of-care diagnostic tool for
detecting disease biomarkers in fresh
urine samples
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6.1 Introduction
Urine samples contain a wide range of constituents that can provide valuable
diagnostic markers of disease states [108]. A range of clinical tests for many of these
are used routinely, although there is still a need for additional simple, rapid and high
throughput methods.
As discussed in the previous chapter, ATR-FTIR spectroscopy provides a simple
and fast means of recording spectra of various samples that are rich in information that
might be useful for diagnosing some diseases [3, 49, 79–81, 153, 154]. Until recently, the
spectrometers required for such analyses were complex and expensive. Since the ad-
vent of commercially available, low maintenance, benchtop instruments, coupled with
advanced and automated methods of data analysis, new possibilities for clinical appli-
cations have emerged. These newer machines are designed for continuous use for basic
mid-IR analysis and allow quick, easy and reliable FTIR analysis with extremely small
footprints. Unlike research-grade spectrometers, benchtop spectrometers operate with
room temperature detectors and permanently aligned interferometers that guarantee
precise data acquisition without adjustment.
Biouids are particularly attractive sample types for bedside disease diagno-
sis since they can generally be obtained quickly and non-intrusively. Mitchell et al.
(2014) [155] reviewed a number of studies in which vibrational spectroscopy was used to
identify biomarkers in various biouids (e.g. serum, whole blood and cerebrospinal uid)
for a range of diseases including cancers, diabetes and neurodegeneration. They hypoth-
esised that a microuidic device in combination with ATR-FTIR spectroscopy could be
designed to provide bedside analysis of biouids.
ATR-FTIR spectroscopy has also been used to analyse urine composition. For
example. Heise et al. (2001) [81] and Hoşafçi et al. (2007) [49] used partial least squares
(PLS) analysis to quantitate urea, creatinine, uric acid, phosphate and sulphate from
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urine sample spectra.Such methods could feasibly be translated to a bedside ATR-FTIR
device for point-of-care diagnostics.
Many potential disease biomarkers have been identied in urine using tech-
niques other than vibrational spectroscopy, including, biomarkers for early chronic kid-
ney disease (CKD) [156], acute kidney injury (AKI) [157, 158], bladder cancer [159, 160]
and even lung cancer [161]. Many of these biomarkers are proteins that would be di-
cult to distinguish in FTIR spectra. However, it might be possible to detect some of these
biomarkers from ATR-FTIR spectra of urine samples recorded on benchtop machines,
for example, lipoprotein and glycoprotein for CKD [156], total protein for AKI [157] and
hyaluronic acid for bladder cancer [159, 160]. This would enable a diverse range of dis-
eases to be diagnosed or screened rapidly and non-invasively using a single diagnostic
test.
The purpose of this study was to explore further the use of ATR-FTIR spec-
troscopy as a point-of-care diagnostic tool. A benchtop spectrometer was installed in the
Kidney and Urology Centre at the Royal Free Hospital (RFH), London (UK) to explore
the feasibility of operating such an instrument in a clinical setting and assess whether
suciently high quality spectral data can be obtained. Two nurses in the clinic were
asked to record spectra of wet urine samples collected from as many patients seen in the
clinic as possible, so as to generate a large database of urine spectra from a variety of
patients without targeting a particular kidney-related disease or patient demographic.
6.2 Development of protocols formeasuringurine sam-
ples on the benchtop spectrometer
Since the benchtop spectrometer was to be installed in a hospital clinic and
operated by non-specialists with limited training (mainly sta nurses) it was important
to ensure that good quality reproducible data could be generated with relative ease. A
crucial aspect was that the sta recording the measurements could do so with minimal
interruption to their normal working day. Therefore, the protocols for measuring the
urine sample spectra were developed to be as simple and quick as possible.
Problems associated with drying urine samples on to the ATR prism had been
previously observed and reported in earlier chapters. These include: hydration eects;
partitioning of urine components; variations in drying times; saturation of the IR signal
at high urine concentrations; and the need for very precise sample volumes. Further-
more, a protocol involving drying the urine samples would require additional equipment,
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training and time. Therefore, it was decided that urine samples would be recorded wet
and unprocessed.
A short manual was produced for sta operating the benchtop spectrometer
describing the protocol for recording the urine sample spectra (Appendix A). A macro
was also written in OPUS 7 which enabled sta to record background and sample mea-
surements without viewing or adjusting any software/hardware settings. Buttons were
placed on the main OPUS interface that could be clicked to call either the background
measurement or sample measurement macros (Figure 6.1). Easy-to-follow instructions
were then displayed on screen.
Sta were asked to start by thoroughly cleaning the prism with distilled water
followed by absolute ethanol using a lint-free tissue. Once the ethanol had completely
evaporated (3-5 seconds) a background measurement was recorded (before each sample
measurement, or every 30 minutes if recording several samples). Once the ‘RECORD
SPECTRUM’ option was selected a text box appeared with the option to input a sample
name and any additional details. Here, sta were asked to enter information about the
main diagnosis associated with the sample. A live spectrum of the blank prism was
displayed and this was examined to ensure the prism was clean. Around 100 μL of fresh
unprocessed liquid urine was then pipetted directly onto the prism so that it covered
the entire prism and the measurement was started. The urine samples were removed
from the prism as soon as the measurements had nished. The macro automatically
unloaded the spectrum from the OPUS interface and saved it to a specied directory on
the computer.
Figure 6.1: Simplied buons for evoking macros in OPUS 7.
6.3 Final dataset after quality control
All samples were collected from patients of the Kidney and Urology Centre at
the RFH. Age, sex, primary diagnosis (associated with visit to the clinic), confounding
diagnoses and current medications, as well as estimated glomerular ltration rate (eGFR)
were recorded for each patient. Two hundred and ninety-ve spectra of wet urine sam-
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ples from 256 patients were recorded. To determine whether a sample should be taken
forward for further analysis the signal size of the urea absorbance band at 1468 cm−1 was
considered along with the signal to noise ratio (SNR) of the spectrum. To be included
in the analyses the intensity of the absorbance at 1468 cm−1 after water subtraction and
before normalisation had to be above 1.5 x10−3 absorbance units. The SNR cut-o for
inclusion in the analyses was 1.3 at 1468 cm−1. After quality control, 206 spectra from
190 patients were taken forward for subsequent analyses. The age and sex distribution
of these 190 patients is summarised in Table 6.1.
Common diagnoses included:
• Stone disease (calcium phosphate/calcium oxalate, urate and cystine stones) as
well as hyperoxaluria, hypercitraturia and hypercalciuria, which are all associated
with increased risk of stone disease;
• Various diseases associated with kidney damage including polycystic kidney dis-
ease and renal cysts, chronic and familial kidney disease (CKD), end stage renal
failure (ESRF), nephritis and proteinuria;
• Recurrent urinary tract infections (UTI);
• Renal transplants.
An additional 42 urine samples were collected from healthy volunteers (no known med-
ical conditions), including sta at the RFH and individuals from University College Lon-
don (UCL) and Imperial College London. In most cases these urine samples were donated
anonymously and so age and sex information is not available.
Table 6.1: Ages and sex of patients donating urine samples to study. An additional 42 urine
samples from healthy volunteers were collected but age and sex information is not available for most
of these individuals.
Age Sex
18-30
yrs
31 - 50
years
51 - 70
years
>71
years
Male Female
Urine samples
collected at
RFH
22 83 76 9 116 74
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6.4 Identication of spectral variation and compari-
son to model compound spectra
Examination of the individual pre-processed urine spectra showed that whilst
the overall spectral band pattern was similar across all samples, there were a number of
prominent dierences as well as subtle changes in the shape or position of some bands.
Some of these changes fall in regions that are associated with specic biochemical com-
pounds such as proteins or sugars and can therefore be correlated with known disease
phenotypes. For example, the presence of an amide II band at around 1550 cm−1 in-
dicates the presence of protein in the urine and suggests the patient may have kidney
disease. The ngerprint regions of seven example spectra showing several variations are
plotted in Figure 6.2.
900100011001200130014001500160017001800
Wavenumber cm−1
A
bs
or
ba
nc
e
1.0Abs
0.2
Renal transplant / recurrent UTI
ESRF / renal transplant
Stone disease / calciuria
Stone disease / ESRF / renal transplant
Diabetes / nephritis / renal transplant
Stone)disease
Stone)disease
Sugars
900100011001200130014001500160017001800
Wavenumber cm−1
d2
(A
bs
) /
d 
 (c
m
   
 )
2
 
−1
Abs
0.002
Protein Urea
Sugars
Creatinine
Creatinine
U
re
a
Protein
A B
Figure 6.2: Examples of urine spectra recorded in the RFH clinic. Absorbance (A) and second
derivative (B) spectra showing specic biochemical components including urea, creatinine, protein
and sugars. Stars represent spectral features that vary between individual spectra and may be of
diagnostic interest.
To conrm that the protein amide II, urea, creatinine and sugar absorbance
bands identied in Figure 6.2 are correctly assigned, the urine spectra were compared
to some model compound spectra. In Figure 6.3, three example urine spectra are plotted
along with spectra of pure urea, creatinine, protein (BSA, as a model protein), glucose,
lactose, potassium phosphate (pH 7) and potassium sulphate (pH 7).
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Figure 6.3: Comparison of three example urine spectra with model urinary compound
spectra.
6.5 Comparison of all renal-related disease urine spec-
tra with healthy urine spectra
As an initial comparison, the urine spectra collected from diseased patients at
the RFH were compared to set of urine spectra from healthy individuals to determine
whether there were any common spectral features associated with renal-related diseases.
Figure 6.4 A shows an average of the 206 absorbance spectra of diseased urine samples
compared with an average of 42 absorbance spectra of healthy urine samples. The sec-
ond derivatives of these absorbance spectra were also calculated to give better resolution
of shoulders and remove broad baseline artefacts. Figure 6.4 B shows the averaged sec-
ond derivative spectra of all RFH disease samples and of the 42 healthy (control) urine
samples, while Figure 6.4 C shows the individual second derivative spectra. Peaks of
potential diagnostic interest have been highlighted with the arrows and numbered 1 to
17; where two arrows are indicated for a single peak, both peak intensity and peak shift
were analysed.
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Figure 6.4: Healthy vs. diseased urine spectra recorded in RFH clinic. All RFH disease urine
spectra (red) versus healthy urine spectra (black). (A) Average of all RFH disease urine absorbance
spectra and of all healthy absorbance spectra. (B) Second derivative transformations of averages
shows in A. (C) Individual second derivative spectra. Blue arrows represent features found to be sig-
nicantly dierent between the disease and healthy groups at signicance levels of at least 0.05. Black
arrows represent additional features that showed variation but were not statistically signicantly dif-
ferent between the two groups. All spectra were normalised to the area of their urea/creatinine band
range at 1468 cm−1 between 1487 and 1436 cm−1.
Some specic components can be identied from these spectra. Absorbance
bands of urea at ~1668, ~ 1630, ~1595, ~1468 (feature 9) and 1157 cm−1 can be clearly
seen, along with creatinine bands at ~1492, ~1426 and 1252 cm−1, which can be seen in
several of the urine spectra. Absorbance bands of phosphate can also be correlated with
the urine spectra at ~1157, ~1076 (features 7 and 13), ~991 (feature 16) and 939 cm−1. The
other absorbance bands and potential diagnostic features have not been assigned but can
be be correlated with general compounds such as sugars, proteins and lipids.
A peak area analysis of each of the features indicated in Figure 6.4 B & C was
performed. A simple comparison analysis was performed to determine whether there
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was a signicant dierence between the mean areas of the healthy and RFH disease
urine spectra for each of the 17 peaks. Since the data were not normally distributed,
according to Shapiro-Wilk normality tests performed in Origin 8.6, the Mann-Whitney
U test was applied. The peaks that were statistically signicantly dierent between the
healthy and RFH disease samples, at a signicance level of 0.05, are indicated with blue
arrows on Figure 6.4 B. Only four of the 17 features analysed did not show a signicant
dierence between the two groups; these are indicated by black arrows on Figure 6.4
B. Table 6.2 details the p-values for each feature comparison and indicates which peaks
are signicantly dierent between the healthy and RFH diseased samples at signicance
values of 0.05 and 0.01.
Table 6.2: p values for comparison of 17 spectral features between healthy and diseased
samples. * indicates features for which there was a dierence between the two groups at a signi-
cance level of 0.05 and ** indicates dierences at signicance level of 0.01.
Feature number p-value
1 0.99**
2 0.99**
3 0.99**
4 0.96*
5 0.49
6 0.82
7 0.94
8 0.99**
9 0.99**
10 0.65
11 0.99**
12 0.97*
13 0.99**
14 0.99**
15 0.99**
16 0.99**
17 0.99**
Since the standard deviation for any single peak for this dataset was large and
there was considerable overlap in the peak area distributions between the healthy and
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RFH disease samples, it was useful to combine several peaks in an attempt to improve
separation of the data. Scatter plots of the areas of two or three features were used to
see if there was any clustering of samples based on their diagnoses. Figure 6.5 shows a
selection of 2D and 3D scatter plots of features that gave the best separation.
The three dierent spectral feature combinations, shown in Figure 6.5, produced
clear clustering of the healthy samples away from the RFH disease samples, with a small
region of overlap. This suggests that it might be possible to identify patients with kidney-
related diseases based on infrared spectra of their urine.
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Figure 6.5: Healthy vs. diseased urine scaer plots. (A) Two-dimensional and (B & C) three-
dimensional scatter plots comparing the areas of spectral features found to be signicantly dierent
between the disease (red) and healthy (black) urine spectra. Each data point represents an individual
spectrum and has been plotted based on the calculated areas of features specied.
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6.6 Spectral identication of urine from patients with
abnormal glomerular ltration rate (GFR)
6.6.1 Patients with estimated GFR below 60 mL/min (CKD stage
3+)
The RFH urine sample spectra shown here represent patients with a variety of
diseases. Glomerular ltration rate (GFR) can be used as a measure of kidney function.
Abnormal GFR can indicate kidney damage arising from a variety of underlying diseases.
Since GFR is dicult to measure directly it is often estimated from serum creatinine
levels. To determine whether any spectral change can be correlated with specic clinical
indicators of kidney damage the RFH urine spectra were grouped according to estimated
GFR (eGFR). The threshold corresponding to normal eGFR is 60 mL/min, although most
healthy normal individuals would be expected to have a GFR > 90 mL/min. Patients
with eGFR < 60 mL/min are classed as having stage 3+ chronic kidney disease (CKD3+)
[162, 163]. The urine spectra of these patients were compared with spectra of healthy
urine samples, and to a second disease group of urine spectra from patients with eGFR
>60 mL/min.
The averaged second derivative spectra of these three groups (healthy, CKD3+
and eGFR>60) are plotted in Figure 6.6. The features that were previously found to vary
between healthy and diseased urine spectra were also found to be the most relevant for
comparing these groups. The areas of the 17 features for each of the spectra in the CKD3+
group were compared with the areas of the corresponding peaks of the eGFR>60 (normal)
group and the healthy group using Mann Whitney U analysis. The features that showed
signicant dierences at a signicance level of 0.05 are indicated by arrows in Figure 6.6.
Table 6.3 details the p-values for each feature comparison and indicates which peaks are
signicantly dierent between the healthy and diseased samples at signicance levels of
0.05 and 0.01.
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Figure 6.6: CKD3+ patient urine spectra. Averaged second derivative urine spectra of all healthy
(black), all CKD3+ (red, abnormal) and all eGFR>60 (blue, normal) groups. Red arrows represent
features found to be signicantly dierent between both the healthy and CKD3+ groups and the
eGFR>60 and CKD3+ groups at signicance levels of at least 0.05. Black arrows represent additional
features that showed signicant dierences between CKD3+ and healthy groups at signicance levels
of at least 0.05, but not between CKD3+ and eGFR>60 groups. The blue arrow represents a feature
that showed a signicant dierence between CKD3+ and eGFR>60 groups at a signicance level of
at least 0.05, but not between CKD3+ and healthy groups. All spectra were normalised to the area of
their urea/creatinine band range at 1468 cm−1 between 1487 and 1436 cm−1.
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Table 6.3: p values for comparison of 17 spectral features between healthy and CKD3+,
and between CKD3+ and eGFR>60 samples. * indicates features for which there was a dierence
between the two groups at a signicance level of 0.05 and ** indicates dierences at signicance level
of 0.01.
Feature number p-value CKD3+ vs. healthy p-value CKD3+ vs. eGFR>60
1 0.99** 0.95*
2 0.99** 0.97*
3 0.99** 0.99**
4 0.61 0.89
5 0.79 0.36
6 0.59 0.03
7 0.32 0.99**
8 0.25 0.76
9 0.99** 0.04
10 0.07 0.41
11 0.99** 0.99**
12 0.99** 0.99**
13 0.99** 0.99**
14 0.99** 0.24
15 0.99** 0.06
16 0.99** 0.67
17 0.99** 0.99**
Good separation of the healthy and CKD3+ groups could be achieved by plotting
the areas of three selected features in a 3D scatter plot; comparison of features 1, 15 and
17 gave the best separation of the two groups (Figure 6.7). Feature 17 corresponds to
the amide II vibration of protein and the presence of this band in a spectrum indicates
that the urine contained protein. Since proteinuria is an indicator of kidney damage, this
observation validates the use of feature 17 in discriminating between healthy urine and
urine from patients with abnormal GFR.
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Figure 6.7: CKD3+ vs. healthy scaer plot. Three-dimensional scatter plot comparing the areas
of 3 spectral features found to be signicantly dierent between the CKD3+ (red) and healthy (black)
urine groups.
For comparing the eGFR>60 and CKD3+ groups three dierent features were
selected for optimal separation as shown in Figure 6.8, although considerable overlap of
the two groups was observed.
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Figure 6.8: CKD3+ vs. the rest scaer plot. Three-dimensional scatter plot comparing the areas
of 3 spectral features found to be signicantly dierent between the CKD3+ (red, abnormal) and
eGFR>60 (blue, normal) groups.
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6.6.2 Patients with eGFR below 30 mL/min (CKD stage 4+)
Patients with eGFR values lower than 30 mL/min are classied as having stage
4 CKD (CKD4+), corresponding to severe kidney damage and kidney function of less
than 30%. Urine spectra from these patients were compared with healthy urine spectra
and to a second disease group containing spectra of urine samples from patients with
eGFR >30 mL/min. The averaged second derivative spectra of these three groups can be
seen in Figure 6.9. Table 6.4 details the p-values for each feature comparison and indi-
cates which peaks are signicantly dierent between the healthy and diseased samples
at signicance values of 0.05 and 0.01.
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Figure 6.9: CKD4+ patient urine spectra. Averaged second derivative urine spectra of all healthy
(black), all CKD4+ (red, eGFR<30) and all eGFR>30 (blue) groups. Red arrows represent features
found to be signicantly dierent between both the healthy and CKD4+ groups and the eGFR>30
and CKD4+ groups at signicance levels of at least 0.05. Black arrows represent additional features
that showed signicant dierences between CKD4+ and healthy groups at signicance levels of at
least 0.05, but not between CKD4+ and eGFR>30 groups. All spectra were normalised to the area of
their urea/creatinine band range at 1468 cm−1 between 1487 and 1436 cm−1.
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Table 6.4: p values for comparison of 17 spectral features between healthy and CKD4+,
and between CKD4+ and eGFR>30 samples. * indicates features for which there was a dierence
between the two groups at a signicance level of 0.05 and ** indicates dierences at signicance level
of 0.01.
Feature number p-value CKD4+ vs. healthy p-value CKD4+ vs. eGFR>30
1 0.81 0.01
2 0.81 0.33
3 0.98* 0.74
4 0.42 0.49
5 0.16 0.58
6 0.33 0.03
7 0.25 0.88
8 0.94 0.43
9 0.99** 0.37
10 0.05 0.32
11 0.98* 0.83
12 0.94 0.77
13 0.93 0.69
14 0.98* 0.13
15 0.87 0.05
16 0.99** 0.50
17 0.99** 0.98*
A 2D scatter plot comparing three features that gave the best separation of the
healthy and CKD4+ groups is shown in Figure 6.10.
167
−10 −8 −6 −4 −2 0 2 4
x 10−3
−3.5
−3
−2.5
−2
−1.5
−1
−0.5
0
0.5 x 10
−3
Ar
ea
 fe
at
ur
e 
16
 (9
97
−9
82
 cm
−
1 )
Area feature 17 (1564−1536 cm−1)
Figure 6.10: CKD4+ vs. healthy scaer plot. Two-dimensional scatter plot comparing the areas
of 2 spectral features found to be signicantly dierent between the CKD4+ (red) and healthy (black)
groups.
Only one spectral band, feature 17, was found to be signicantly dierent be-
tween the CKD4+ and eGFR>30 groups at a signicance level of 0.05 but not at 0.01.
A plot of the mean areas of feature 17 for each of the CKD4+, eGFR>30 and healthy
groups, indicates that the area of feature 17 becomes more negative (corresponding to
an increasing trough size) with increasing kidney damage (Figure 6.11).
Figure 6.11: Comparison of amide II absorbance between diseased and healthy groups.
Plot of the mean areas of feature 17 (amide II band) for the CKD4+, eGFR>30 and healthy groups.
Error bars represent standard error of mean.
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6.7 Discussion and conclusions
As well as an exploratory investigation of the diagnostic potential of urine FTIR
spectra, this project aimed to establish the feasibility of installing an infrared machine
in a hospital clinic to be run by a nurse. It was found that the sta nurses operating
the machine were able to incorporate easily the measurement of urine FTIR spectra in
their normal working day and record good quality, useable spectra. Two hundred and
ninety-ve spectra were recorded and 206 were taken forward for analysis. Of the 89
spectra not used in the analysis, most were rejected due to poor signal-to-noise. A small
number were rejected because of erroneous peaks in the spectrum. In particular, spectra
containing negative absorbance bands were removed as this indicates that the prism was
contaminated when the background scans were recorded and that this contamination
was subsequently removed when the prism was cleaned. Low signal to noise spectra
generally corresponded to very dilute urine samples.
Examination of the individual spectra after pre-processing revealed that several
biochemical components can be identied and that these displayed signicant inten-
sity dierences between between spectra from dierent patients. Compounds that have
particular diagnostic relevance include glucose and protein, which may be elevated in
the urine of patients with diabetes or kidney damage. Glucose and other sugars absorb
strongly in the 1000-1150 cm−1 region whilst protein has a distinctive amide II absorp-
tion band at around 1550 cm−1. These features can be identied with condence when
they appear in urine spectra. Other spectral features were also identied that were not
attributed to a specic biochemical, but may have diagnostic implications.
For all the disease groups studied there were clear dierences in their urine
spectra compared with the healthy group. However, it would be more useful clinically
to be able to distinguish dierent forms of kidney injury and disease. Unfortunately, the
sample numbers are currently too small to allow a robust analysis of individual kidney
disease groups. Furthermore, many of the patients included in the study suered from
multiple kidney-related illnesses or other confounding conditions.
One factor that could be compared to IR features is glomerular ltration rate
(GFR), which is used clinically as a measure of overall kidney function and can be a
useful indicator of disease. In healthy young adults GFR is generally around 120 to 130
mL/min but a decline in GFR is considered part of the normal aging process. Excessive
reduction in GFR is however used as an indicator of chronic kidney disease (CKD). CKD
is dened as the condition in which kidney damage or a decrease in kidney function
persists for 3 months or longer. CKD can have multiple causes and as such describes a
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number of conditions in which kidney damage is sustained. When GFR falls below 60
mL/min there is an increased risk of complications associated with CKD as 50% or more
of normal kidney function is lost. A GFR of 15 mL/min indicates kidney failure. Markers
of CKD include proteinuria (protein in the urine), an albumin to creatinine ratio greater
than 30 mg/g in spot urine, abnormal urine and serum biochemistries and abnormal
urine sedimentation. CKD is staged according to the level of kidney function as dened
by the GFR. GFR is dicult to measure directly and is therefore estimated from serum
creatinine levels using, for example, the following Modication of Diet in Renal Disease
(MDRD) equation:
GFR(mL/min per 1.73m2) = 186× (SCr)−1.154 × (Age)−0.203
× (0.742 if female)× (1.210 if African− American)
(6.1)
where SCr is serum creatinine concentration in mg/dL and age is in years [164]. An
alternative equation, the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation, is also widely used and is reportedly more accurate at higher GFR values:
GFR = 141×min(SCr/κ, 1)α ×max(SCr/κ, 1)−1.209
×0.993Age × (1.018 if female)× (1.159 if black) (6.2)
where SCr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for fe-
males and -0.411 for males, min indicates the minimum SCr/κ or 1, and max indicates
the maxSCr/κ or 1 [165]. However, CKD is underdiagnosed due to disagreement in the
staging classication, lack of accuracy in eGFR calculations and lack of diagnostic tests.
Furthermore, patients with ‘normal’ eGFR may still exhibit markers of kidney damage,
such as proteinuria, which could go undetected. As a result preventative treatment can-
not always be administered [162, 164–167].
Comparison of urine spectra from patients with abnormal eGFR with healthy
patients showed that there were dierences in several spectral features that allowed good
separation of the two groups. A similar comparison of eGFR>60, CKD3+ and CKD4+
patient urine indicated that it might be possible to discriminate among patients based
on the extent of kidney damage. This method could be used as a rapid screening tool
to determine whether a patient has kidney damage and to indicate the extent of the
damage, irrespective of the underlying cause. In addition, other diagnostic information,
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including proteinuria, could be obtained without the need for further tests which could
be useful for detecting early stage disease.
Many of the patients in this study were on medications for treatments of kidney-
related diseases and other conditions. In some cases, this will reduce the symptoms of
a disease and could lead to a patient presenting as ‘normal’. For example, elevated uri-
nary glucose in an untreated diabetic patient may return to a normal level on starting
treatment. It may therefore not be possible to distinguish a true healthy patient from
one whose disease is being corrected with medication. An additional consideration con-
cerning medication is that some medicines will be excreted in the urine (as either native
drug or as a derivative) and may lead to drug-associated spectral features. While this
may complicate analyses of urine spectra, if a drug can be detected in urine it may be a
useful measure of the patient’s compliance to their treatment programme.
Other confounding variables may include age, sex and race related dierences in
the levels of some compounds in urine. The sample size is currently not large enough to
reliably account for such dierences. In addition and importantly, this study was unable
to take into account the time of day of urine collection, which is likely to result in large
variations in the urine composition because of factors such as diet, activity level and
timing of medication administration. It would be informative to track a single patient
with a known disease over a period of time of treatment, with collection and analyses
of multiple urine samples at regular intervals, to determine whether any patterns of IR
features and their responses to treatments can be detected.
This initial study on the feasibility of using a benchtop infrared spectrometer
‘at the bedside’ in a hospital clinic has shown that it has potential as a diagnostic tool. It
was possible to detect a number of biochemical compounds in a single urine spectrum.
Further data collection and analyses development will be required to establish to what
extent this method can give more detailed diagnostic information for specic diseases.
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Chapter 7
Detection of pancreatic cancer by
ATR-FTIR spectroscopy
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7.1 Introduction
Cancer is a progressive disease characterised by uncontrolled cell proliferation.
This occurs when the tightly controlled mechanisms for regulating cell growth and repli-
cation fail and the tumour mass is able to induce angiogenesis and activate metasta-
sis. Accumulation of epigenetic and genetic damage involving mainly oncogenes, tu-
mour suppressor genes and DNA repair genes all contribute to the development of a full
blown cancer. These processes are accompanied by biochemical changes in both tumour
and neighbouring cells that can potentially be detected before any signicant structural
changes occur [168, 169].
Tumours range in aggressiveness from slow growing benign lesions to fast
growing fully invasive and metastatic cancers, with 5-year survival rates varying ac-
cordingly. Pancreatic cancer is associated with a very poor 5-year survival rate of 5 %,
and a 10-year survival rate of only 1 %. It is the fourth most common cause of cancer
deaths in men and the fth in women, and there has been little improvement in survival
rates since the 1970s. The poor survival statistics are in large part a result of diagnosis
only at the advanced metastatic stage of the disease, since there are no current screening
programmes and symptoms tend to be general or absent in the early stages [170–172].
Although population screening for pancreatic cancer is not currently practised, some in-
dividuals have an increased risk of developing pancreatic cancer and can be monitored
for disease even if symptomless. In particular, there are known genetic aberrations as-
sociated with pancreatic cancer and individuals with an aected rst-degree relative are
particularly at risk. Lifestyle factors such as diets high in fat, meat and nitrates, and med-
ical conditions including diabetes mellitus and chronic pancreatitis also increase the risk
of developing the disease [170–177].
Tumours of the pancreas are categorised based on the types of cells from which
they originate; these may be cells of the exocrine pancreas, the endocrine pancreas or
the lymphatic system of the pancreas. Ductal adenocarcinomas (ADCs), the most com-
mon type of pancreatic cancer, originate in the exocrine cells which are responsible for
producing digestive juices. Across North America and parts of Europe and South Amer-
ica the incidence rate of pancreatic ductal ADC is approximately 10 in 100 000 per year,
increasing to 200 in 100 000 per year for over-80-year-olds. Pancreatic neuroendocrine
tumours (pNETs) originate in the endocrine cells where hormones such as insulin are
produced. Ampulloma tumours arise at the boundary of the pancreatic duct, bile duct
and duodenum. Although not technically a pancreatic tumour the ampulloma is treated
in much the same way as an exocrine-type malignancy. The symptoms, treatments and
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prognosis of exocrine and endocrine tumours dier (Cancer Research UK) [172, 177].
Staging of pancreatic tumours usually follows the widely used TNM system.
The tumour is assessed for size and invasion of surrounding tissue (T), spread of cancer
cells to regional lymph nodes (N) and presence or absence of distant metastases (M) in
which the cancer has spread to distant lymph nodes or other tissues or organs. Hyperpla-
sia, metaplasia and dysplasia may be observed in pre-invasive and early stage tumours
although these are not well documented in the literature [174,178]. The TNM stage can
be summarised to give an overall stage or score from 0 to 3, where 0 represents benign
tumours and 3 represents the most aggressive malignant tumours. Alternative staging
scores based on the tumour’s resectability may also be assigned [170].
Diagnosis and staging may be achieved by histological analysis of a biopsy sec-
tion, or through other methods such as imaging. Computed tomography (CT) is the
imaging method of choice, but MRI or ultrasound can be used as alternative or comple-
mentary techniques. If a diagnosis can be conrmed through imaging methods alone
then a biopsy conrmation before tumour resection is not necessarily required. How-
ever, histological analysis of the resected tumour is usually performed [170,173,175,179].
There is a need for more sensitive diagnostic procedures that can detect early
stage disease and dierentiate tumour types. Currently, the high false negative rate of
pancreatic biopsy analysis has resulted in clinicians operating on patients without prior
biopsy. In addition, dierent tumour types are associated with dierent prognoses so
a more reliable biopsy analysis method would better inform the decision on treatment
and whether or not to operate.
ATR-FTIR spectroscopy might provide a rapid and quantitative method for analysing
pancreatic biopsies and has the potential to detect the subtle compositional changes that
are associated with the early stages of tumour development. Whilst there is a rich lit-
erature describing the application of FTIR spectroscopy to the diagnosis of many other
cancers, there are only a handful of groups who have attempted applying the technology
to pancreatic cancer.
Kondepati et al. (2006) [180] studied DNA isolated from pancreatic adenocar-
cinoma samples for structural changes associated with carcinogenesis. Spectra were
classied by HCA and peaks responsible for clustering were identied. Cluster analy-
sis using the 1192 – 1059 cm−1 spectral region, which includes contributions from the
deoxyribose-phosphate backbone of DNA, discriminated the tumour and normal DNA
spectra with a sensitivity of 87 % and specicity of 80 %, where two tumour and three
normal spectra were misclassied.
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Another study sampled normal and cancerous tissue from the pancreas of a sin-
gle patient for investigation by FTIR imaging [181]. Amide bands at 1659, 1547 and 1232
cm−1 were all reportedly reduced in cancerous samples when compared to normal tissue,
along with other bands associated with protein. Decreases were also seen in the inten-
sity of bands associated with lipid in cancerous tissue. However, there was no mention
of spectra normalisation so these changes may be an artifact of sample thickness.
Clearly, further investigations are warranted of the FTIR characteristics of nor-
mal and tumorous pancreatic tissue samples, particularly to identify early changes in
cells that could be used as an early detection method.
Pancreatic tissue resections were collected during major pancreatic surgery, in
most cases samples were matched so that a sample of pancreatic tumour tissue and a
sample of ‘healthy’ pancreatic tissue was taken from each patient. Therefore, all ‘nor-
mal’ samples were taken form patients with a tumour elsewhere in the pancreas. ATR-
FTIR spectra of 43 fresh pairs of matched human pancreas tissue resections (43 tumour
and 43 healthy) plus 3 unmatched tumour resections and 1 unmatched normal pancreas
resection were recorded without any sample manipulation. Tumour staging informa-
tion was also recorded and spectra of normal pancreas were compared to tumours of
dierent stages in an attempt to identify the spectral features associated with pancre-
atic tumour progression. Table 7.1 summarises the number and stages of the pancreatic
tissue resections received.
Table 7.1: Summary of numbers and stages of pancreatic tumour samples received.
Tumour type No. samples No. spectra
Stage 0 (benign) 6 12
Stage 1 10 20
Stage 2 13 26
Stage 3 17 34
Normal (non-tumour) 44 86
7.2 Summary of ATR-FTIR spectra collected of pan-
creatic resections
For detailed analyses the spectra were converted to their second derivatives
to remove broad baseline artefacts, sharpen peaks and allow easier deconvolution of
overlapping bands. The individual processed second derivative sample spectra can be
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seen in Figure 7.1 and the averaged second derivative spectra of all tumour samples
and of all normal pancreas samples are plotted in Figure 7.2, along with the computed
dierence between them.
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Figure 7.1: Individual second derivative spectra of normal and tumour pancreatic tissue.
Normal pancreas tissue spectra are shown in black and tumour sample spectra are shown in red. The
1800 – 950 cm−1 range of the ngerprint region only is shown. All spectra were normalised to the
intensity of the amide II band (intensity at 1547 cm−1 minus intensity at 1527 cm−1).
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Figure 7.2: Averaged second derivative spectra of normal and tumour pancreatic tissue.
The black spectrum represents the mean of all normalised normal pancreas tissue spectra and the red
spectrum is the mean of all normalised tumour sample spectra. The blue trace shows the dierence
spectrum. Green boxes represent the peaks chosen for integration and comparison between normal
and tumour samples.
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7.3 Integration analysis of healthy and cancerous pan-
creas biopsy spectra
Seven potential peaks of interest/dierences between the pancreas and tumour
spectra were identied. The frequency limits for integrations were chosen based on a
comparison of Figures 7.1 and 7.2. The chosen features are summarised in Table 7.2.
Table 7.2: Summary of potential features selected to distinguish between normal and tu-
mour pancreas samples.
Feature Number Wavenumber range (cm−1)
1 1329 - 1311
2 1232 - 1213
3 1169 - 1146
4 1105 - 1092
5 1088 - 1070
6 1066 -1053
7 1051 - 1028
The integrals of the areas of these features were calculated for each sample
spectrum and were plotted against one another to generate 3D scatter plots. A combina-
tion of features 2, 3 and 7 were found to give the best separation of normal and tumour
samples in a scatter plot of this kind (Figure 7.3).
177
0
0.5
1
1.5
−1
−0.8
−0.6
−0.4
−0.2
0
−2.5
−2
−1.5
−1
−0.5
0
0.5
Area feature 3 
(1169 − 1146 cm−1)
Area feature 2 
(1232 − 1213 cm−1)
Ar
ea
 fe
at
ur
e 
7 
(1
05
1 
− 1
02
8 
cm
−1
)
x10-3
x10-3
x10-3
Figure 7.3: Scaer plot comparing normal pancreatic and tumour tissue. Comparison of
integrals of spectral features 2, 3 and 7 (Table 7.2). Each data point represents a single spectrum from
a normal pancreas (black) or tumour (red) tissue sample.
The tumour samples were scored/staged from 0 (benign) to 3 (most advanced
stage) based on histological analysis under the light microscope of H&E stained tissue
sections (this was performed externally by Dr. Jorge Paulino Pereira, Universidade Nova
de Lisboa, Portugal). Scores were assigned based on the TNM staging system. The mean
averages of the IR spectra of each of the tumour groups (0-3) were computed and com-
pared to determine whether there were any spectral changes that could be correlated
with tumour progression stage (Figure 7.4). Figure 7.5 is a replication of Figure 7.3 in
which each point has been coloured according to its corresponding staging score.
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Figure 7.4: Averaged second derivative spectra of normal pancreatic tissue and tumour
stages 0-3. Second derivative spectra of normal pancreas (black) and stage 0 (blue), stage 1 (green),
stage 2 (red) and stage 3 (magenta) tumour samples.
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Figure 7.5: Scaer plot comparing normal pancreatic and tumour stages 0-3. Comparison
of integrals of spectral features 2, 3 and 7 (Table 7.2). Each data point represents a single spectrum
from a normal pancreas (black) or a stage 0 (blue), 1 (green), 2 (red) or 3 (magenta) tumour tissue
sample.
Figures 7.4 and 7.5 indicate that there are several spectral transitions that may
be correlated with dierent stages as the tumours develop although there is considerable
overlap between samples. The clearest transition can be seen in the band at ~1050-1000
cm−1, where there is both a shift to lower wavenumbers and an increased absorbance
intensity (larger trough) from normal to stage 3 tumour. Other possible transitions occur
at ~1310 cm−1 and at ~1120 cm−1.
7.4 PLS-logistic regression model: staging of tumour
tissue
Partial least squares (PLS) logistic regression of the IR spectral data was used
in order to improve the separation of dierent stages, to make the analysis more statis-
tically robust and to provide quantitative results. PLS was used to minimise the chance
of overtting by reducing the dimensionality of the data whilst maintaining the rela-
tionship between the spectral pattern and the disease groups. Logistic regression is a
common classication method to use on categorical data, such as this pancreatic spec-
tra dataset. After optimisation, it was found that three PLS-logistic regression models
used in series gave the best separation of the data. Figure 7.6 summarises the proposed
diagnostic pipeline.
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Figure 7.6: Proposed diagnostic pipeline for classifying FTIR spectra from pancreatic can-
cer patients according to tumour stage using PLS logistic regression.
Model 1: separating all normal spectra fromall tumour spectra. The 1175
- 1025 cm−1 regions of the second derivative spectra were extracted and mean centred.
Five PLS latent variables (LVs) were chosen for the logistic regression because this gave a
good compromise between specicity and sensitivity of separation into the two classes.
A cost of 1.5 was applied for incorrectly assigning a tumour spectrum as normal (correct
classication of normal and tumour had no cost).
Model 2: separating stage 3 tumour spectra from all other tumour spec-
tra. The 1450 - 1050 cm−1 regions of the second derivative spectra were extracted and
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mean centred. Six PLS LVs were chosen for the logistic regression. A cost of 1.25 was
applied for incorrectly assigning a stage 3 tumour spectrum as any other stage tumour
(correct classication had no cost).
Model 3: separating stage 0 and 1 tumour spectra from stage 2 tumour
spectra. The 1150 - 1025 cm−1 regions of the second derivative spectra were extracted
and mean centred. Five PLS LVs were chosen for the logistic regression.
In all cases, leave-one-patient-out cross validation was used to assess the pre-
dictive ability of the PLS logistic regression model.
7.4.1 Performance ofmodel 1: separating all normal spectra from
all tumour spectra
Before assessing the performance of the model it was important to conrm that
the largest features in the loadings plots (i.e. those features with the biggest contribution)
corresponded to true signal variations rather than dierences in noise. Examination of
the loadings on the rst ve LVs of model 1 (Figure 7.7) conrmed that they are likely
to represent true signal dierences between normal and tumour sample spectra.
181
1040106010801100112011401160
−0.2
−0.1
0
0.1
0.2
0.3
Wavenumber (cm−1)
Lo
ad
in
g
1040106010801100112011401160
−0.2
−0.1
0
0.1
0.2
0.3
Wavenumber (cm−1)
Lo
ad
in
g
1040106010801100112011401160
−0.2
−0.1
0
0.1
0.2
0.3
Lo
ad
in
g
Wavenumber (cm−1)
1040106010801100112011401160
−0.2
−0.1
0
0.1
0.2
0.3
Wavenumber (cm−1)
Lo
ad
in
g
1040106010801100112011401160
−0.2
−0.1
0
0.1
0.2
0.3
Wavenumber (cm−1)
Lo
ad
in
g
LV1 LV2
LV3 LV4
LV5
Figure 7.7: Loadings on the rst ve latent variables for PLS logistic regression model 1.
Figure 7.8 shows the scatter plot of scores of LVs 1, 2 and 4 for each spectrum.
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Figure 7.8: 3D scaer plot for model 1. Scores plot of LVs 1, 2 and 4 for normal pancreas (black)
and tumour (red) tissue samples.
The scores on the LVs for each spectrum were used to build the logistic re-
gression model. Probability scores were computed for each spectrum that describe the
likelihood of that spectrum belonging to the either the normal or the tumour classes.
The nal assignment of the spectrum to either class was achieved by selecting the class
associated with the highest probability. Since this was a two-class model this is equiv-
alent to setting a class threshold of 0.5 where a value closer to 1 (above 0.5) indicates
membership to the given class. Each spectrum was assigned by choosing the most prob-
able class, meaning every spectrum was classied into one or other class and none were
unassigned.
Table 7.3 shows the confusion table for the Normal vs Tumour PLS logistic re-
gression model (model 1), where values on the main diagonal (top left to bottom right)
show the number of correctly assigned spectra and the o-diagonal values are the num-
bers of incorrect assignments. Calculated sensitivities and specicities for predicting
spectra as normal or tumour are listed in Table 7.4. Sensitivity is a measure of the model’s
ability to identify all spectra that belong to the class in question (i.e. the extent that false
negatives are minimised). Conversely, specicity is measure of the model’s ability to
exclude all other classes from the class in question (i.e. the extent that false positives
are minimised). The overall accuracy of the model was 84%. To maximise the sensitivity
of the model for detecting tumour spectra a cost was applied for incorrect classication
of tumour spectra as normal. Consequently, the specicity of tumour detection is de-
creased and an increased number of normal spectra were classied as tumour. If an equal
cost for incorrect classication was applied the sensitivity of detecting normal spectra
increased to 81% but the sensitivity of detecting tumour spectra fell to 82%.
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Table 7.3: Confusion table for model 1. Confusion table showing number of normal and tumour
spectra correctly predicted after cross validation.
Predicted class
Normal Tumour
Actual class
Normal 66 20
Tumour 9 83
Table 7.4: Sensitivities and specicities formodel 1. Sensitivities and specicities for predicting
normal and tumour spectra after cross validation.
Sensitivity (%) Specicity (%)
Normal 77 90
Tumour 90 77
7.4.2 Performance of model 2: separating stage 3 tumour spectra
from stages 0-2 tumour spectra
A second PLS logistic regression model was built to separate tumour spectra
according to stage. Since the stage 3 tumour group was bigger than any of the stage 0, 1
or 2 tumour groups a model was built to rst separate the stage 3 tumour spectra from
the rest of the tumour spectra. Examination of the loadings on the rst 6 LVs (Figure
7.9) conrmed that they are likely to represent true signal dierences between normal
and tumour sample spectra.
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Figure 7.9: Loadings on the rst 6 LVs for PLS logistic regression model 2.
Figure 7.10 shows a scatter plot of the scores of LVs 1, 2 and 5 for each spectrum.
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Figure 7.10: 3D scaer plot for model 2. Scores plot of LVs 1, 2 and 5 for stage 0 - 2 tumours
(blue) and stage 3 tumours (magenta).
Table 7.5 shows the confusion table for model 2 (stage 0 - 2 tumours versus stage
3 tumours) and calculated sensitivities and specicities for predicting spectra as stage 0
- 2 or stage 3 are listed in Table 7.6. The overall accuracy of this model was 84%.
Table 7.5: Confusion table for model 2. Confusion table showing number of stage 0 - 2 and stage
3 tumour spectra correctly predicted after cross validation.
Predicted class
Stage 0 - 2 Stage 3
Actual class
Stage 0 - 2 50 8
Stage 3 7 27
Table 7.6: Sensitivities and specicities formodel 2. Sensitivities and specicities for predicting
stage 0 - 2 and stage 3 tumour spectra after cross validation.
Sensitivity (%) Specicity (%)
Stage 0 - 2 86 79
Stage 3 79 86
7.4.3 Performance ofmodel 3.: separating stage 2 tumour spectra
from stages 0 & 1 tumour spectra
Since early-stage detection of pancreatic cancer is key to increasing survival
rate, a model was built to try to further distinguish early-stage tumour spectra. Limited
availability of early stage tumours meant that there were relatively few samples in each
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of the stage 0, 1 and 2 classes, therefore stage 0 and stage 1 tumours were grouped into
a single class. Five PLS LVs were used in the PLS regression model and the loadings
on these LVs are shown in Figure 7.11 to demonstrate that they represent true signal
dierences.
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Figure 7.11: Loadings on the rst 5 LVs for PLS logistic regression model 3.
Figure 7.12 shows a scatter plot of the scores of LVs 3, 4 and 5 for each spectrum.
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Figure 7.12: Scores plot for model 3.. Scores plot of LVs 3, 4 and 5 for stage 0 and 1 tumours
(green) and stage 2 tumours (cyan).
Table 7.7 shows the confusion table for model 3 (stages 0 and 1 tumours versus
stage 2 tumours) and calculated sensitivities and specicities for predicting spectra as
stages 0 and 1 or stage 3 are listed in Table 7.8. The overall accuracy of this model was
64%.
Table 7.7: Confusion table for model 3. Confusion table showing number of stages 0 and 1 and
stage 2 tumour spectra correctly predicted after cross validation.
Predicted class
Stage 0 and 1 Stage 2
Actual class
Stage 0 and 1 23 9
Stage 2 12 14
Table 7.8: Sensitivities and specicities formodel 3. Sensitivities and specicities for predicting
stages 0 and 1 and stage 2 tumour spectra after cross validation.
Sensitivity (%) Specicity (%)
Stage 0 and 1 72 54
Stage 2 54 72
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7.5 Correlation of pancreas biopsy spectrawithmodel
compound spectra
In general it is dicult to assign peaks in tissue spectra to specic biochemical
components since the spectra are complex with many overlapping bands. More con-
dent assignments can be made by correlating multiple peaks with model compound
spectra, or by use of additional complementary biochemical tests. However, compari-
son to model compound spectra can give an indication of the types of compounds that
might be contributing to the sample spectrum or to the dierences between normal and
diseased sample spectra.
In order to support continued proliferation, tumour cells have been reported
to alter their metabolic pathways to generate the energy required for growth [168].
Changes in the content of carbohydrates, particularly glycogen, in tumour cells com-
pared to normal cells have been reported by many groups who have used FTIR spec-
troscopy for cancer diagnostics [18,35,55,56,65,168]. Potential carbohydrate biomarkers
for pancreatic cancer have also been proposed. For example, carbohydrate antigen 19-9
(CA-19-9) is an FDA-approved biomarker for pancreatic cancer, and the levels of other
carbohydrates including CA-50 and CA-242 have been shown to be altered in pancreatic
cancer. It is unlikely that FTIR spectroscopy would be able to detect changes in these
specic carbohydrates but it may be able to report on global changes in carbohydrate
content [182, 183].
Figure 7.13 shows how the pancreatic tissue spectra compare to model spectra
of glycogen and glucose. These sugars absorb strongly in the 1200 - 1000 cm−1 region,
which is also the region associated with the biggest dierences between the normal and
tumour pancreatic tissue spectra, where there is an overall slight increase in absorbance
intensity going from normal tissue to stage 3 tumours. Dierences in carbohydrate con-
tent may contribute these spectral dierences.
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Figure 7.13: Comparison of pancreatic tissue spectra with model sugar spectra. Model
sugars shown are glycogen and glucose. Dashed lines indicated possible correlated peaks between
the pancreatic tissue spectra and model sugar spectra. The overlaid spectra at the bottom of the
plot represent normal pancreas (black) and stage 0 (blue), stage 1 (green), stage 2 (red) and stage 3
(magenta) tumour samples.
Changes in RNA and/or DNA content of tumour tissue compared to normal
tissue have been reported in FTIR spectroscopy studies of cancers [31,35,55,88], includ-
ing in a study looking at pancreatic cancer [180]. These dierences may come about
through changes in chromosome ploidy of tumour cells and dysregulation of gene ex-
pression [184–186]. The model spectra of RNA and DNA (Figure 7.14) show that these
compounds have signicant absorbance bands between 1200 and 1000 cm−1 so may also
contribute to the dierences between normal and tumour pancreatic tissue spectra in
this region.
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Figure 7.14: Comparison of pancreatic tissue spectra with model RNA and DNA spectra.
Dashed lines indicated possible correlated peaks between the pancreatic tissue spectra and model
RNA and DNA spectra. The overlaid spectra at the bottom of the plot represent normal pancreas
(black) and stage 0 (blue), stage 1 (green), stage 2 (red) and stage 3 (magenta) tumour samples.
Although FTIR spectroscopy cannot generally distinguish between dierent
types of protein, collagen and mucin are two proteins with unique compositions that
produce some distinctive IR signals and changes in their cellular content have been cor-
related with pancreatic cancer. Mucin is a highly glycosylated protein that is produced
by epithelial cells and is the main constituent of mucus. Membrane bound mucins also
exist. Mucins are present in normal pancreatic tissue, but are also thought to be involved
in tumour development due to their roles in cell signalling, dierentiation and prolifer-
ation. Indeed, changes in the expression pattern of mucins during pancreatic tumour
progression have been identied [182, 187, 188]. Collagen is an abundant extracellular
protein found in connective tissue. One study found increased expression of type IV
collagen in pancreatic tumour tissue and high levels of circulating type IV collagen in
patients with the disease [189].
Figure 7.15 compares the pancreatic tissue spectra with collagen and mucin
model spectra (with albumin included as a reference for general protein). Multiple bands
can be correlated between the protein and sample spectra, particularly in between 1200
and 1000 cm−1 but the spectra are complex and specic assignment is not possible.
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Figure 7.15: Comparison of pancreatic tissue spectra with model protein spectra. Model
proteins shown are albumin, mucin and collagen. Dashed lines indicated possible correlated peaks
between the pancreatic tissue spectra and model protein spectra. The overlaid spectra at the bottom
of the plot represent normal pancreas (black) and stage 0 (blue), stage 1 (green), stage 2 (red) and
stage 3 (magenta) tumour samples.
7.6 Discussion and conclusions
The individual normal and tumour tissue spectra and their respective averaged
spectra show that there are several spectral dierences between the normal and tumour
tissue. Some of these dierences are subtle (e.g. features 3, 4 and 5) whilst others are
more pronounced (e.g. features 1, 6 and 7). One of the normal sample spectra was
considerably dierent to the others and may represent an outlier. Examination of the
individual sample spectra in Figure 7.1 reveals that the tumour samples exhibit more
variation, particularly between 1200 and 1000 cm−1, than the normal samples. This may
be the result of increased heterogeneity in tumorous tissue compared to healthy tissue,
or may arise from dierent stages of malignancy in the tumour samples.
The scatter plot in Figure 7.3 showed that, although some separation of the
normal and tumour sample spectra could be achieved based on the integration of three
features of interest, there was considerable overlap. PLS logistic regression gave better
separation of the normal and tumour data (model 1) based on the scores on the LVs 1, 2
and 4 for each spectrum. Two clear clusters, representing the normal samples and the
tumour samples, can be seen in Figure 7.8, with a smaller region of overlap than was ob-
served with the peak integration method. Cross-validation allowed the predictive ability
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of the PLSDA model to be assessed. Class assignments predicted by the model also in-
dicated good separation of the normal and tumour spectra with the overall accuracy of
the model being 84% with 90% sensitivity for detecting tumour spectra. The sensitivity
for detection of tumour spectra was maximised by applying a cost to incorrectly clas-
sifying tumour spectra as normal (false negatives) during the model construction. This
slightly reduced the specicity of detection of tumour spectra but minimises the chances
of missing a tumour in a patient.
Model 1 was built using the 1175-1025 cm−1 region of the IR spectra of the pan-
creatic tissue sample. Kondepati et al. (2006) [190] used a similar region (1192-1059 cm−1)
to separate DNA from normal and tumour pancreatic tissue, suggesting that changes in
the DNA or RNA content of the pancreatic tumour samples studied here may have con-
tributed to the spectral dierences. The model spectra of DNA and RNA (Figure 7.14)
show that these compounds do have strong absorbance signals in this region, but these
could not be distinguished from the signals of the other model compounds that absorb
in this region.
It is important to note that the tumour spectra used to build model 1 included a
range of tumours at dierent stages from 0 (benign) to 3 (most advanced). Since cancer is
a progressive disease a region of overlap between normal and tumour might be expected
in any diagnostic model, representing a transition from normal pancreas through early
tumour stages to advanced stage tumour.
Since the ability to dierentiate intermediate tumour stages is more clinically
relevant than being able to separate normal and tumour samples (as the latter is already
relatively straightforward using existing methods) an attempt was made to stage the
tumour spectra using PLS logistic regression.
It was not possible to separate, with good accuracy, the sample spectra into
normal and the four tumour stages using a single multinomial model. Therefore, a series
of models was built to provide a diagnostic pipeline (Figure 7.6) in which all tumour
spectra could be separated into stages 0 - 2 and stage 3 (model 2), and subsequently
stage 0 - 2 tumour spectra could be separated into stages 0 plus 1 and stage 2 (model 3).
Model 2 performed with 84% overall accuracy, 86 % sensitivity for detecting
stage 0 - 2 spectra and 79% sensitivity for detecting stage 3 spectra. Model 3 performed
with 64% overall accuracy and 72% sensitivity for detecting stage 0 and 1 spectra. How-
ever the sensitivity for detecting stage 2 spectra using model 3 was only 54%.
The performance of all the models, but particularly those aimed at separating
the tumour samples into stages, is compromised by the limited number of patient sam-
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ples in each class. Expanding the dataset, to both increase total sample numbers and
increase the proportion of early stage tumour samples, would likely further increase the
accuracies of the models. Indeed, to reach statistically signicant accuracy that meets
clinical guidelines a much larger study would be required.
The models in the diagnostic pipeline described are designed in series so that
the output of model 1 (those spectra predicted to be tumour) would pass into model 2
and, in turn, the output of model 2 (those spectra predicted to be stage 0 - 2 tumours)
would pass into model 3. Since none of the models are 100% specic the error of one
model is carried on to subsequent models. This means that the realised accuracies of
models 2 and 3 are lower than the values quoted, as the output of the preceding model
contains some incorrectly assigned spectra (false positives). For example, the model
1 predicts that 103 of the 178 spectra are tumour; of these, 83 are tumour and 20 are
normal. However, all 103 are passed to model 2, which does not have the capacity to
predict normal so must classify those 20 normal spectra as either stages 0-2 or stage 3.
The maximum performance of model 2 is therefore 84% of the 84% accuracy of model 1.
Comparison of the pancreatic tissue spectra to a set of model compound spec-
tra gives an indication of the kinds of compounds that might contribute to the sample
spectra and to the dierences between normal and tumour samples. The spectral re-
gion showing the most obvious dierences between tumour stages and types is between
1200 and 1000 cm−1. As demonstrated, the model spectra of mucin, glycogen, glucose,
DNA and RNA all have strong absorbance bands in this region, as do other types of
compounds, such as lipids. Other studies have also identied changes in these types
of compounds in relation to the development of pancreatic cancer [180, 182, 187–189].
However, the 1200-1000 cm−1 region of the IR spectrum, identied here as being poten-
tially signicant in diagnosis, is complex and without further biochemical tests it is not
possible to attribute the spectral changes to any specic compound(s).
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Chapter 8
Concluding remarks and future
prospects
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This thesis concerns the application of ATR-FTIR spectroscopy to the diagnosis
of kidney diseases and pancreatic cancer, as well as the inuence of hydration state on
IR spectra which has proved important when analysing dried biological samples. A step
has also been taken towards translating IR technology from the research laboratory to
the hospital clinic.
FTIR spectroscopy and its use in medical diagnostics is a fast growing eld that
has been applied to a wide range of diseases and samples types. In many ways, FTIR
spectroscopy is an ideal technique for analysing biological samples because it is quanti-
tative, sensitive to subtle compositional changes, and can provide a lot of information in
a single spectrum. Furthermore, with advancing technology, in terms of both hardware
and software, good quality IR spectra can be recorded and processed without detailed
technical knowledge and with minimal training. However, IR spectra are subject to many
types of interferences and artefacts that, if not adequately identied and dealt with, can
lead to misinterpretation of spectra.
To illustrate this point, the inuence of hydration state on the IR spectra of
urinary components has been described. Dramatic changes were observed in the IR
spectrum of urea with only a small change in humidity. Throughout the FTIR spec-
troscopy in medical diagnostics literature there are examples of dried sample analy-
sis [73,74,83,90,91], but there is little indication that rehydration levels were controlled
or considered. More generally, results of FTIR analyses are often presented without suf-
cient supporting spectra so that it is not possible to critically evaluate the validity of the
work. This is a particular problem when complex statistical methods have been applied
to data, as these methods are not capable of distinguishing real signal dierences from
spectral artefacts. It is therefore necessary that each step of spectral analysis is carefully
monitored by someone who understands the complexity of the data and limitations of
the technology. Ultimately, although IR spectroscopy is quantitative, a value judgement
is always required at some stage to decide which spectral features and changes are bio-
logically relevant.
The main focus of clinical FTIR spectroscopy is to provide new and improved
methods of diagnosing diseases that are currently dicult or expensive to diagnose ac-
curately using existing methods. Disease diagnosis using FTIR spectroscopy may be
achieved by analysing a sample spectrum for specic biomarkers that have distinctive
IR signals, or by looking for global pattern changes in spectra that can be correlated to
disease but which do not necessarily have known origins.
Urine is a relatively simple mixture of known composition and it is possible to
196
identify and quantitate some of its constituents from its IR spectrum, and to identify the
specic compounds that dier between two samples. Kidney stone diseases represent a
good example of how FTIR spectroscopy can be used to detect specic disease biomark-
ers. Here, it has been demonstrated that the stone disease, cystinuria, can be diagnosed
from ATR-FTIR spectra of the dried insoluble fractions of urine samples. It is likely that
similar protocols could be used to detect any other insoluble stone component, provided
it is IR active and present at a concentration sucient to meet the sensitivity limit of the
spectrometer. This was demonstrated for detection of DHA in the diagnosis of stone dis-
ease, APRT-deciency, although limited samples were available. Kidney stone diseases
are often dicult to diagnose at the early pre-stone stage, and distinguishing between
stones types is also problematic , but with ATR-FTIR spectroscopy a single sample spec-
trum could be simultaneously screened for a wide range of kidney stone types.
One of the diculties encountered in the analysis of urine samples is that com-
ponents at high concentrations, such as urea, dominate spectra. If the component of
interest is insoluble, as in the case of kidney stone diseases, centrifuging the samples is
an eective way to remove the high concentration soluble components. However, for
detection of some low concentration soluble biomarkers, further development may be
required to maximise their IR signals. For example, an additional sample processing step
could be used to separate soluble components, perhaps using the laminar ow microu-
idic device [83] described in the introduction. Alternatively, an additional data process-
ing step, such as subtracting model spectra of high concentration components from the
sample spectrum, taking into account the hydration state as described in results Chapter
4, could be used to reveal underlying absorbance bands.
The laboratory-grade spectrometers that were used in the development of the
cystinuria diagnostic protocol, and in much of the literature, require liquid nitrogen and
are too large, expensive and complex to realistically be used routinely in hospital clinics,
or even in pathology laboratories. In addition, the method of separating the insoluble
material and drying it on the prism is relatively slow. If FTIR spectroscopy is to be
used clinically for this purpose, research must move towards use of devices that can
be installed in hospitals, and protocols must be simplied so that they can be carried
out by a nurse or other sta member without major disruption to the clinical workow.
Sample processing must also be made high-throughput, and potentially automated, so
that multiple samples can be processed and dried simultaneously and reproducibly.
The portable benchtop spectrometers that have recently been developed for
eld work, primarily in forensics and chemistry, are small and stable enough for in-
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clinic use. One such machine was installed at the Royal Free Hospital and operated by
sta nurses who were able to produce good quality data. Useful diagnostic information
could be obtained from unprocessed wet urine samples that gave an indication of kidney
function. However, it was not possible to identify the causes of loss of kidney function,
meaning that additional tests are currently required for more specic diagnosis. With
further research into the inuence of interfering factors, such as age, ethnicity, diet and
confounding diseases, it may be possible to extract more specic diagnostic information
from such spectra. However, unless a disease is associated with a urinary biomarker that
has a unique IR signal it is likely that this technology will be more useful as a screening
tool rather than a standalone diagnostic.
The protocol for recording and analysing urine spectra on the benchtop spec-
trometer in the clinic was made as simple and automated as possible for proof of concept
purposes. However, with some optimisation it should be possible to adapt the protocols
developed for detecting cystine and other stone compounds so that they could be per-
formed in the clinic for rapid kidney stone disease screening. Similarly, where other
groups have used ATR-FTIR spectroscopy for disease diagnosis, using blood products,
urine or other biouids [73–78, 80], translation to in-clinic analysis should be possible.
In contrast to the relatively straightforward analyses of urine composition, anal-
yses of pancreas tissue resections, described in results Chapter 7, is an example of how
statistical methods can be used to identify spectral patterns, rather than specic bio-
chemicals, associated with disease. It is not usually possible to assign bands with high
condence in tissue IR spectra as the spectra are complex with many overlapping bands,
and dierent tissue constituents often exhibit very similar spectral signatures (e.g. dif-
ferent types of protein). It is generally only possible to make speculative assignments
based on the spectral region in which an absorbance band falls, with reference to known
biological processes that have been shown to be relevant to the disease process by com-
plementary biochemical tests. Using PLS logistic regression to extract spectral patterns
from the pre-processed ATR-FTIR spectra of pancreatic tissue resections, it was possi-
ble to discriminate between normal and tumour tissue, and to a lesser extent between
early and late tumour stages. One of the biggest limitations of this study was the lack of
availability of early-stage tumour samples, resulting in diagnostic models that may not
accurately represent all tumours of a given stage. Furthermore, dierent cell types and
tumour types may generate dierent absorbance patterns. Ideally, samples should rst
be classied by cell/tumour type before being further divided into disease stages.
There has been increased interest in the use of FTIR microscopy for cancer di-
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agnostics, as well as for a number of other biological and diagnostic applications [14–
19, 21, 27]. The popularity of this technique is due to the high spatial resolution that
can be obtained and because it oers a visual means, comparable to light microscopy, of
analysing a sample whilst obtaining a huge amount of biochemical information. How-
ever, although this technology can provide a unique insight in to cancer development, it
is unlikely that it will be suitable for clinical use in the near future due to its cost, com-
plexity and because of the major disruption this would cause to existing practice. For
this reason, the focus here has remained on ATR-FTIR spectroscopy applications which,
as already discussed, can be achieved with portable benchtop machines that could be
used point-of-care.
For all of the applications of FTIR spectroscopy in medical diagnostics described,
large scale clinical studies using protocols and hardware suitable for hospital installa-
tion are now required to prove the statistical signicance and ecacy of the diagnostic
methods and the potential benets over existing methods.
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Instructions for recording infrared spectra on bench top Alpha ATR-FTIR 
spectrometer. 
The Alpha machine should be on permanently and Opus can be left running (skip to 
step 5 if Opus is already running). However, please switch off the monitor when not 
in use to extend its lifetime. 
 
Starting Up Opus 
1. Upon computer start-up open Opus 7 by double clicking the icon on the desk 
top 
2. Enter password OPUS (in capitals) when prompted 
3. When Opus starts up a license window appears, click ‘OK’. 
4. Wait for performance tests to finish (status bar at bottom of screen will be 
green when tests are running and grey when finished). 
 
Check Status 
5. Check that traffic light symbol in bottom right-hand corner of main Opus 
workspace is green. 
 
To Record Background (once a day) 
6. Clean prism with water and ethanol and wait until prism is dry. 
7. Click ‘REFRESH BACKGROUND’. 
8. Click ‘Continue’ to run background.  Wait until background has finished, 
indicated by grey status bar (approx. 2 minutes). 
 
To Run Sample Urine Spectrum 
9. Click ‘RECORD SPECTRUM’. 
10. Clean prism (as above) and click ‘Continue’. 
11. Enter sample name (and additional information if required). Click ‘Continue’. 
12. Before putting a sample on the prism click ‘Continue’.  This will bring up a live 
spectrum of the prism surface. 
13. If you are happy that the prism is clean place 50 µL of sample urine on to 
prism.  Ensure entire prism is covered. Click the ‘Start Measurement’ button at 
the bottom left-hand side of the spectrum window. 
a. If the spectrum is not flat click the ‘Abort’ button at the bottom left-hand 
side of the spectrum window (close the 3 error messages that pop up) 
and run a new background (steps 6-8).  
14. Wait for sample scan to finish (approx. 1 minute). 
15. To take further measurements, clean the prism with water and ethanol, and follow 
the protocol steps 9-14. 
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1. Starting up Opus 
Opus can be left running all the time.  In the event that you find Opus has been 
closed, double left click on the ‘Opus 7.0’ icon on the desktop. 
 
Figure 1: Opus 7.0 shortcut on desktop 
Upon opening Opus you will be prompted to input a password:  
User ID: Default 
Password : OPUS 
Assigned workspaces: C:\OPUS_7.2.139.1294\RFHfull_access.ows 
 
Figure 2: Opus password prompt. 
On this page you will usually only have to put in the password.  You will only need to 
change the user ID or assigned workspace if the user before you has changed these 
settings. 
Figure 3 shows the layout of the main Opus workspace . 
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Figure 3: Main Opus workspace.  Red box indicates location of status light. 
Opus usually automatically runs some performance tests upon Opus start up.  
Please wait for these to be complete before performing any other tasks.  A window 
will appear in the bottom right-hand corner of the screen once the tests are complet 
click close (Fig. 4).  If the status bar reads ‘No active task’ then you can continue 
with set up. 
 
Figure 4: Window reporting on results of start-up performance tests. 
 
 
 
Spectra load 
into the main 
panel 
The file 
names of 
loaded 
spectra are 
shown in the 
left-hand 
panel 
Status bar 
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2. Running performance checks 
There is a traffic light symbol in the bottom right-hand corner for the main Opus 
workspace (Fig. 5).  This should always be green during operation.  If the light is 
yellow or red, left click on it and a diagnostics window will open (entitled “Instrument 
Status”, Fig. 6).  Typically, the traffic light will be yellow if the diagnostics tests are 
out of date.  
 
Figure 5: Traffic light symbol. 
 
 
Figure 6: Diagnostics window that appears after clicking on the traffic light symbol. 
Red box indicates warning showing that diagnostic tests are out of date. 
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The ‘Instrument Status’ window shows several boxes corresponding to difference 
aspects of the machine.  If there is a problem with any of these an error message will 
be shown underneath the symbol for that component. 
Underneath the ‘ATR-Diamond’ box it will say ‘EXPIRED’ if the diagnostic tests are 
out of date.  In this case, left click on the box and a further dialog window will open 
(Fig. 7). 
 
Figure 7: Run diagnostics window. 
Ordinarily you do not need to change any settings on this page, simply left click on 
‘Run Tests’ and the diagnostic tests will begin.  Usually you will only need to run a 
PQ test, however, if either OQ test is reported as expired then ensure that the check 
boxes for these tests are also ticked before clicking ‘Run Tests’.  A status bar at the 
bottom of the main Opus workspace will indicate the progress of these tests.  Whilst 
the status bar is green (Fig. 8 top), tests are still running and the machine should be 
left alone.  If the status bar is grey and reads ‘No active task’ (Fig. 8 bottom), all 
processes are finished and you can proceed with measurements. 
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Figure 8: Status bar showing that a process is running (top) and when no tasks are 
running (below). 
After the diagnostic tests are finished a report will load.  This is a PDF file that is 
saved automatically.  All you need to do is check that the diagnostic tests were 
passed and then close this window (Fig. 9). 
 
Figure 9: Diagnostic tests report.  Red box highlights the overall result of the test. 
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3. The spectrometer 
Figure 17 shows the Alpha machine and the computer.  Figure 11 shows the position 
of the prism on the machine.  This prism is the active area and where you should 
load your sample.  It is important that the entire prism is covered with sample (the 
prism is only a few millimetres square so this should be no problem.  The light 
(indicated by the red box in Fig. 10) should be green during operation.  If it is not 
green this indicates that there is a problem with the spectrometer or the software. 
 
 
Figure 10: The bench top Alpha spectrometer and accompanying computer.  Red 
box indicates the status light. 
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Figure 11: The position of the prism on the Alpha. 
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4. Cleaning the prism 
Before starting any measurements ensure that the prism is clean and dry.  The prism 
can be cleaned with water followed by ethanol.  Ensure all the ethanol has 
evaporated before continuing. Tissues can be used to wipe the prism but ensure that 
no tissue fibres are left on the prism surface. 
 
5. Refreshing the background 
A background spectrum should be run once a day.  If you are unsure when the last 
background was performed then run a background anyway. 
To begin an experiment click the ‘REFRESH BACKGROUND’ button in the top left-
hand side of the main Opus workspace (Fig. 12). 
 
 
Figure 12: Location of ‘REFRESH BACKGROUND’ button in main Opus workspace. 
A dialog box will open asking whether you want to run a background (Fig. 13).  Click 
‘Continue’ to run the background or ‘Cancel’ to close the window without running a 
background. 
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Figure 13: Run background window. 
The background takes approx. 2 mins and 4 secs (100 background scans). 
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6. Recording a sample spectrum 
To begin recording sample data click the ‘RECORD SPECTRUM’ button in the top 
left-hand side of the Opus main workspace (Fig. 14). 
 
Figure 14: Location of ‘RECORD SPECTRUM’ button in main Opus workspace. 
 
A dialog box will open asking you to clean the prism (Fig. 15).  This should be done 
at the beginning of the experiment, and after each sample measurement (see 
section 4). 
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Figure 15: Instruction to clean prism 
Once you are happy that the prism is clean and dry, click continue. 
You will be then be taken to the next dialog screen (Fig. 16), where you will input a 
file name.  The file name should contain the date that the sample is being recorded 
followed by an underscore and then a number identifying the sample, which will later 
be correlated with the patient data. Please do not include any spaces in the file 
name. There is also a box available to input any additional information that you think 
should be noted.  In most cases, this field can be left blank. 
The file name should be in the format: 
‘mmddyy_IDnumber’,  
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The date should be input in the American format, with month before day, to enable 
easy sorting of the data into months (it is not the end of the world if the file name is in 
the incorrect format, but please ensure that the IDnumber is clearly included). 
Please keep any additional information short (a few words, no more than 10). Click 
‘Continue’. 
 
Figure 16: Enter file name and additional information if necessary.  Ensure file 
names are of the format: mmddyy_ID-number. 
Another dialogue window opens.  Do not load a sample yet.  Click ‘Continue’ to start 
a live spectrum of the prism surface.  When there is no sample on the prism this 
should be a relatively flat (but noisy) line.  If you are happy that the prism is clean 
then load 50 µL of your sample on to the prism surface, ensuring the entire prism 
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area is covered.  Click the ‘Start Measurement’ button in the bottom left-hand corner 
of the spectrum window.  The sample scan will begin. 
If the prism does not look clean click ‘Abort’, clean the prism, and run a new 
background.  When you click ‘Abort’ three error messages will pop up in turn – click 
‘Cancel’ on the first and ‘OK’ on the following two. 
The status bar at the bottom of the main Opus workspace will be green and a 
progress bar in the bottom right-hand corner will show percentage completion.  Once 
the scan has finished the status bar will be grey and read ‘No active task’ (See Fig. 
8).  The spectrum will be unloaded automatically so you will not see any spectrum in 
the Opus workspace.   
The sample scan takes approximately 1 min and 2 secs. 
The spectrum is saved automatically. If you want to see the spectrum you can find it 
in directory: 
C:\\OPUS_7.2.139.1294\MEAS\RFH (see section 6 for information regarding loading 
spectra). 
You are now free to continue with further samples.  To record another sample simply 
click the ‘RECORD SPECTRUM’ button and repeat the procedure as before. 
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7. Loading an Opus Spectrum 
This must be done from within OPUS. To load a file you can either click on the 
shortcut button in the top left-hand side of the main Opus workspace (Fig. 17 top) or 
go to File – Load File (Fig. 17 bottom). 
 
 
Figure 17: Options for loading a file into Opus, using the shortcut (top) or the file 
menu (below). 
Either option opens up a dialog box and the spectra can be found in (Fig. 18): 
C:\\OPUS_7.2.139.1294\MEAS\RFH 
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Figure 18: Location of spectra saved after measurement. 
Double click on a file to load it into Opus.  To unload the file, right click on the file 
name in the left-hand panel of the main Opus workspace and left click ‘Unload File’ 
(Fig. 19). Please do not save any changes you make to the spectra.  
 
Figure 19: Unloading a file in Opus 
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8. Troubleshooting 
What happens if Opus crashes? 
This can happen from time to time. Close Opus by clicking the cross in the top right-
hand corner of the window.  Optionally restart the computer.  If Opus crashes during 
a measurement and you have to shut down Opus then the spectrum will not be 
saved.  Please repeat the measurement when Opus has restarted.  
What happens if I give two files the same name? 
Opus does not overwrite files when they are saved with the same name, but instead 
keeps both files and increases the extension.  If you are doing a repeat 
measurement of the same sample without making any changes then you can keep 
the file name the same.  A note can be made in ‘Additional information’ about any 
changes that have been made to the sample.  It might also be helpful to note down 
in a spread sheet any errors made, or email Katie Oliver (contact details in section 
8). 
Why is the light on the machine not green? 
Usually, the light on the machine will be green when everything is OK and it is ready 
to use.  If it is not green then left click the traffic light symbol in Opus (Fig. 5) and 
check whether any of the components have errors reported.  Run any diagnostic 
tests if expired. If one of the components is reported as faulty or has an error then 
contact a member of the research team (contact details in section 8). 
 
 
9. Contact details 
In the event of any problems with the machine, computer or software, or if you have 
any questions please contact a member of the research team. 
In the first instance contact: 
Katie Oliver 
katherine.oliver.11@ucl.ac.uk 
Mobile: 07814 606 765  
 Or 
Professor Peter Rich 
prr@ucl.ac.uk 
